Download Wednesday, April 22 - American Association for Cancer Research

14_15AM_Wed_Layout 1 3/27/15 12:25 PM Page 573
WEDNESDAY, APRIL 22 AT-A-GLANCE
All sessions eligible for CME credit unless otherwise noted.
7:00 a.m.-8:00 a.m.
Meet-the-Expert Sessions
574-575
8:00 a.m.-10:00 p.m.
Plenary Session
576
8:00 a.m.-12:00 p.m.
Poster Sessions
577-609
8:00 a.m.-12:00 p.m.
Late-Breaking Poster Sessions
610
10:00 a.m.-11:30 p.m.
NCI/NIH-Sponsored Session
611
10:00 a.m.-12:00 p.m.
Major Symposia
612-615
10:00 a.m.-12:00 p.m.
Recent Advances in Epidemiology and
Prevention Research
616
10:00 a.m.-12:00 p.m.
Recent Advances in Organ Site Research
617-618
12:00 p.m.-1:30 p.m.
Plenary Session
619
April 18-22, 2015 • Philadelphia, PA
573
14_15AM_Wed_Layout 1 3/27/15 12:25 PM Page 574
MEET-THE-EXPERT SESSIONS
Wednesday, 7:00 a.m.-8:00 a.m.
Room 113, Pennsylvania Convention Center
Beyond Oncogenes: What Are the Next
Categories of Anticancer Targets?
Tak W. Mak, Campbell Family Institute for Breast Cancer
Research, Toronto, ON, Canada
For the last three decades, the “Oncogene Revolution”
prompted investigators to concentrate on the development
of agents against oncogenes, with the goal of blocking cell
growth and metastasis. It has now become clear that the
cancer cell genome is too varied and the number of
oncogenes too numerous for this strategy to work
effectively for most tumors. A relatively new and promising
approach is to enhance the infiltration into the tumor
microenvironment of leukocytes that can kill cancer cells.
Two other classes of target genes relevant in this context
are those involved in cancer cell metabolic adaptation and
the maintenance of aneuploidy. In this review, I discuss
recent data from our group and other laboratories aimed at
exploiting these strategies.
Abnormalities in the gut microbiota have been implicated
in a variety of diseases including obesity, inflammatory
bowel diseases, and cancer. However, most of these studies
have largely focused on “Who is there?” There is a need for
functional and mechanistic studies to determine how the
microbiota or microbial products initiate and promote
carcinogenesis. One might then take this bench to bedside
and bedside to bench approaches. This session will discuss
results from recent studies that provide evidence that shifts
in microbial communities or specific microbes promote or
protect against colorectal adenomas and cancer. The
presentation will also include a discussion of potential
mechanisms and associations with diet and inflammation,
and will address future directions in the field.
Room 121, Pennsylvania Convention Center
Multiple Biochemical Pathways Controlling
Cell Death
Xiaodong Wang, National Institute of Biological Sciences,
Beijing, China
Room 108, Pennsylvania Convention Center
DNA Damage, Checkpoint Signaling, and
Therapeutic Opportunities
Helen M. Piwnica-Worms, The University of Texas MD
Anderson Cancer Center, Houston, TX
Genotoxic stress induces cells to adopt alternate fates
depending on the cell type and the extent of accumulated
DNA damage. These include cell death (apoptosis),
permanent cell cycle arrest (senescence), or recoverable cell
cycle arrest (through activation of cell cycle checkpoints and
DNA repair). DNA damage activates the ATM and ATR
signaling pathways, which in turn utilize downstream
checkpoint proteins including CHK1, CHK2, and p53 to
regulate the cellular response to DNA damage. Loss of
checkpoint integrity is a universal feature of cancer cells. This
session will discuss how an understanding of fundamental
principles governing cell cycle and checkpoint control can
potentially be exploited to target cancer cell vulnerabilities.
Efficacy of different cancer therapies often depends on the
efficiency of these therapies, regardless if it is chemo,
radiation, or immune-based, to induce cancer cell death.
Apoptosis, a form of cell death mediated by the activities
of a group of intracellular proteases named caspases, has
been occupying the center stage of cell death research.
Recently, a new form of programmed cell death mediated
by receptor-interacting kinase 3, RIP3, and its substrate
MLKL, a pseudokinase, has drawn major attention from the
research field. This form of cell death is negatively
regulated by caspase activities and is dispensable for
animal development reproduction. However, emerging
evidence has indicated that this form of cell death, also
termed necroptosis, has a significant involvement in the
pathological process of many diseases.
Room 119, Pennsylvania Convention Center
Reporting Germline Findings from Clinical
Genome Sequencing Trials
Room 122, Pennsylvania Convention Center
Sharon E. Plon, Baylor College of Medicine, Houston, TX
The Gut Microbiome and Colorectal Cancer:
Who Is There and What Are They Doing?
In this session, Dr. Plon will review some of the recently
developed projects that involve performing whole exome
or genome sequencing of pediatric and adult cancer
patients and returning germline results to patients/families
as part of the study design. Several trials are well
underway through the NHGRI Clinical Sequencing
Temitope O. Keku, University of North Carolina at Chapel
Hill, Chapel Hill, NC
The human gut is home to a complex microbiota that
contributes to the overall homeostasis of the host.
574
AACR ANNUAL MEETING 2015
14_15AM_Wed_Layout 1 3/27/15 12:25 PM Page 575
Exploratory Research Consortium. Issues that investigators
need to consider which will be discussed include: 1)
consenting patients/parents to clinical genomics, 2) the
range of pathogenic mutations related to the patient’s
phenotype being returned, 3) how to handle variants of
uncertain significance in cancer genes, 4) how to approach
the return of incidental findings, 5) planning for the
possibility of patient demise prior to return of results and
6) what forms of validation are being used prior to
returning results.
and enhance integrin signaling in a vicious feed forward
circuit. The relevance of these findings to tumor prevention
and therapy will be discussed. (Supported by DOD BCRP
W81XWH-05-1-0330 and NIH U54CA163155-01,
1U01CA151925-01, RO1CA138818-01A1, 2RO1CA085492-11A1,
and R01CA140663-01A2 to VMW, NIH 1U01ES019458-01 to
ZW and U54CA143836-01 to JL, NCI P50CA058207 to
VMW, CP, LC and SH and KG110560 to SH and LC.)
Room 120, Pennsylvania Convention Center
Tissue Tension Engages Developmental
Programs to Promote Tumor Progression
Understanding Sensitivity and
Resistance to Targeted Therapeutics
and Immunotherapeutics Using Mouse
Models of Lung Cancer
Valerie M. Weaver, UCSF Medical Center, San Francisco, CA
Kwok-Kin Wong, Dana-Farber Cancer Institute, Boston, MA
All cells experience force and possess mechanosensory
mechanisms that enable them to detect physical stimuli
and to transduce these cues into biochemical signals that
modulate cell and tissue behavior. Tumors consistently
exhibit abnormally high cell and tissue level forces and
transformed cells demonstrate perturbed mechanosensing.
We have been studying how cells sense and transduce
mechanical cues to regulate their behavior and the
physiological relevance of altered mechanical force in cells
and tissues to tumor formation and metastasis. Using an
array of in vitro and in vivo models we find that the ECM
progressively stiffens in various solid tumors including
breast, pancreas, glioblastoma, and skin, and we have been
able to show that ECM tension modulates transition to
invasion and metastasis. ECM stiffness compromises tissue
morphogenesis and destabilizes tissue architecture by
promoting integrin focal adhesions which potentiate
growth factor receptor signaling and induce cytoskeletal
remodeling and actomyosin contractility. By enhancing
integrin signaling to ERK and PI3 kinase, ECM stiffness
potentiates the tumorigenic effects of oncogenes and
promotes tumor progression and aggression. Recently, we
could show that a stiff ECM promotes tumor aggression by
compromising the tissue vasculature to induce hypoxia and
activate HIF1a and by directly activating HIF1a. High tumor
HIF1a in turn alters tissue metabolism, stimulates
inflammation and induces an epithelial to mesenchymal
transition. We also find that many oncogenes such as Ras
or ErbB2 or the loss of signaling in tumor cells such as the
absence of TGF beta increase tumor cell contractility. We
find that high tumor cell tension also induces malignancy
and contributes to tumor aggression by inducing ECM
remodeling and stiffening to drive focal adhesion assembly
Genetically engineered mouse (GEM) cancer models have
proved invaluable in cancer drug development. In the era
of precision medicine, these models facilitate the
understanding of primary and acquired resistance
mechanisms to novel therapeutics stratified by the
genotypes of the cancers in these GEM models. In addition,
GEM models are one of the few model systems in which
cancers are initiated and progressed within an intact
immune system. This session will highlight the recent
advances in the different approaches used with the lung
cancer GEM models to understand the mechanisms of
sensitivity and resistance to targeted therapeutics,
immunotherapeutics, as well as combination therapies.
Room 115, Pennsylvania Convention Center
April 18-22, 2015 • Philadelphia, PA
Room 103, Pennsylvania Convention Center
Update on Targeting PI3Kα in
Breast Cancer
José Baselga, Memorial Sloan Kettering Cancer Center,
New York, NY
PIK3CA, the gene encoding for p110α, is frequently mutated
in hormone-dependent breast cancer. PI3Kα specific
inhibitors have shown remarkable clinical activity in the
phase I setting in patients with breast tumors that harbor
PI3Kα mutations and these agents are also entering now
phase III studies in combination with hormonal therapies.
The underlying reason to study these agents in combination
with hormonal therapies is compelling. The PI3K and ER
pathways cooperate in tumor progression. In addition, antiestrogen therapy induces the activation of the PI3K
pathway in vitro and we have also observed that PI3K
inhibition results in a powerful activation of ER signaling.
575
14_15AM_Wed_Layout 1 3/27/15 12:25 PM Page 576
PLENARY SESSION
Wednesday, 8:00 a.m.-10:00 a.m.
Terrace Ballroom I-IV (400 Level), Pennsylvania Convention Center
Oncology Meets Immunology: Not Just Another “Hallmark”
Chairperson: Robert H. Vonderheide, Abramson Cancer Center of the University of Pennsylvania,
Philadelphia, PA
It is now well-appreciated that a fundamental aspect of cancer biology involves interactions of
neoplastic cells with the immune system, which can either promote or inhibit tumor growth,
depending on complex networks in the tumor microenvironment. Mechanistic insights from basic
studies in cancer immunology have resulted in novel, rational therapeutics for patients with advanced
cancer that have produced unprecedented clinical results, even in tumors not previously regarded as
amenable to such approaches. The consensus in the field – to be illustrated in this Plenary Session – is
that we have only seen the tip of the iceberg for cancer immunotherapy, posing a challenge to
investigators, advocates, government, industry, and others to capture this opportunity quickly and
fully for the benefit of our patients.
8:00 a.m. Engineering improved cancer vaccines
Glenn Dranoff, Novartis Institutes for BioMedical Research, Cambridge, MA
8:30 a.m. Leukocytes as targets for therapy in solid tumors
Lisa M. Coussens, OHSU Knight Cancer Institute, Portland, OR
9:00 a.m. Fatal attraction: A new story featuring the immune system and
pancreatic cancer [PL04-03]*
Elizabeth M. Jaffee, Johns Hopkins University, Baltimore, MD
9:30 a.m. The mechanistic basis of cancer immunotherapy
Ira Mellman, Genentech, Inc., South San Francisco, CA
*An extended abstract for this presentation is available in the Invited Abstracts section of the Proceedings (the abstract number is listed in brackets above).
576
AACR ANNUAL MEETING 2015
POSTER SESSION
Poster Section 1 • Wednesday, 8:00 AM-12:00 PM
Molecular and Cellular Biology
Advances in Genomics and Transcriptomics
Poster
:LJ[PVU
(not eligible for CME credit)
Poster
Board
Abstract
Number
1.
4735 Single-cell sequencing from formalin-fixed paraffinembedded breast cancers: a powerful tool to address intratumor
genetic heterogeneity. Luciano G. Martelotto, Rita A. Sakr, Timour
Baslan, Linda Rodgers, Hilary Cox, Jude Kendall, Tari A. King, Britta
Weigelt, James Hicks, Jorge S. Reis-Filho.
2.
4736 Absolute quantification of BCR-ABL RNA using
multiplexed digital RT-PCR. Maria E. Arcila, Ryma Benayed, Iwona
Kiecka, Coren Milbury, Michael Mauro, Michael L. Samuels.
3.
4737 Comprehensive profiling of immunoglobulin sequences
using hybrid capture-based next generation sequencing in B-cell
hematologic malignancies. Michelle K. Nahas, Lauren E. Young, Jeff
Gardner, Omar Abdel-Wahab, Jie He, Amy L. Donahue, Kristina M.
Knapp, Geoff A. Otto, Doron Lipson, Vincent A. Miller, Ross L. Levine,
Philip J. Stephens.
Poster
Board
Abstract
Number
14.
4748 Revealing the molecular portrait of triple negative
breast tumors from an understudied population through omics
analysis of formalin-fixed and paraffin-embedded tissues. Felipe
Vaca-Paniagua, Rosa María Alvarez-Gomez, Carlos Perez-Plasencia,
Hector Aquiles Maldonado-Martínez, Veronica Fragoso-Ontiveros,
Federico Lasa-Gonsebatt, Luis A. Herrera, David Cantú, Enrique
Bargallo-Rocha, Alejandro Mohar, Geoffroy Durand, Nathalie Forey,
Catherine Voegele, Maxime Vallee, Florence Le Calvez-Kelm, James
McKay, Maude Ardin, Stephanie Villar, Jiri Zavadil, Magali Olivier.
15.
4749 Simultaneous multi-omic measurement of nucleic-acids
and proteins at 800-plex using single-molecule optical barcodes:
Application to cancer immunotherapy. Joseph M. Beechem, Gary
Geiss, Brian Filanoski, Brian Birditt.
16.
4750 Transcriptome sequencing of the Reed-Sternberg cells
of classical Hodgkin lymphoma. Jonathan Reichel, Joshua Brody,
Olivier Elemento, Raul Rabadan, Ethel Cesarman.
17.
4751 Simple modifications in Ion Torrent Variant Caller (TVC)
parameters improve somatic variant detection from circulating
tumor cells and cell free DNA to 1% allele frequency. Colin
Davidson, Yongming Sun, Christopher Davies, Chaitali Parikh, Warren
Tom, Fiona Hyland, Charles Scafe, Dalia Dhingra.
18.
4752 Genomic cytometry: Single cell mutation analysis
combining PCR with flow cytometry. William C. Hyun, Adam
Sciambi, Maurizio Pellegrino, Dennis Eastburn.
19.
4753 An effective detection method for the EGFR single
mutation T790M using BNA-NC clamping real-time PCR. Sung-Kun
Kim, Xiaoyun Liu, Aaron Castro, Leticia Loredo, Miguel Castro.
20.
4754 Development of fluorescent probes for detection of DNA
base excision repair in human cancer cells. Allison G. Condie, Yan
Yan, Stanton L. Gerson, Yanming Wang.
21.
4742 Using 1ng of DNA to detect haplotype phasing and gene
fusions from whole exome sequencing of cancer cell lines. Mirna
Jarosz, Michael Schnall-Levin, Grace X. Zheng, Patrick Marks, Sofia
Kyriazopoulou-Panagiotopoulou, Patrice Mudivarti, Kristina Giorda.
4755 Maximize genomic analysis through dual recovery of
DNA and RNA from the same clinical sample. Angie Cheng, Natalie
Hernandez, Mu Li, Charmaine San Jose Hinahon, Susan Magdaleno.
22.
4756 Genomic profile of AML-ETO rearranged acute myeloid
leukemia. Youngil Koh, Dae-Yoon Kim, Jong-Kwang Kim, Yeun-June
Chung, Sung-Soo Yoon, Hyung-Lae Kim.
9.
4743 A population-based approach to address clinical cancer
care: The national genomics platform. Ogan Abaan, Amrita Basu,
Noah Brown, Bret Light, David Deal, Michael Hultner.
23.
10.
4744 Solving genomic assay trade-offs with an optimized,
extended cancer gene panel for research and clinical applications.
Michael J. Clark, Sean M. Boyle, Elena Helman, Shujun Luo, Gabor
Bartha, Massimo Morra, Anil Patwardhan, Christian Haudenschild,
Mirian Karbelashvili, Parin Sripakdeevong, Jason Harris, Deanna
Church, Stephen Chervitz, John West, Richard Chen.
4757 Whole exome sequencing reveals a distinct mutation
pattern in metastatic small cell lung cancer compared to non-small
cell lung cancer. Ali Saber, Klaas Kok, Martijn M. Terpstra, Wim
Timens, Sijmen Aukema, T. Jeroen Hiltermann, Harry J. Groen, Anke
van den Berg.
24.
4758 Genomic profiling of prostate cancer in Korean
population. Ha Young Park, Jong-il Kim, Weon Seo Park, Kang Hyun
Lee.
25.
4759 Whole genome sequencing of sequentially acquired lung
and lymph node metastatic sites from a never smoker lung
adenocarcinoma patient revealed extensive genomic
heterogeneity. Shaojian Gao, Constance Cultraro, Romi BIswas,
Corey A. Carter, Tapan K. Maity, Anish Thomas, Arun Rajan, Paul
Meltzer, David Schrump, Giuseppe Giaccone, Javed Khan, Udayan
Guha.
26.
4760 Stromal contribution to the colorectal cancer
transcriptome. Claudio Isella, Andrea Terrasi, Sara E. Bellomo,
Consalvo Petti, Andrea Muratore, Alfredo Mellano, Mark De Ridder,
Paola Cassoni, Guy Storme, Andrea Bertotti, Enzo Medico.
27.
4761 Characterization of individual foci of multifocal invasive
lobular breast cancer using gene expression profiling. Pooja
Advani, Nadine Norton, Daniel J. Serie, Xochiquetzal Geiger, Julia E.
Crook, Aubrey E. Thompson, Edith A. Perez, Alvaro Moreno Aspitia.
4.
Maximize recovery of quality nucleic acid from formalinfixed paraffin-embedded tissue samples using a novel, flexible
purification technology. Doug Wieczorek, Brad Hook, Eric Vincent,
Trista Schagat.
5.
4739
6.
7.
8.
4738
Genetic predisposition to DNA double strand break
repair defect defines a new class of familial colon cancer.
Sanjeevani Arora, Hong Yan, Iltaeg Cho, Hua-Ying Fan, Biao Luo,
Xiaowu Gai, Dale Bodian, Joe Vockley, Yan Zhou, Elizabeth Handorf,
Mark Andrake, Emmanuelle Nicolas, Ilya Serebriiskii, Tim Yen, Michael
Hall, Greg Enders, Erica Golemis.
4740 Evaluation of highly-multiplexed custom panels for
targeted massively parallel semiconductor sequencing on paraffin
DNA. Vassiliki Kotoula, Aggeliki Lyberopoulou, Kyriaki
Papadopoulou, Elpida Charalambous, Sotiris Lakis, Zoi Alexopoulou,
Eleftheria Tsolaki, Konstantinos Lilakos, George Fountzilas.
4741 Improving pancreatic cancer drug discovery by
leveraging genomics to select better in vitro models. Yoonjeong
Cha, Andrew Lysaght, Rain Cui, Brian Weiner, Sarah Kolitz, Fadi
Towfic, Jason Funt, Kevin Fowler, Badri Vardarajan, Maxim
Artyomov, Benjamin Zeskind, Rebecca Kusko.
11.
4745 Precision cancer medicine program for whole-exome
sequencing of metastatic tumors reveals biomarkers of response.
Himisha Beltran, Kenneth Eng, Juan Miguel Mosquera, Alexandros
Sigaras, Alessandro Romanel, Hanna Rennart, Myriam Kossai, Chantal
Pauli, Bishoy Faltas, Jacqueline Fontugne, Brian Robinson, David M.
Nanus, Scott T. Tagawa, Jenny Z. Xiang, Francesca Demichelis, David
Rickman, Andrea Sboner, Olivier Elemento, Mark A. Rubin.
12.
4746 Mapping the “dark matter” of cancer genome - Long
repeats, complex structural variations with nanochannel
technology. H. Cao, A Hastie, A. Pang, W. Andrews, T.
Anantharaman, T. Chan, M. Saghbini, H. Sadoski, M. Austin, Z.
Dzakula, T. Dickinson, E. Holmlin, X. Xun, P. Kwok, M. Rossi.
13.
4747 Genomic alterations in ductal carcinoma in situ
compared with Invasive breast cancer: a quantitative real-time
PCR study. Trillium E. Chang, Keisha Warren, Ranju Nair, Tian Y. Lu,
Adewunmi Adeoye, Vladimir Iakovlev, Susan J. Done.
April 18-22, 2015 • Philadelphia, PA
1
1
577
POSTER SESSION
Poster Section 2 • Wednesday, 8:00 AM-12:00 PM
Molecular and Cellular Biology
Poster
:LJ[PVU
2
2
Epigenetic Changes in Cancer 2
(not eligible for CME credit)
Poster
Board
1.
2.
3.
4.
5.
6.
8.
9.
10.
11.
12.
13.
14.
578
Abstract
Number
4762 ITPKA expression in lung and other cancers,
regulated via gene body methylation, functions as an
oncogene. Yi-Wei Wang, Xiaotu Ma, Yu-An D. Zhang, MeiJung Wang, Yasushi Yatabe, Stephen Lam, Luc Girard, JeouYuan Chen, Adi F. Gazdar.
4763 Correlation of CpG island methylation with
clinical and pathologic characteristics in metastatic
colorectal cancer patients. Shailesh M. Advani, Michael S.
Lee, Michael J. Overman, David Fogelman, Bryan K. Kee,
Shanequa D. Manuel, Jennifer Davis, Van Karlyle Morris,
Callisia N. Clarke, Carrie R. Daniel, David G. Menter, Stanley R.
Hamilton, Dipen M. Maru, Scott Kopetz.
4764 The Bromodomain inhibitors regulate long
noncoding RNAs controlling glioblastoma progression.
Chiara Pastori, Philip Kapranov, Clara Penas, Georges St.
Laurent, Nagi Ayad, Claes Wahlestedt.
4765 A drill-down approach to identifying an ER
negative-specific gene signature. Maria J. Worsham,
Dhananjay Chitale, Kang Mei Chen, Indrani Datta, Josena K.
Stephen, George Divine.
4766 DNA methylation changes in Lynch syndrome
associated colorectal adenomas and carcinomas. Satu
Valo, Sippy Kaur, Ari Ristimäki, Laura Renkonen-Sinisalo,
Heikki Järvinen, Jukka-Pekka Mecklin, Minna Nyström, Päivi
Peltomäki.
4767 DNA sequences differentially associated with
Sirt1 and Dnmt3b during melanoma progression. Fabiana
Marcelino Meliso, Camila T. da Silva, Simon Coetzee, Thaís
Sarraf Sabedot, Houtan Noushmehr, Regine Schneider-Stock,
Miriam Galvonas Jasiulionis.
4769 CHFR methylation is an independent prognostic
marker of poor prognosis in gastric cancer. Kiichi
Sugimoto, Alicia Hulbert, Zhihao Lu, Chen Chen, Tomoaki Ito,
Hiromitsu Komiyama, Yutaka Kojima, Michitoshi Goto, Yuichi
Tomiki, Hajime Orita, Kazuhiro Sakamoto, Koichi Sato,
Malcolm V. Brock.
4770 Levels of 5-methyl-cytosine and 5hydroxymethyl-cytosine in hepatocellular carcinoma
prognosis. Lissette Delgado-Cruzata, Hui Chen Wu, Tiffany
Thomas, Abby B. Siegel, Jing Shen, Yu-Jing Zhang, Abhishek
Goyal, Christine C. Hsu, Helen Remotti, Regina M. Santella.
4771 Epigenetic modification of LY6K in CGI shore and
CGI regulates LY6K gene activation and metastatic
function in breast cancer. Hyun Kyung Kong, Sae Jeong
Park, Ye Sol Kim, Jong Hoon Park.
4772 Aberrantly hypermethylated Homeobox A2
derepresses metalloproteinase-9 through TBP and
promotes invasion in nasopharyngeal carcinoma. CHENCHING PENG.
4773 Aberrant methylation at chromosome 6p as novel
biomarkers for diagnosis and prognosis of nasopharyngeal
carcinoma. Wei Dai, Arthur Kwok Leung Cheung, Josephine
Mun Yee Ko, Hong Zheng, Yue Cheng, Roger Kai Cheong
Ngan, Wai Tong Ng, Anne Wing Mui Lee, Chun Chung Yau,
Victor Ho Fu Lee, Maria Li Lung.
4774 Histone H2AX is a novel regulator of epithelial to
mesenchymal transition. SOSSOU U. WEYEMI, Christophe E.
Redon, Rohini Choudhuri, Daisuke Maeda, Manjula Kasoji,
Natalie Abrams, William M. Bonner.
4775 Gene-specific methylation profiles in male breast
cancer. Piera Rizzolo, Valentina Silvestri, AnnaSara Navazio,
Virginia Valentini, Veronica Zelli, Mario Falchetti, Ines Zanna,
Simonetta Bianchi, Domenico Palli, Laura Ottini.
Poster
Board
16.
17.
18.
19.
20.
21.
22.
23.
24.
25.
26.
27.
28.
29.
Abstract
Number
4777 Triptolide inhibits Wnt signaling due to DNA
methylation alteration that is determined by dynamic
histone 3 K79 lysine methylation in NSCLC. Youqiang Li,
Binghui Shen, Jae Kim, Dan Raz.
4778 HP1-mediated spatiotemporal control of
estrogen-responsive transcription in breast cancer cells.
Pei-Yin Hsu, Hang-Kai Hsu, Victor X. Jin, Zelton D. Sharp, Tim
H.-M. Huang.
4779 RUVBL1 and RUBVL2 are chromatin remodelers
that represent prognostic and novel therapeutic targets
for a subset of non-small cell lung cancers (NSCLCs). Paul
M. Yenerall, Rahul Kollipara, Ryan Carstens, Kenneth
Huffman, Luc Girard, Jaime Rodriguez, Ignacio Wistuba,
David Mangelsdorf, John Minna, Ralf Kittler.
4780 Nucleosome organization and accessibility of p53
response elements in the chromatin context. Peter R.
LoVerso, Victor B. Zhurkin, Feng Cui.
4781 A comprehensive screen for protein kinases
involved in histone phosphorylation using a biochemical
in-vitro approach. Daniel Mueller, Frank Totzke, Constance
Ketterer, Christian Beisenherz-Huss, Diane Krämer, Thomas
Weber, Carolin Heidemann-Dinger, Michael H. Kubbutat.
4782 Genome-wide chromatin profiling in bladder and
prostate cancers. Sohyoung Kim, Lyuba Varticovski, Qizong
Lao, Songjoon Baek, Myong-Hee Sung, Lars Grøntved,
Michael L. Nickerson, Bethtrice Thompson, Dan Theodorescu,
Michael Dean, Gordon H. Hager.
4783 Novel molecular markers of bladder cancer
progression identified by global chromatin profiling.
Lyuba Varticovski, Sohyoung Kim, Michael L. Nickerson,
Bethtrice Thompson, Qizong Lao, Lars Grøntved, Songjoon
Baek, Myong-Hee Sung, Dan Theodorescu, Michael Dean,
Gordon L. Hager.
4784 Effect of epigenetic drugs on chromatin
remodeling complexes disrupted in cancer. Montserrat
Pérez-Salvia, Laia Simó-Riudalbas, Manel Esteller.
4785 Deficiency of cystathionine beta synthase gene
does not affect tumor formation and survival of E␮-myc
mice. Sapna Gupta, Warren D. Kruger.
4786 Cellular localization of PRMT5 correlates with
poor recurrent free survival in triple-negative breast
cancer (TNBC). Elaine P. Alexander, Christian T. Earl, Xiaokui
Mo, Konstantin Shilo, Robert A. Baiocchi, Maryam B.
Lustberg.
4787 Cyclin G2, a novel target of the SNF5/BAF47
tumor suppressor gene. Darmood Wei, Aubri Charboneau,
Ho-yoon Chung, Donastas Sakellariou-Thompson, Brian
Davies, Dennis A. Simpson, Yasumichi Kuwahara, William K.
Kaufmann, Charles W. Roberts, Bernard E. Weissman.
4788 Enhancer of zeste homolog 2 couples with
HOTAIR to inhibit tumor suppressor miR-34a in human
pancreatic ductal adenocarcinoma. Samson Li, Yangchao
Chen.
4789 Epigenetic targeting of triple negative breast
cancer. Sylvia S. Gayle, Jennifer Brancato, Kristen W. Bonk,
Ruth Keri.
4790 Noncanonical functions of EZH2 in triple-negative
breast cancers. Talha Anwar, Heather Moore, Sarah
Bergholtz, Celina Kleer.
AACR ANNUAL MEETING 2015
POSTER SESSION
Poster Section 3 • Wednesday, 8:00 AM-12:00 PM
Molecular and Cellular Biology
Genomics 3
Poster
:LJ[PVU
(not eligible for CME credit)
Poster
Board
Abstract
Number
1.
4791 Prognostic model of lower grade gliomas. Kosuke Aoki,
Hiromichi Suzuki, Hideo Nakamura, Masahiro Mizoguchi, Tetsuya Abe,
Satoru Miyano, Ichiro Takeuchi, Toshihiko Wakabayashi, Seishi Ogawa,
Atsushi Natsume.
2.
4792 Comprehensive molecular pathology analysis of small bowel
adenocarcinoma reveals novel targets with clinical utility. Muhammad
A. Alvi, Darragh G. McArt, Paul Kelly, Marc-Aurel Fuchs, Matthew
Alderdice, Clare M. McCabe, Victoria Bingham, Claire McGready, Stephen
McQuaid, Perry Maxwell, Peter Hamilton, Jacqueline A. James, Richard
Wilson, Manuel Salto-Tellez.
Poster
Board
Abstract
Number
16.
4806 Characterizing the genomic landscape of premalignant
colorectal polyps using next-generation sequencing. Ester Borras,
Anthony San Lucas, Kyle Chang, Gita Bhatia, Hong Wu, Jerry Fowler, Y.
Nancy You, Patrick M. Lynch, Melissa W. Taggart, Ernest T. Hawk, Gabriel
Capella, Paul Scheet, Eduardo Vilar.
17.
4807 Discovery of novel alternative splicing events in human
papillomavirus-related oropharyngeal squamous cell carcinoma.
Theresa Guo, Daria Gaykalova, Michael Considine, Justin A. Bishop, William
H. Westra, Zubair Khan, Elana Fertig, Joseph A. Califano.
18.
4808 Identification of genes with variants in HPV-associated head
and neck squamous cell carcinoma. Shama Virani, Pelle B. Hall, Yanxiao
Zhang, Lada A. Koneva, Alisha Virani, Katie M. Rentschler, Thomas E.
Carey, Laura S. Rozek, Maureen A. Sartor.
3.
4793 Rapid pan-cancer identification of previously unidentified
fusion genes to enable novel targeted therapeutics. Henrik Edgren,
Kalle Ojala, Anja Ruusulehto, Gopi Ganji.
4.
4794 Identification of FOXM1 driven gene network as a prognostic
marker in breast cancer. In-Sun Chu, Seon-Kyu Kim, Yun-Gil Roh, SunHee Leem.
19.
5.
4795 A novel gene fusion in glioblastoma and a radiation
response methylation signature identified by genomic characterization
of glioma sphere-forming cells. Qianghu Wang, Ravesanker Ezhilarasan,
Lindsey D. Goodman, Joy Gumin, Siyuan Zheng, Kosuke Yoshihara, Peng
Sun, Jie Yang, Tim Heffernan, Giulio Draetta, Kenneth D. Aldape, Frederick
F. Lang, Roel G. Verhaak, Erik P. Sulman.
4809 Validation of molecular subtypes of urothelial carcinoma of
bladder in multi-institutional and public cohorts. Vipulkumar Dadhania,
Charles G. Guo, Tadeusz Majewski, Li Zhang, Jolanta Bondaruk, Shizhen
Zhang, Woonyoung Choi, David McConkey, Colin Dinney, Keith Baggerly,
Bogdan A. Czerniak.
20.
4796 A founder mutation in the BAP1 gene among four caucasian
families with high incidences of malignant peritoneal mesothelioma
and uveal melanoma: a molecular and genealogical study in a 10generation BAP1 cancer syndrome kindred. Erin Flores, Mitsuru Emi,
Todd Johnson, Tatsuhiko Tsunoda, Dusty Behner, Harriet Hoffman, Mary
Hesdorffer, Masaki Nasu, Andrea Napolitano, Francine Baumann, Haining
Yang, Michele Carbone.
4810 Exome sequencing of refractory diffuse large B-cell
lymphomas highlights candidate genes for targeted resequencing.
Sylvain Mareschal, Pierre-Julien Viailly, Philippe Bertrand, Elodie Bohers,
Jean-Philippe Jais, Martin Figeac, Thierry J. Molina, Fabienne Desmots,
Thierry Fest, Gilles Salles, Corinne Haioun, Hervé Tilly, Karen Leroy, Fabrice
Jardin.
21.
4811 Pro-oncogenic role of NOTCH1 in early tongue squamous
cell carcinoma. Pawan Upadhyay, Jyotirmoi Aich, Vidyalakshmi
Sethunath, Prachi Dani, Sadhana Kannan, Pratik Chandrani, Kavitha
Sonawane, Beamon Agarwal, Shubhada Kane, Sudhir Nair, Amit Dutt.
22.
4812 Creation of a novel gene delivery system for high
throughput candidate oncogene validation. Charlotte R. Feddersen.
23.
4813 High-depth sequencing of 800 cancer-associated genes in 48
matched tumor-normal tissues to identify somatic alterations including
low-frequency variants in colorectal cancer. Clarinda Chua, Dan Liang
Ho, Yuka Suzuki, Simeen Malik, John McPherson, Anna Gan, Dennis Koh,
Choon Leong Tang, Sarah Boon Hsi Ng, Patrick Tan, Steve Rozen, Iain
Beehuat Tan.
24.
4814 Inferring liver cancer evolution from spatial and temporal
genomic heterogeneity. Qiang Gao, Zhi-Chao Wang, Rui-Bin Xi, Jia Fan.
25.
4815 Tumor heterogeneity of advanced primary lung cancer
evaluated by multiregion sequencing. Sang-Won Um, Je-Gun Joung, Su
Yeon Lee, Joon Seol Bae, Jinha Park, Woong-Yang Park.
26.
4816 Design, validation, and interpretation of an NGS assay for
actionable variants in solid tumors. Susan M. Mockus, Guruprasad
Ananda, Micaela Lundquist, Vanessa Spotlow, Al Simons, Talia Mitchell,
Grace A. Stafford, Christopher S. Potter, Vivek Philip, Timothy Stearns,
Anuj Srivastava, Mary Barter, Lucy Rowe, Joan Malcolm, Carol Bult, Radha
Krishna Murthy Katuturi, Karen Rasmussen, Douglas Hinerfeld.
27.
4817 Microsatellite instability status in endometrioid endometrial
carcinomas is associated with distinct types and patterns of PI3K
pathway mutations. Caterina Marchio, Maria R. De Filippo, Charlotte K.
Ng, Robert A. Soslow, Jorge S. Reis-Filho, Britta Weigelt.
6.
7.
4797 Mutation signature and intratumor heterogeneity of
esophageal squamous cell carcinoma in a Chinese cohort. Qingxuan
Song, Mengfei Liu, Jian Bai, Amir Abliz, Wenqing Yuan, Zhen Liu, Jingjing
Liu, Changhong Zeng, Hong Cai, Yang Ke, Jun Li.
8.
4798
Genomic alterations in ERBB2 define a subset of
pleomorphic invasive lobular breast cancer. Kim M. Hirshfield, Renee
Sanders, Heather K. Feld, Nicola Barnard, Li Liang, Hua Zhong, Gyan
Bhanot, Amrik S. Sahota, Andrew Brooks, Lorna Rodriguez-Rodriguez,
Shridar Ganesan.
9.
4799 Variation in mutational landscape among small colonic
polyps with differential growth rates. Chelsie K. Sievers, Perry J.
Pickhardt, Kristina Matkowskyj, Dawn Albrecht, Luli Zou, David Kim,
Meghan Lubner, Mark Reichelderfer, Richard Halberg.
10.
4800 Identification of candidate predisposition genes for familial
uterine leiomyomas. Hanna-Riikka Heinonen, Outi Uimari, Jaana
Tolvanen, Markku Ryynänen, Lauri A. Aaltonen, Pia Vahteristo.
11.
4801 Integrated genomic analysis of chromosome 11 in squamous
tumors. Vonn Walter, Ying Du, Xiaoying Yin, Wei Sun, Matthew D.
Wilkerson, Michele C. Hayward, Ashley H. Salazar, Charles M. Perou, David
N. Hayes.
12.
4802 Transcriptional landscape of lung squamous cell carcinoma
in Northeast Asian patients. Arang Rhie, Hyesun Cho, Min Hwan Son,
Seong-Keun Yoo, Jong-Yeon Shin, Jeong-Sun Seo.
13.
4803 BAP1 mutation is a frequent somatic event in peritoneal
malignant mesothelioma. Olivier Harismendy, Hakan Alakus, Shawn Yost,
Brian Woo, Randall French, Grace Y. Lin, Kristen Jepsen, Kelly A. Frazer,
Andrew M. Lowy.
28.
4804 High throughput whole exome DNA and transcriptome RNA
sequencing to identify genetic drivers and alterations in HPV-negative
and HPV-positive HNSCC cell lines. Hui Cheng, Xinping Yang, Han Si,
Anthony Saleh, Jamie Coupar, Robert L. Ferris, Wendell G. Yarbrough,
Mark E. Prince, Thomas E. Carey, Carter Van Waes, Zhong Chen.
4818 Array-CGH and miRNA expression profiling of triple negative
breast cancer in African-American women. Kenny Regis, Michelle Jaldin,
Akanksha Mahajan, Anju Duttargi, Laura Sheahan, Yuriy Gusev, Subha
Madhavan, Luciane R. Cavalli.
29.
4819 Differential evolution of tumor heterogeneity in
leiomyosarcomas and liposarcomas suggested by genomic profiling.
Ali Amin-Mansour.
30.
4820 A comparison of bulk versus single-cell whole-exome
sequencing to study cancer genetic heterogeneity. John B. Williamson,
Hongyong Zhang, Paul Lott, Ruta Sahasrabudhe, Stephanie Soares, Susie
Airhart, Clifford Tepper, Chong-Xian Pan, Ralph DeVere-White, Luis
Carvajal-Carmona.
14.
15.
4805 Whole genome sequencing of primary breast cancers and
matched distant metastases. Man-Hung Tang, Malin Dahlgren, Christian
Brueffer, Christof Winter, Yilun Chen, Eleonor Olsson, Martin Sjöström,
Pär-Ola Bendahl, Emma Niméus-Malmström, Lao H. Saal, Åke Borg, Sofia
K. Gruvberger-Saal.
April 18-22, 2015 • Philadelphia, PA
3
3
579
POSTER SESSION
Poster Section 4 • Wednesday, 8:00 AM-12:00 PM
Molecular and Cellular Biology
Poster
:LJ[PVU
4
4
Identification of Molecular Markers
(not eligible for CME credit)
Poster
Board
1.
2.
3.
4.
5.
6.
7.
8.
9.
10.
11.
12.
13.
14.
580
Abstract
Number
4821 Association of polymorphisms in TP53, CXCL2, MDM2,
MDM4 and BCL2 genes and proliferative prostate diseases among
Lebanese men. Ruhul H. Kuddus, Asmahan A. El Ezzi, Mohammed A.
El-Saidi, Scott Baker, Wissam Zaidan.
4822 Lack of expression of FOXO3 correlates with poor
prognosis on uterine sarcomas. Thais G. Almeida, Natalia Garcia,
Isabela W. Cunha, Glauco Baiocchi, Fernando A. Soares, Gustavo A.
Maciel, Edmund C. Baracat, Katia C. Carvalho.
4823 Serum level of urokinase plasminogen activator
receptor is suggested as diagnostic and prognostic biomarker in
prostate cancer. Sven Wach, Omar Al-Janabi, Katrin Weigelt,
Kersten Fischer, Thomas Greither, Marios Marcou, Gerit Theil, Elke
Nolte, Hans-Juergen Holzhausen, Robert Stoehr, Verena Huppert,
Arndt Hartmann, Paolo Fornara, Bernd Wullich, Helge W. Taubert.
4824 Pancreatic adenocarcinoma: Comparative analysis of
cancer stem cell markers between neoadjuvant and treatment
naïve specimens. Whitney Horsley, Melissa Stanley, Bert O’Neil, Safi
Shahda, George Sandusky.
4825 Association between genetic profiles and histological
classifications of 18 Japanese pseudomyxoma peritonei. Rei
Noguchi.
4826 Cancer/testis antigen expression pattern is a potential
biomarker for prostate cancer aggressiveness. Luciane T.
Kagohara, Prakash Kulkarni, Takumi Shiraishi, Guangjing Zhu, Robert
Vessella, Robert Veltri.
4827 Gene copy number and protein expression of growth
factor receptors EGFR and HER2 and their prognostic potential in
penile squamous cell carcinoma. Alice M. Silva-Amancio, Jose I.
Neves, Isabela W. Cunha, Walter da Costa, Gustavo C. Guimarães,
Fernando A. Soares.
4828 Differential gene expression profile of tissue factor
pathway inhibitor-2 (TFPI-2) in malignant pleural mesothelioma.
Anil Wali, Ying Wang, Adi Tarca, Fulvio Lonardo, Zhandong Liu, Arun K.
Rishi, Harvey I. Pass.
4829 The clinical significance of APOBEC3B in esophageal
squamous cell carcinoma. Keisuke Kosumi, Yoshifumi Baba,
Takatsugu Ishimoto, Kenichi Nakamura, Kazuto Harada, Mayuko
Ohuchi, Yuki Kiyozumi, Daisuke Izumi, Ryuma Tokunaga, Junji
Kurashige, Ryuichi Karashima, Yukiharu Hiyoshi, Shiro Iwagami,
Yasuo Sakamoto, Yuji Miyamoto, Naoya Yoshida, Masayuki
Watanabe, Hideo Baba.
4830 The correlation between CXCR7 expression and EGFR
mutation in non-small cell lung cancer. Yiping Han.
4831 Analysis of genetic variations in neuroblastoma using
deep targeted sequencing. Niloufar Javanmardi, Susanne Fransson,
Malin Ostensson, Rose-marie Sjoberg, Per Kogner, Tommy
Martinsson.
4832 Independent prognostic role of chromosome 12p
deletion in prostate cancer. Sarah J. Minner, Ramin Ahray, Martina
Kluth, Thorsten Schlomm, Ronald Simon, Guido Sauter, Maria
Christina Tsourlakis.
4833 Single-cell genetic analysis reveals insights into clonal
development of cervical cancer and confirms TERC as an early and
dominant aberration. Leanora S. Hernandez, Amanda Bradley, Timo
Gaiser, Sonia Andersson, E. Michael Gertz, Salim A. Chowdhury,
Russel Schwartz, Alejandro Schäffer, Kerstin Heselmeyer-Haddad,
Thomas Ried.
4834 Single cell multiplex gene expression analysis to unravel
heterogeneity of PDX samples established from tumors of breast
cancer patients with different ethnicity. Ebrahim Azizi, Evelyn M.
Jiagge, Shamileh Fouladdel, Shukmei Wong, Michele L. Dziubinski, Mary
Sehl, Anahita Kyani, Jun Li, Hui Jiang, Tahra K. Luther, Shawn G. Clouthier,
Sean P. McDermott, John Carpten, Lisa A. Newman, Sofia D. Merajver,
Max S. Wicha.
Poster
Board
15.
16.
18.
20.
21.
22.
23.
24.
25.
26.
27.
28.
Abstract
Number
4835 A new biomarker of response to 5-azacitidine therapy in
MDS and AML patients: SIRPB1. Viviana Guadagnuolo, Cristina
Papayannidis, Ilaria Iacobucci, Giorgia Simonetti, Antonella Padella, Stefania
Paolini, Mariachiara Abbenante, Sarah Parisi, Francesca Volpato, Chiara Sartor,
Maria Chiara Fontana, Massimo Delledonne, Michele Malagola, Carla Filì,
Domenico Russo, Sandro Grilli, Michele Cavo, Giovanni Martinelli.
4836 Presence of FTO rs9939609 and rs9930506 and severity
of prostate cancer in Puerto Ricans. Jeannette Salgado-Montilla,
Jorge Rodríguez-Caban, Lorena Gonzalez-Sepulveda, Ricardo SanchezOrtiz, Margarita Irizarry-Ramirez.
4838 Inhibitor of differentiation-1 (Id1) expression correlates
with epithelial-mesenchymal transition (EMT)-related proteins in
epithelial ovarian cancer (EOC) and constitutes a novel prognostic
factor. Victoria Heredia, Andres Redondo, Jorge Barriuso, Alberto
Berjón, Cristian Perna, Patricia Cruz, Alicia Hernández, Javier de
Santiago, Esther Díaz, María Miguel, Beatriz Castelo, Laura Yébenes,
Jaime Feliú, David Hardisson, Marta Mendiola.
4840 The role of miR-146a and novel Rhenium compounds on
prostate cancer cell lines derived from African Americans and
European American patients. Monet Stevenson, Jameel Joyner,
Khadija Dildar, Oladipo Adedeji, Krishnan Prabhakaran, Hirendra N.
Banerjee, Santosh Mandal, Fazlul Sarkar.
4841 NF-kB - p53 gene associations and prostate cancer risk.
Radhika G. Andavolu, Catherine Stafford, Murthy V. Andavolu, JeanLuc Cardenas, Jacob Rubin, Ross Shore, Svetlana Rubakovic.
4842 Pharmacodynamic stratification of metastatic colorectal
cancer patients using genomic datasets. Sharon Austin, Fang Yin
Lo, Kellie Howard, Mollie McWhorter, Heather Collins, Amanda Leonti,
Lindsey Maassel, Christopher Subia, Tuuli Saloranta, Nicole Heying,
Leila Ritter, Kerry Deutsch, James Cox, Steven Anderson, Anup
Madan, Timothy Yeatman.
4843 A next generation sequencing (NGS) genome wide copy
number variation (CNV) assay for comparison of circulating tumor
cell (CTC) heterogeneity. Stephanie Green, Mark Landers, Jessica
Louw, Adam Jendrisak, Ryan Dittamore, Dena Marrinucci.
4844 High throughput detection of PRKD1 mutations in
salivary gland tumors using in situ mutation detection in tissue
microarrays. Piotr T. Wysocki, William H. Westra, Shahnaz Begum,
David Sidransky, Mariana Brait.
4845 Microarray analysis of melanoma autologous tumor cell
lines used as the source of tumor associated antigens in patientspecific dendritic cell immunotherapy phase II trial in patients with
metastatic melanoma. Andrew N. Cornforth, Gary Fogel, Denysha
Carbonell, Robert O. Dillman.
4846 Automated RNA and DNA purification from FFPE
samples. Michelle Mandrekar, Douglas Horejsh, Samantha Lewis,
Chris Moreland, Marjeta Urh.
4847 Identifying molecular targets and mechanisms of
treatment resistance in inflammatory breast cancer (IBC) using
next-generation sequencing (NGS) and reverse-phase protein
microarrays (RPMA). Laura K. Austin, Keithe Shensky, Juan Palazzo,
Tiffany Avery, Rebecca Jaslow, Corrine Ramos, Nicholas Hoke,
Emanuel Petricoin, Massimo Cristofanilli.
4848 SNP array reveals a new deletion of JAK2 in AML
patients. Viviana Guadagnuolo, Maria Chiara Fontana, Antonella
Padella, Ilaria Iacobucci, Cristina Papayannidis, Giorgia Simonetti,
Anna Ferrari, Giovanni Marconi, Stefania Paolini, Maria Chiara
Abbenante, Sarah Parisi, Francesca Volpato, Chiara Sartor, Emanuela
Ottaviani, Massimo Delledonne, Michele Cavo, Guido Biasco, Giovanni
Martinelli.
AACR ANNUAL MEETING 2015
POSTER SESSION
Poster Section 5 • Wednesday, 8:00 AM-12:00 PM
Molecular and Cellular Biology
Methods and Tools in Computational Cancer Biology
(not eligible for CME credit)
Poster
Board
Abstract
Number
Poster
Board
1.
4849 GenomeSpace: An environment for frictionless
bioinformatics. Michael M. Reich.
2.
4850 Identifying copy number alterations from
targeted sequencing data. Bernard Fendler, Ryan Abo,
Samuel Hunter, Matthew Ducar, Elizabeth Garcia, Paul Van
Hummelen, Neal Lindeman, Laura MacConaill.
3.
4851 BubbleTree: an intuitive visualization to elucidate
tumoral aneuploidy and clonality in somatic mosaicism
using copy number ratio and allele frequency. Wei Zhu,
Mike Kuziora, Chris Morehouse, Tianwei Zhang, Yinong
Sebastian, Zheng Liu, Dong Shen, Jiaqi Huang, Zhengwei
Dong, Yi Gu, Feng Xue, Liyan Jiang, Yihong Yao, Brandon W.
Higgs.
Abstract
Number
16.
4864 VarDict: A novel and versatile variant caller for
next-generation sequencing in cancer research. Zhongwu
Lai, Aleksandra Markovets, Miika Ahdesmaki, Justin Johnson.
17.
4865 PhyloSpan: using multi[[Unsupported Character Codename ­]]-mutation reads to resolve subclonal
architectures from heterogeneous tumor samples. Amit G.
Deshwar, Levi Boyles, Jeff Wintersinger, Paul C. Boutros, Yee
Whye Teh, Quaid Morris.
18.
4866 Modeling synergistic anti-PD-1 immunotherapy
combinations with virtual tumor. Frances A. Brightman,
David Orrell, Eric Fernandez, Christophe Chassagnole.
19.
4867 Comparative analysis of RNA sequencing
methods for characterization of cancer transcriptomics.
Ryan P. Abo, Ling Lin, Samuel S. Hunter, Deniz N. Dolcen,
Rachel R. Paquette, Angelica Laing, Luc de Waal, Aaron R.
Thorner, Matthew D. Ducar, Liuda Ziaugra, William C. Hahn,
Matthew L. Meyerson, Laura E. MacConaill, Paul Van
Hummelen.
4.
4852 Performances evaluation of algorithms for
identifying differentially expressed genes in RNA-seq
data. Chin-Ting Wu, Mong-Hsun Tsai, Tzu-Pin Lu, LiangChuan Lai, Eric Y. Chuang.
5.
4853 A bioinformatics approach to drug discovery:
patient based connectivity mapping. Brooke L. Fridley,
Rama Raghavan, Gottfried E. Konecny, Chen Wang, Ellen L.
Goode, Harsh B. Pathak, Stephen Hyter.
20.
4854 A computational framework for prioritizing
noncoding regulatory variants in cancer. Yao Fu, Zhu Liu,
Shaoke Lou, Vincenza Colonna, Jason Bedford, Xinmeng Mu,
Kevin Y. Yip, Hyun M. Kang, Tuuli Lappalainen, Andrea
Sboner, Haiyuan Yu, 1000 Genomes Project Consortium,
Mark Rubin, Chris Tyler-Smith, Ekta Khurana, Mark Gerstein.
4868 CODEX: a normalization and copy number
variation detection method for whole-exome sequencing.
Yuchao Jiang, Derek A. Oldridge, Sharon J. Diskin, Nancy R.
Zhang.
21.
4869 Validation of a procedure for simultaneous
variant calling and differential expression in cancer study.
Gang Feng, Jamie Osman, Sean Leighton, Lynn Carmichael,
Yuchen Bai, John Begemann, Richard Mazzarella.
7.
4855
22.
8.
4856 ITD Assembler: An algorithm for internal tandem
duplication discovery from short-read sequencing data.
Oliver A. Hampton, Navin Rustagi, Jie Li, Liu Xi, Richard A.
Gibbs, Sharon E. Plon, Marek Kimmel, David A. Wheeler.
4870 GenePool: A cloud-based technology for rapidly
data mining large-scale, patient-derived cancer genomic
cohorts including The Cancer Genome Atlas. Sandeep
Sanga, Antoaneta Vladimirova, Richard D. Goold, Tod M.
Klingler.
9.
4857 The Stanford-Cancer Genome Atlas Portal: A
web/mobile navigation interface for exploring the clinical
associations of cancer drivers. HoJoon Lee, Jennifer Palm,
Hanlee P. Ji.
23.
4871 A new multiple feature approach for rapid and
highly accurate somatic structural variation discovery from
whole cancer genome sequencing. Li C. Xia, John Bell,
Jiamin Chen, Nancy R. Zhang, Hanlee P. Ji.
10.
4858 Cloud-based variant analysis solution using
control-accessed sequencing data. Chunlin Xiao, Eugene
Yaschenko, Stephen Sherry.
24.
4872 Improving bioinformatic analysis pipelines for
calling somatic mutations in tumors and tumor derived cell
lines. Bradley Wubbenhorst.
11.
4859 Development of a cancer transcriptome analysis
toolkit: identification of gene fusions in chronic
lymphocytic leukemia. Nikolaus D. Obholzer, Brian J. Haas,
Dan-Avi Landau, Nathalie Pochet, Aviv Regev, Catherine Wu.
25.
4873 Epicopy: Measuring DNA copy number variation
using high-density methylation microarrays. Soonweng
Cho, Hyun-seok Kim, Leslie M. Cope, Christopher B. Umbricht.
12.
4860 Detection of genetically distinct subclones in
cancer: a novel NGS algorithm with high spatial and
genetic resolution. Konstantinos Karagiannis, Konstantin
Chumakov, Vahan Simonyan, Raja Mazumder.
26.
4874 OASIS: A centralized portal for cancer omics data
analysis. Julio Fernandez-Banet, Anthony Esposito, Scott
Coffin, Sabine Schefzick, Ying Ding, Keith Ching, Istvan
Horvath, Peter Roberts, Paul Rejto, Zhengyan Kan.
13.
4861 Hybrid clustering methodologies to distinguish
CNAs and/or SNVs that drive subclonal differentiation in
samples from a breast cancer patient primary tumor and
metastatic lymph nodes. Mia D. Champion, Princy Francis,
Barbara A. Pockaj, Michael T. Barrett.
27.
4875 HIVE Proteomics: Integrated, cloud-based RNASeq and proteomics analysis of prostate adenocarcinoma
samples. Hayley Dingerdissen, Raja Mazumder.
28.
4876 An integrated pipeline for detecting and
characterizing structural variation in cancer. Minita Shah,
Dayna M. Oschwald, Soren Germer, Michael C. Zody, Toby
Bloom, Anne-Katrin Emde.
29.
4877 A modular software solution (under
development) to expedite sequencing workflow and
mitigate legacy workflow issues in regulatory
environments. Lisa Kelly, Jessica Gordon.
6.
DBGC: database of gastric cancer. Yingyan Yu.
14.
4862 PredICT: a novel solution for capturing,
assembling and combining in vivo data. Rhys D. Jones,
Marie Cooke, James Hinchliffe, Justin Morley, Simon T. Barry.
15.
4863 Streamlining NGS workflows using cancer
samples by the application of the DNA Integrity Number
(DIN) from the Genomic DNA ScreenTape assay. Eva
Schmidt, Isabell Pechtl, Barry McHoull, Melissa Liu.
April 18-22, 2015 • Philadelphia, PA
Poster
:LJ[PVU
5
5
581
POSTER SESSION
Poster Section 6 • Wednesday, 8:00 AM-12:00 PM
Molecular and Cellular Biology
Poster
:LJ[PVU
6
6
New Developments in Sequencing
(not eligible for CME credit)
Poster
Board
1.
2.
3.
4.
5.
6.
7.
8.
9.
10.
11.
12.
13.
14.
582
Abstract
Number
4878 Analytical and technical validation of a costeffective diagnostic test for BRCA1, BRCA2 and TP53.
Manimala Sen, Pooja Agrawal, Vikram Vittal P., Mithua
Ghosh, M.L. Sheela, Divya Vishwanath, Kiran Kumari, Swetha
N.S.N., Vaibhavi Pathak, Gouri Deshpande, Ashraf Mannan,
Rupali Gadkari, Suman Kapoor, Jamuna Yadhav, Mohammed
Yousuff, Satish Sankaran, Ramesh Hariharan, Preveen
Ramamoorthy, Kalyanasundaram Subramanian, Vaijayanti
Gupta.
4879 Reducing amplification artifacts in highly
multiplex amplicon sequencing by using molecular
barcodes. Quan Peng, Ravi Vijaya Satya, Marcus Lewis,
Pranay Randad, John DiCarlo, Yexun Wang.
4880 Characterization of genetic concordance between
primary tumor cells, circulating tumor cells, and
metastatic tumor cells from patients with prostate cancer.
Lixin Yang, Linling Chen, Yafan Wang, Jeremy Jones, Yun
Yen, Sofia Loera, Raju Pillai, Peiguo Chu, Dennis
Weisenburger.
4881 Analysis of long-noncoding RNA interaction at
chromatin by chromatin isolation by RNA purification
(ChIRP). Kan Saito, Konstantin Taganov, John M. Rosenfeld,
Nick Asbrock, Vi Chu.
4882 Megabase-scale phased haplotypes of genetic
aberrations from whole cancer genome sequencing of
primary colorectal tumors. Billy Lau, John M. Bell, Michael
Schnall-Levin, Mirna Jarosz, Erik Hopmans, Christina M.
Wood, Grace X. Zheng, Kristina Giorda, Hanlee P. Ji.
4883 A novel target capture approach for next
generation sequencing and its application to oncogenic
mutation detection. Yanxia Bei, Brendan Galvin, Cynthia
Richard.
4884 Highly sensitive fusion transcript detection and
quantification in cancer. Lisa C. Watson, Stephen M. Gross,
Irina Khrevtukova, Smita Pathak, Claire Attwooll, Jason
Goode, Anthony Mai, Gary P. Schroth.
4885 TOMA OS-Seq: A clinically oriented targeted
resequencing method for detecting all mutation classes in
DNA isolated from FFPE, FNAs and plasma. Yosr Bouhlal,
Alexander McKenzie, Austin P. So.
4886 Repair of challenging FFPE DNA improves library
success rate and sequencing quality. Pingfang Liu, Lixin
Chen, Laurence Ettwiller, Christine Sumner, Fiona Stewart,
Eileen Dimalanta, Theodore Davis, Thomas Evans.
4887 TCR profiling of T lymphocytes in ovarian tumors
and malignant ascites using next-generation sequencing.
Miran Jang, Poh-Yin Yew, Kosei Hasegawa, Yuji Ikeda, Keiichi
Fujiwara, Gini F. Fleming, Yusuke Nakamura, Jae-Hyun Park.
4888 Clinical sequencing in the National Institute of
Health’s Clinical Sequencing Exploratory Research (CSER)
Program. Catherine Crawford, Charlisse Caga-Anan, Dave
Kaufman, Alexander Lee, Jean Mcewen, Sheri Schully,
Carolyn Hutter, Lucia Hindorff.
4889 Clonal structure analysis of cancer genomes at
single molecule resolution. Billy Lau, Hanlee Ji.
4890 Duplex sequencing of AML reveals extensive sub
clonal heterogeneity. Lawrence A. Loeb, Michael W. Schmitt,
Mark J. Prindle, Pamela S. Becker.
4891 Comprehensive genetic profiling of chromosomal
translocations in lung cancer tumors: development and
validation of a next-generation sequencing panel in an
international multicenter study. Pierre Laurent - Puig, Jose
Louis Costa, Orla Sheils, Bastiaan Tops, Andrea Mafficini,
Delphine Le Corre, Henriette Kurth, Anna Maria Rachiglio,
Helene Blons, Eliana Amato, Christoph Noppen, Renato
Franco, Anne Reiman, Roy Bastien, Noah Welker, Jose Carlos
Machado, Ian Cree, Harriet Feilotter, Marjolijn Ligtenberg,
Aldo Scarpa, Nicola Normanno, Kazuto Nishio, Cecily Vaughn.
Poster
Board
15.
16.
17.
18.
20.
21.
22.
23.
24.
25.
26.
27.
Abstract
Number
4892 Methods for accurate reporting of confidence
intervals in clinical applications of next generation
sequencing (NGS). Erin L. Crawford, Thomas Blomquist,
James C. Willey.
4893 High-throughput mutation sequencing of the full
exon regions in BRCA1 and BRCA2 genes using
nanofluidic-PCR prepared libraries. Jun Wang, Guoli Li,
Ming Chen, Jianfu Heng, Xinwu Guo, Limin Peng, Fan Zhang,
Zibo Li, Shouman Wang, Zhi Xiao, Lizhong Dai, Wenjun Yi, Lili
Tang.
4894 Targeted sequencing of myeloid cancers using
single-molecule enrichment in picodroplets. Michael L.
Samuels, Steve K. Kotsopoulos, Frances Long, Holly Gettler,
Omo Clement, Jeff Olson.
4895 A one-tube assay for simultaneous detection of
gene mutation, fusion, copy number alteration and
expression. Zongli Zheng, Ranjit Shetty, Matthew Liebers,
Jessica L. Cambry, Lindsay A. Bernardo, Darrell Borger, Long
P. Le, John A. Iafrate.
4897 Accurate variant detection using molecular
barcodes. Charmian Cher, Henrik Johansson, Javelin Chi,
Katie Zobeck, Linus Forsmark, Magnus Isaksson, Holly
Hogrefe.
4898 Full-length isoform sequencing of the human
MCF-7 cell line using PacBio long reads. Elizabeth Tseng,
Tyson Clark, Meredith H. Ashby, Gloria Shenykman.
4899 Tumor T-cell receptor (TCR) diversity elucidates
the immune response to genetic alterations of muscleinvasive bladder cancer. Noura Choudhury, Kai Lee Yap,
Kazuma Kiyotani, Poh Yin Yew, Alexa Campanile, Tatjana
Antic, Gary Steinberg, Jae-Hyun Park, Peter H. O’Donnell,
Yusuke Nakamura.
4900 A highly multiplexed control material to satisfy
the complex needs of targeted next generation
sequencing (NGS) oncology assays. Nakul Nataraj, Mona D.
Shahbazian, Aron Lau, Mahjabeen Yucekul, Patty Chiang,
Suzy V. Le, Kara Norman.
4901 Comparison of gene expression platforms: RNASeq, Fluidigm, and Nanostring. Erica B. Schleifman, Maipelo
Motlhabi, Craig Cummings, Rin Nakamura, Linda Bosch,
Rajesh Patel, An Do, Andrew Watson, Thomas Sandmann,
Walter Darbonne, Ian McCaffery, Eric Peters, Rajiv Raja.
4902 Detecting low abundant mutations in circulating
cell free DNA and FFPE samples. Julie Laliberte, Catherine
Couture, Vladimir Makarov, Cassie Schumacher, Sukhinder
Sandhu, Laurie Kurihara, Timothy Harkins.
4903 Microarray gene expression analysis of human
prostate cancer PC-3 cells targeted by Salmonella
typhimurium A1-R. Ming Zhao, Wen Wu, Chongyi Lu, Yong
Zhang, Robert M. Hoffman, Hui Qi, Meng Yang, Yanqin Gu,
Yiyu Lu, Shibing Su, Hui Zhang, Qianmei Zhou, Qilong Chen.
4904 Developing a universal target retrieval solution
and protocol for RNA in situ hybridization based on
RNAscope technology. Li-chong Wang, Liuliu Pan, KuangJung Chang, Daniel Kim, Xingyong Wu, Hongwei Wang,
Casey Kernag, Bingqing Zhang, Mingxiao He, Nan Su, XiaoJun Ma, Yuling Luo.
AACR ANNUAL MEETING 2015
POSTER SESSION
Poster Section 7 • Wednesday, 8:00 AM-12:00 PM
Molecular and Cellular Biology
New Technologies to Identify Genetic Alterations
(not eligible for CME credit)
Poster
Board
Abstract
Number
Poster
Board
Abstract
Number
1.
4905 Comprehensive genomic analyses of oral squamous cell
carcinoma tissues by semiconductor-based next-generation
sequencing. Takafumi Nakagaki, Yasushi Sasaki, Kenta Kobashi, Kousuke
Takeda, Miyuki Tamura, Tomoko Ohashi, Kazuhiro Ogi, Masashi Idogawa,
Hiroyoshi Hiratsuka, Takashi Tokino.
14.
4918 Concordance of circulating tumor DNA (ctDNA) and nextgeneration sequencing (NGS) as molecular monitoring tools in
metastatic breast cancer (MBC). Laura K. Austin, Tiffany Avery, Rebecca
Jaslow, Paolo Fortina, Dragan Sebisanovic, LaiMun Siew, Aubrey Zapanta,
AmirAli Talasaz, Massimo Cristofanilli.
2.
4906 TP53 mutations are mutually exclusive with FLT3 and NPM
mutations in AML patients and are strongly associated with complex
karyotype and poor outcome. Anna Ferrari, Cristina Papayannidis, Elisa
Zuffa, Carmen Baldazzi, Antonella Padella, Eugenia Franchini, Ilaria
Iacobucci, Stefania Paolini, Viviana Guadagnuolo, Margherita Perricone,
Valentina Robustelli, Claudia Venturi, Maria Chiara Abbenante, Sarah
Parisi, Chiara Sartor, Francesca Volpato, Federica Cattina, Giorgia
Simonetti, Maria Chiara Fontana, Maria Teresa Bochicchio, Federica
Frabetti, Elisa Lani, Katia Mancuso, Beatrice Zannetti, Simona Luatti,
Emanuela Ottaviani, Nicoletta Testoni, Giovanni Martinelli.
15.
4919 Tumor heterogeneity represented in human cancer cell lines.
Lysa-Anne Volpe, John Foulke, Michael Jackson, Luping Chen, David H.
Randle, Hannah J. Gitschier, Kelly Gardner, Fang Tian.
16.
4920 The detection of circulating tumor DNA using Quantstudio
3D digital PCR. Adam H. Greer, Glenn Mills, Hong Yin.
17.
4921 Next-generation sequencing as a potential tool in the
diagnostics of APC mosaicism in FAP patient. Kiyoshi Yamaguchi,
Mitsuhiro Komura, Rui Yamaguchi, Seiya Imoto, Eigo Shimizu, Shinichi
Kasuya, Tetsuo Shibuya, Seira Hatakeyama, Norihiko Takahashi, Tsuneo
Ikenoue, Keisuke Hata, Giichiro Tsurita, Masaru Shinozaki, Yutaka Suzuki,
Sumio Sugano, Satoru Miyano, Yoichi Furukawa.
18.
4922 Analysis of copy number changes in HNSCC by MLPA. Nejat
Dalay, Orkun Gurbuz, Elif Baltaci, Emin Karaman, Nur Buyru.
19.
4923 Detecting copy number variation using dNTP limited PCR
and high-resolution melting. Luming Zhou, Bobert Palais, Carl Wittwer.
20.
4909 Increased IR-A/IR-B ratio in non-small cell lung cancers
associates with lower epithelial-mesenchymal transition signature and
longer survival in squamous cell lung carcinoma. Jiaqi Huang, Wei Zhu,
Liyan Jiang, Katie Streicher, Chris Morehouse, Philip Brohawn, XiaoXiao
Ge, Zhengwei Dong, Xiaolu Yin, Guanshan Zhu, Yi Gu, Parthiv Mahadevia,
Brandon W. Higgs, Yihong Yao.
4924 Multiparameter ploidy profiling: a powerful tool to
investigate the genomics of diploid tumor populations. Thomas Lorber,
Sabrina Rau, Valeria Perrina, Michael Barrett, Christian Ruiz, Lukas
Bubendorf.
21.
4925 Liquid biopsy using the ion AmpliSeq v2 cancer panel.
WeiHua Liu, Zhenyu Yan, Candice L. Horn, Fabio Nunes, Steven M. Bray,
Philip J. Ebert, Peng Fang, Jennifer Biroschak, Cindy Spittle, Chad
Galderisi, Jin Li.
6.
4910 Sensitive, specific and highly multiplexed mutation
detection for cancer management. Lit Yeen Tan, Elisa Mokany, Samantha
Walker, Tina Lonergan, Alison Todd.
22.
4926 EML4-ALK pre-mRNA and mature mRNA fusion detection
using RNA fluorescence in situ hybridization (RNA FISH). Sally R.
Coassin, Byung-Chul Kim, Hans E. Johansson.
7.
4911 Mutually exclusive FGFR2, HER2, and KRAS gene
amplifications in gastric cancer revealed by multicolor FISH. Kakoli Das,
Bavani Gunasegaran, Iain Beehuat Tan, Niantao Deng, Kiat Hon Lim,
Patrick Tan.
23.
8.
4912 Screening of multiplex gene mutations using cell-free DNA
in lung cancer patients. Nak-Jung Kwon, Jae Sook Sung, Ahreum Seong,
Hyunmi Kim, Woo Chung Lee, Yeul Hong Kim, Kap-Seok Yang, Jeong-Sun
Seo.
4927 Next-generation sequencing enables new approach to
molecular cytogenetics. Jie He, Jeffrey Gardner, James X. Sun, Omar
Abdel-Wahab, Andrew M. Intlekofer, Michelle K. Nahas, Jo-Anne Vergilio,
Jeffery S. Ross, Roman Yelenskey, Ross Levine, Geoff Otto, Doron Lipson,
Vincent Miller, Philip Stephens.
24.
4913 Highly complex oligonucleotide libraries for use in highresolution RNA and RNA/DNA fluorescence in situ hybridization in
various sample types. Robert A. Ach, Mistuni Ghosh, Peter Tsang, Alicia
Scheffer-Wong, Laurakay Bruhn, Alice Yamada.
4928 Clinical utility of circulating tumor DNA (ctDNA) in advanced
and metastatic breast cancer. Laura K. Austin, Rebecca Jaslow, Tiffany
Avery, Paolo Fortina, Dragan Sebisanovic, LaiMun Siew, Aubrey Zapanta,
AmirAli Talasaz, Massimo Cristofanilli.
25.
4929 An ARMS PCR assay for detection of PI3KCA mutations in
FFPE tumor samples. Dehua D. Yu.
3.
4.
5.
9.
4907 The Emerging technology of Yb2Ti2O7 electrolyte-insulatorsemiconductor biosensors for rapid screening of targeted mutation.
Jhou Cheng Han, Kao Shin Hsun, Pang Sow Neng, Pan Tung Ming, Weng
Wen Hui.
4908 Establishment of multiplexed ultra-sensitive detection of
epidermal growth factor receptor mutations using picodroplet digital
PCR. Hiroaki Akamatsu, Yasuhiro Koh, Masaru Watanabe, Takashi Kikuchi,
Masanori Nakanishi, Kazuto Matsunaga, Nobuyuki Yamamoto.
10.
4914
Polymorphism analysis of the enzymes MTHF and DPD
mutation in patients with colorectal cancer submitted to chemotherapy
treatment with 5-Fluorouracil (5-FU). Diego M. de Souza.
26.
4930 Next generation sequencing performance for the detection
of mutations in plasma cell free DNA. Ana Justino, Gabriela Fernandes,
Ana Barroso, Barbara Parente, Venceslau Hespanhol, Jose C. Machado,
Jose L. Costa.
11.
4915 Tracking genomic alterations in young patients with head
and neck carcinomas using whole-exome sequencing. Priscila M.
Miranda, Fabio A. Marchi, Maísa Pinheiro, Luiz P. Kowalski, Silvia R.
Rogatto.
27.
4931 A circulating cell free DNA workflow for targeted sequencing
- from isolation through validation. Dalia Dhingra, Xingwang Fang, Matt
Carter, Dumitru Brinza, Charles Scafe, Christopher Davies, Fiona Hyland.
12.
4916 Development of a NGS-based method for EGFRvIII
detection: sequence analysis of the junction. Jianhua Zhao, Shrey
Sukhadia, Alan Fox, David Lieberman, Barnett Li, Robert D. Daber,
Matthew C. Hiemenz, David B. Roth, Maria Martinez-Large, Arati Desai,
Donald M. O’Rourke, Marcela V. Maus, Jennifer J. Morrissette.
28.
4932 Development of a highly sensitive library prep method for
identifying pathogenic variants from FFPE tumor samples. Amanda G.
Young, Charles Lin.
29.
4933 Sanger sequencing of low amount of genomic DNA and FFPE
DNA with PCR primers derived from the Ion AmpliSeq cancer hotspot
panel. Edgar H. Schreiber, Adam Broomer, Mark Andersen, Kamini Varma.
30.
4934 Mosaic RNase IIIb domain DICER1 mutations in children with
multiple primary tumors. Leanne de Kock, Barbara Rivera Polo, Mona Wu,
Evan Weber, Claudio Sandoval, Saskia M. Hopman, J. Hans M. Merks, Annet
van Hagen, D. A. Plager, Nelly Sabbaghian, Nancy Hamel, Dorothée
Bouron-Dal Soglio, John R. Priest, William D. Foulkes.
13.
4917 Identification of genetic heterogeneity by whole exome
sequencing using cell free DNA from blood samples. Kayo Asada,
Katsutoshi Oda, Kengo Gotoh, Reiko Kurikawa, Shogo Yamamoto, Kenji
Tatsuno, Hiroki Ueda, Yuji Ikeda, Yuriko Uehara, Kenbun Sone, Osamu
Hiraike-Wada, Kei Kawana, Tetsu Yano, Yutaka Osuga, Tomoyuki Fujii,
Hiroyuki Aburatani.
April 18-22, 2015 • Philadelphia, PA
Poster
:LJ[PVU
7
7
583
POSTER SESSION
Poster Section 8 • Wednesday, 8:00 AM-12:00 PM
Molecular and Cellular Biology
Poster
:LJ[PVU
8
8
Oncogenes and Tumor Suppressors 3
(not eligible for CME credit)
Poster
Board
2.
4.
5.
6.
7.
8.
9.
10.
11.
12.
13.
14.
15.
16.
584
Abstract
Number
4936 The interaction and effects of hypoxia,
surrounding fibroblasts and p16 expression on breast
cancer cell migration and invasion. Yi Lu, Jun Zhang.
4938 APC in breast cancer: the ABCs of gene
expression. Katia Fernandez Soto, Monica K.
VanKlompenberg, Jennifer Cole, Jenifer R. Prosperi.
4939 The baffling effect of bafilomycin on Notch
signaling in triple-negative breast cancer. Sahithi
Pamarthy, Mukesh K. Jaiswal, Arpita Kulshrestha, Gajendra
Katara, Safaa Ibrahim, Alice Gilman-Sachs, Kenneth D.
Beaman.
4940 Role of Smad3 linker phosphorylation in breast
cancer progression. Fang Liu, Wen Xie, Zhengxue Liu,
Tanima Roy, Eunjin Bae, Lalage M. Wakefield, Seong-Jin Kim,
Akira Ooshima, Michael Reiss, Isao Matsuura.
4941 Profilin-1 is a key determinant for tumorigenic
potential of breast cancer cells. Chang Jiang, Zhijie Ding,
Marion Joy, Laura Vollmer, Dave Gau, Su Hyeong Kim,
Shivendra Singh, Andreas Vogt, Partha Roy.
4942 Activation of Phosphatase toward the
Retinoblastoma protein in breast and colorectal cancer cell
spheroids. Jacklynn Egger, Lisa Antonucci, Maria Lane,
Nancy A. Krucher.
4943 Engulfment gene GULP1 is a functional tumor
suppressor through influencing TGF-␤ pathway and is
silenced by promoter methylation in urothelial carcinoma.
Masamichi Hayashi, Leonardo O. Reis, Alexander Baras,
Leonel Maldonado, Eliza Guida, Evgeny Izumchenko, Mariana
Brait, Trinity Bivalacqua, George J. Netto, Wayne Koch, David
Sidransky, Mohammad O. Hoque.
4944 Identification of B-cell lymphoma 6 as a novel
therapeutic target in glioblastoma. Ye Chen, Liang Xu,
Masaharu Hazawa, Anand M. Thippeswamy, Henry Yang,
Markus Müschen, De-Chen Lin, Phillip Koeffler.
4945 A novel role for drebrin in regulating progranulin
bioactivity in bladder cancer. Shi-Qiong Xu, Simone
Buraschi, Alaide Morcavallo, Marco Genua, Tomoaki Shirao,
Stephen C. Peiper, Leonard G. Gomella, Antonino Belfiore,
Renato V. Iozzo, Andrea Morrione.
4946 Investigating candidate genomic alteration which
affects the local recurrence in patients with desmoid
fibromatosis. Sehhoon Park, Youngil Koh, Se-Hoon Lee,
Chan-Young Ock, Bhumsuk Keam, Tae Min Kim, Dong-Wan
Kim, Dae Seog Heo.
4947 HACE1 is a putative tumor suppressor gene in
B-cell lymphomagenesis down-regulated by both
deletion and epigenetic mechanisms. Abdelilah
Bouzelfen, Marion Alcantara, Hafid Kora, Philippe Bertrand,
Sylvain Mareschal, Elodie Bohers, Catherine Maingonnat,
Philippe Ruminy, Sahil Adriouch, Gaetan Riou, Martin Figeac,
Thierry Fest, Christian Bastard, Hervé Tilly, Jean-Baptiste
Latouche, Fabrice Jardin.
4948 The cytosolic domain of a disintergrin and
metalloprotease (ADAM) 15 promotes non-small cell lung
cancer (NSCLC) proliferation. Hsin-Han Hou.
4949 HAS2 is a critical effector for AGL mediated
regulation of tumor growth. Sunny Guin, Yuanbin Ru,
Carolyn R. Lew, Neeraj Agarwal, Charles Owens, Dan
Theodorescu.
4950 Defective expression of partition-defective 3
(PAR-3) is associated with adverse prognostic factors in
esophageal squamous cell carcinoma. Tomoko Kitaichi,
Koichiroh Yasui, Akira Tomie, Yasuyuki Gen, Osamu Dohi, Yuji
Naito, Yoshito Itoh.
Poster
Board
17.
18.
19.
20.
21.
22.
23.
24.
25.
26.
27.
28.
29.
30.
Abstract
Number
4951 Expression analysis of the LOT1 gene in head and
neck cancer. SEDA EKIZOGLU ERATAK, Emin Karaman, NUR
A. BUYRU.
4952 WWOX and LOT1 genes are down-regulated in
non-small cell lung cancer (NSCLC). Onur Baykara, Seda
Ekizoglu Eratak, Kamil Kaynak, Hikmet Koseoglu, Nur Buyru.
4953 Molecular and cellular localization profiles of
tristetraprolin in colorectal cancer: Implications for tumor
progression in diverse patient populations. Esther A.
Suswam, Balananda-Dhurjati K. Putcha, Amit K. Tiwari,
Trafina Jadhav, Kiera D. Walker, Lualhati Harkins, Samir
Amer, Isam-Eldin Eltoum, Sejong Bae, Upender Manne.
4954 Serine/arginine splicing factor 1 (SRSF1)
mediates DNA repair and chemo-sensitivity and drives
growth in small cell lung cancer. Sarah J. Conley, Xin Yao,
Jiaqi Huang, Brandon Higgs, Zhibin Hu, Zhan Xiao, Haihong
Zhong, Zheng Liu, Philip Brohawn, Xiaoxiao Ge, Meggan
Czapiga, Vaheh Oganesyan, Haihua Fu, David Tice, Ronald
Herbst, Xinying Su, Yi Gu, Jianren Gu, Baohui Han, Laura
Richman, Bahija Jallal, Liyan Jiang, Hongbing Shen, Yihong
Yao.
4955 Somatic alteration and depleted nuclear
expression of BAP1 in human esophageal squamous cell
carcinomas. Takahiro Mori, Makiko Sumii, Fumiyoshi
Fujishima, Kazuko Ueno, Masao Nagasaki, Chikashi Ishioka,
Natsuko Chiba.
4956 Hsp27 negatively affects Hippo tumor suppressor
pathway to regulate cell survival in cancer. Sepideh Vahid,
Daksh Thaper, Amina Zoubeidi.
4957 Next generation sequencing demonstrates
association between tumor suppressor gene aberrations
and poor outcome in patients with cancer. Maria
Schwaederle, Gregory A. Daniels, David E. Piccioni, Paul T.
Fanta, Richard B. Schwab, Kelly A. Shimabukuro, Barbara A.
Parker, Razelle Kurzrock.
4958 Melanoma transition is frequently accompanied
by a loss of cytoglobin, a putative tumor suppressor, in
melanocytes. Yoshihiko Fujita, Satoshi Koinuma, Marco De
Velasco, Bolz Jan, Yosuke Togashi, Masato Terashima,
Hidetoshi Hayashi, Takuya Matsuo, Kazuto Nishio.
4959 Klotho suppresses colon cancer through
modulation of the Wnt pathway and unfolded protein
response. Tammi Rubinstein, Shiri Shahmoon, Gil Har Zahav,
Nir Skalka, Tal Etan, Rina Arbesfeld, Metsada Pasmanik-Chor,
Tami Rubinek, Ido Wolf.
4960 ERp46 (thioredoxin domain-containing protein 5,
TXND5) promotes prostate cancer growth in vitro and in
vivo. Jehonathan H. Pinthus, Sarah N. Hopmans, Stephanie
Federov, Wilhelmina C. Duivenvoorden.
4961 Functional analysis of prostate cancer-specific
MED12 mutation. Kati Kämpjärvi, Nam Hee Kim, Min Ju Park,
Mikko Turunen, Netta Mäkinen, Tuomas Heikkinen, Salla
Keskitalo, Markku Varjosalo, Thomas G. Boyer, Pia Vahteristo.
4962 Inhibition of TGF-␤-RUNX3 signaling by activated
Shh is correlated with the development of TGF-␤
resistance in gastric cancer cells. Seong Hye Park, Jung Lim
Kim, Bo Ram Kim, Yoo Jin Na, Sang Cheul Oh.
4963 Prognostic significance of the expression of
nuclear EIF5A2 in human melanoma. Shahram Khosravi,
Magdalena Martinka, Christopher J. Ong.
4964 Nonsense MED12 mutation in a patient with T-cell
acute lymphoblastic leukemia. Tuomas Heikkinen, Kati
Kämpjärvi, Salla Keskitalo, Mikko Turunen, Heikki
Kuusanmäki, Netta Mäkinen, Satu Mustjoki, Caroline
Heckman, Markku Varjosalo, Pia Vahteristo.
AACR ANNUAL MEETING 2015
POSTER SESSION
Poster Section 9 • Wednesday, 8:00 AM-12:00 PM
Molecular and Cellular Biology
Protein and Lipid Modifications in Cancer
Poster
:LJ[PVU
(not eligible for CME credit)
Poster
Board
Abstract
Number
1.
4965 Multiple ubiquitin-conjugating enzymes
modulate the ubiquitination and downregulation of the
EGFR by the Cbl RING finger ubiquitin ligase. Ke Ma, Philip
Ryan, Rachel Klevit, Stanley Lipkowitz.
2.
4966 Identification of deubiquitinating enzyme USP19
as a regulator of EWS/FLI1 protein turnover in Ewing
sarcoma. Maria E. Gierisch, Laura A. Lopez-Garcia, Franziska
Pfistner, Felix K. Niggli, Beat W. Schaefer.
3.
4.
4967 The BAP1 deubiquitinase promotes triplenegative breast cancer partially by stabilizing the KLF5
transcription factor. Ceshi Chen, Junying Qin, Zhongmei
Zhou.
Poster
Board
Abstract
Number
11.
4975 All-trans retinoic acid induces proliferation,
survival and migration in A549 lung cancer cells by
activating the ERK signaling pathway through a
transcription independent mechanism. Reyna S. Quintero
Barceinas, Alejandro García-Regalado, Elena AréchagaOcampo, Claudia H. González-De la Rosa.
12.
4976 Inhibition of eIF4B suppresses the growth and
induces the apoptosis of Bcr-Abl positive cells. Ke Chen,
Jian-Ling Yang, Guijie Guo, Jilong Chen.
13.
4977 Dramatic differences in the extents and patterns
of PKC delta modification among the different members of
the NCI-60 cancer cell line panel. Noemi Kedei, Jin-Qiu
Chen, Michelle Herrmann, Tiffany Hu, Karina Chang, Peter M.
Blumberg.
4968 microRNA-mediated silencing of COP1 and
altered ubiquitination of key oncogenic transcription
factors promote cancer stem cell (CSC) phenotype and
prostate cancer progression. Cecilia Dallavalle, Domenico
Albino, Gianluca Civenni, Laura Curti, Paola Ostano, Maurizia
Mello-Grand, Ramon Garcia-Escudero, Giovanna Chiorino,
Carlo V. Catapano, Giuseppina M. Carbone.
14.
4978 Identification and therapeutic targeting of
signaling pathways in Ruxolitinib resistant cells. Peter P.
Sayeski, Shireen Vali, Ansu Kumar, Neeraj Singh, Susumu
Kobayashi, Taher Abbasi.
15.
5.
4969 Metformin causes AR degradation via Skp2mediated ubiquitination. Joy C. Yang, Allen C. Gao,
Christopher P. Evans.
4979 SIRT1 regulates the function of the KRABassociated protein 1 (KAP1) in DNA damage response
signaling. Yi-Hui Lin, Zhenkun Lou.
16.
6.
4970 USP15 regulates SMURF2 kinetics through C-lobe
mediated deubiquitination. Pieter J. Eichhorn, Prasanna
Iyengar, Patrick Jaynes, Chandra Verma.
4980 Rational design of combination therapies and
block of acquired targeted drug resistance. Hadas Reuveni,
Lana Kuperschmidt, Shani Carmi, Neta Moskovitz, Salomon
Stemmer, Izhak Haviv.
7.
4971 Detection of receptor and non receptor tyrosine
kinases in the culture filtrates of astrocytes and cancer
cells. Venkateswara R. Gogineni.
17.
8.
4972 Investigating the role of Syk in TGF-␤ induced
P-bodies and breast cancer metastasis. Shana D. Hardy,
Robert L. Geahlen.
4981 Angiotensin-(1-7) targets c-Met signaling by
up-regulating the phosphatase PTP1b to reduce triple
negative breast cancer. Guorui Deng, Linda MethenyBarlow, Patricia E. Gallagher, E. Ann Tallant.
18.
4982 Increased core fucosylation, a glycan alteration
associated with cancer, is the result of hepatocyte
dedifferentiation. Anand S. Mehta, Mary Ann Comunale,
Siddhartha Rawat, Jessica Garner, Lucy Betesh, Mengjun
Wang, Laura Steel, Michael Bouchard.
19.
4983 GALNT3 mediated differential MUC4 glycosylation
in the progression of pancreatic cancer. Seema Chugh,
Vinayaga S. Gnanapragassam, Maneesh Jain, Moorthy
Ponnusamy, Surinder K. Batra.
20.
4984 EMT and breast cancer metastasis driven by
plasma membrane fluidity. Jeffrey T. Chang.
9.
10.
4973 A novel cellular class I phosphoinositide-3-kinase
(PI3K) isoform-specific occupancy assay demonstrates a
direct correlation between PI3K isoform activity and
phospho-AKT levels. Lina Gu, Erin Brophy, Erin Murphy,
Bonnie Tillotson, Jonathan DiNitto, Louis Grenier, Janid Ali.
4974 IL-1 receptor-associated kinase-1 and -4
expression in Hodgkin lymphoma. Victoria S. Giffi, Kenisha
M. Younger, Zeba Singh, Qing Chen, Eduardo Davila, Amy S.
Kimball.
April 18-22, 2015 • Philadelphia, PA
9
9
585
POSTER SESSION
Poster Section 10 • Wednesday, 8:00 AM-12:00 PM
Molecular and Cellular Biology
Poster
:LJ[PVU
10
10
Receptor Signaling and Cancer
(not eligible for CME credit)
Poster
Board
1.
4985 Notch1 as a key mediator in promoting advanced
castration-resistant prostate cancer. Tanya Stoyanova,
Claire Faltermeier, Bryan Smith, Andrew Goldstein, Xi Zhang,
Justin Drake, John Lee, Sandra Orellana, Steven Blum,
Donghui Cheng, Kenneth Pienta, Jiaoti Huang, Owen Witte.
2.
4986 Distinct temporal regulation of RET isoform
internalization: Roles of clathrin and AP2. Mathieu J. Crupi,
Piriya Yoganathan, Leslie N. Bone, Eric Lian, Andrew Fetz,
Costin N. Antonescu, Lois M. Mulligan.
3.
4987 IL8, VEGF and IGF-1 rescue ovarian cancer cells
undergoing ARHI-mediated- autophagic cell death. Zhen
Lu, Aaron F. Orozco, Margie Sutton, Wang Yan, Weiqun Mao,
Robert Bast.
4.
4988 A7 nicotinic acetylcholine receptor mediated the
chemosensitivity of gastric cancer cells. Chien-Yu Huang,
Yu-Jia Chang.
5.
4989 Cannabinoid receptor 2 and C-X-C chemokine
receptor 4 interact to abrogate CXCL12-mediated cellular
response. Christopher Coke, Ahriea Johnson, Kia Jones,
Cimona Hinton.
6.
4990 The RET receptor Y791F variant activates the
kinase but diminishes ligand responsiveness. Andrew Fetz,
Mathieu J. Crupi, Eric Lian, Brandy D. Hyndman, Lois M.
Mulligan.
Poster
Board
Abstract
Number
13.
4997 Phosphorylation of SLAP by the KIT-D816V
oncogenic mutant suppresses SLAP-mediated negative
regulation of KIT signaling. Julhash U. Kazi, Jianmin Sun,
Lars Rönnstrand.
14.
4998 Novel N-glycosilation inhibitor blocks
proliferation of EGFR-dependent NSCLC. Cecilia Lopez
Sambrooks, Joseph N. Contessa.
15.
4999 Signaling-associated complexes to define
targetable vulnerabilities in lung cancer. Matthew Smith,
Thomas Licata, Yun Bai, Guolin Zhang, Vincent Vuaroqueaux,
Heinz-Herbert Fiebig, Eric B. Haura.
16.
5000 The heterogeneous expression and functional
relationship of ALK and NLRR1 in neuroblastoma. Shunpei
Satoh, Atsushi Takatori, Atsushi Ogura, Miki Ohira, Shamim
M. Hossain, Katsuyoshi Koh, Hiroshi Kishimoto, Ryoji Hanada,
Akira Nakagawara.
17.
5001 High dose IL-2 (HDIL-2) results in increased PD-1
expression on CD45RA-CCR7-CD8+ and CD45RA-CCR7CD4+ T cells in melanoma patients. Maggie L. Diller, Susan
Maio, Cabell E. Eysmans, David Lawson, Keith A. Delman,
Ragini R. Kudchadkar, Mandy L. Ford.
18.
5002 Abstract Submission. Swati Acharya, Kira Y.
Petersen, Vladislav Golubkov, Mandy Kwong, Christopher M.
Adams, Peter K. Jackson, David B. Lewis.
7.
4991 RET and integrins cooperate in cellmicroenvironment response. Eric Lian, Mathieu J. Crupi,
Jessica G. Cockburn, Simona M. Wagner, Anirudh Goel, Lois
M. Mulligan.
19.
5003 Differential expression of lysophosphatidic acid
receptors (LPARs) between benign and malignant tissues
in humans. Andrew Bingham, Jinghe Mao, Chunyi Wang,
Janice Lage, Xinchun Zhou.
8.
4992 Nicotinic acetylcholine receptor ␣5 mediates
low-dose nicotine-dependent regulation of tumorigenesis
in lung adenocarcinoma cells. Mong-Lien L. Wang, Yi-Fan
Hsu, Chih-Hsuan Liu, Cheng-Wen Wu.
20.
9.
4993 ␤-arrestin-2 regulates CXCR7-mediated EGFR
transactivation and tumor cell proliferation in prostate
cancer cells. Georgios Kallifatidis, Daniel Munoz, Rajendra K.
Singh, Bal L. Lokeshwar.
5004 Expression profiling of receptor tyrosine kinases
in high-grade neuroendocrine carcinoma of the lung: A
comparative analysis with adenocarcinoma and squamous
cell carcinoma. Yuki Matsumura, Shigeki Umemura,
Genichiro Ishii, Koji Tsuta, Shingo Mastsumoto, Keiju Aokage,
Tomoyuki Hishida, Junji Yoshida, Yuichiro Ohe, Hiroyuki
Suzuki, Atsushi Ochiai, Koichi Goto, Kanji Nagai, Katsuya
Tsuchihara.
10.
4994 RET isoforms differentially contribute to focal
adhesion formation. Piriya Yoganathan, Eric Lian, Lois M.
Mulligan.
21.
5005 Androgen-mediated genomic and non-genomic
regulation of TRPM8 in prostate cancer. Swapna Asuthkar,
Eleonora Zakharian.
11.
4995 HO1 induction interrupts the glucocorticoid
receptor signaling in prostate cancer cells. Daiana B.
Leonardi, Alejandra V. Paez, Federico Schuster, Nicolas
Anselmino, Javier N. Brandani, Mercedes Abbate, Geraldine
Gueron, Javier H. Cotignola, Elba S. Vazquez.
22.
5006 Elucidating the mechanism of bile acid-induced
activation of estrogen receptor ␤ in colorectal
adenocarcinoma. Jesse Trujillo.
23.
5007 A novel polyisoprenylated cysteinyl amide
inhibitor, NSL-BA-055, selectively inhibits proliferation of
hepatocellular carcinoma cells. Michelle K. Naidoo, Nazarius
Lamango, Olorunseun O. Ogunwobi.
24.
5008 The H1047R point mutation in p110 alpha of PI3K
decrease Bcl2 expression in human colon cancer HCT116
cells. Guanghua Wan, Ashwani Rajput.
12.
586
Abstract
Number
4996 Expression of the estrogen receptor,
progesterone receptor and PTEN in endometrial cancers
from women with type II diabetes mellitus. Dario R. Roque,
Arthur M. Dizon, Brooke Rambally, Siobhan O’Connor, Paola
A. Gehrig, Sheri A. Denslow, Victoria L. Bae-Jump.
AACR ANNUAL MEETING 2015
POSTER SESSION
Poster Section 11 • Wednesday, 8:00 AM-12:00 PM
Immunology
Therapeutics and Therapeutic Models
Poster
:LJ[PVU
(not eligible for CME credit)
Poster
Board
1.
2.
3.
4.
5.
6.
7.
8.
9.
10.
11.
12.
13.
14.
15.
Abstract
Number
5009 NKG2D receptor stimulation of effector CD8+ T
cells alters the transcriptome and activation of mTOR to
enhance anti-tumor immunity. Kelsey Trace, Sara Jacobson,
Amorette E. Barber.
5010 A versatile tool to study immune checkpoint
therapeutics: Syngenic tumor mouse models in vivo.
Cynthia Schaefer-Obodozie, Peter Jantscheff, Sandra Moor,
Steffen Hoffmann, Tihomir Saso, Christoph Schaechtele,
Holger Weber.
5011 Generation of rejuvenated murine antigenspecific T cells by reprogramming to pluripotency and
redifferentiation. Fumito Ito, Noemi Fusaki, Hidehito
Saito.
5012 Establishment of a transplantable, NY-BR-1
expressing breast cancer model in HLA-transgenic mice.
Krishna Das, Adriane Gardyan, Mathias Vormehr, Karin
Mueller-Decker, Inka Zörnig, Dirk Jäger, Wolfram Osen,
Stefan B. Eichmüller.
5013 Toward better selection of PD-1 blockade
responders through direct markers of adaptive immune
resistance. Daniel S. Shin, Angel Garcia-Diaz, Helena EscuinOrdinas, Nicolaos J. Palaskas, Sara M. Komenan, Thomas G.
Graeber, Begonya Comin-Anduix, Antoni Ribas.
5014 Neutrophils protect B-cell lymphomas against
chemotherapy via cell-cell interactions mediated by CD44
and ICAM1 receptors. Taghreed Hirz, Justine Esmenjaud,
Anne Evesque, Doriane Mathe-Poloni, Charles Dumontet.
5015 Tumor dependence on HER2 signaling as a player
in immune infiltration required for trastuzumab activity.
Tiziana Triulzi, Viola Regondi, Loris De Cecco, Gaia Ghedini,
Maria Luisa Carcangiu, Serenella M. Pupa, Elda Tagliabue.
5016 Short-term blockade of EGF signaling improves
immune-mediated cytotoxicity of NSCLC cells. Charli
Dominguez.
5017 The discovery of novel therapeutics that restore
antigen processing pathways in immune-edited
metastatic cancers. Lilian Nohara, Reinhard Gabathuler, Paul
Ahn, Ping Cheng, David Williams, Raymond Andersen,
Wilfred A. Jefferies.
5018 HLA class I expression in a tumor is higher than
that out of a tumor: Promising new findings for antigenspecific cancer immunotherapy. Daisule Nobuoka, Mari
Takahashi, Toshiaki Yoshikawa, Takahito Yagi, Toshiyoshi
Fujiwara, Tetsuya Nakatsura.
5019 Characterization of sentinel node-derived
antibodies from breast cancer patients. Girja S. Shukla,
Stephanie C. Pero, Yu-Jing Sun, Chelsea L. Carman, David N.
Krag.
5020 Neutrophils in the bone marrow niche promote
multiple myeloma chemoresistance. Indu Ramachandran,
Cindy Lin, Thomas Condamine, Maria Ozerova, Alfred Garfall,
Dan Vogl, Dmitry Gabrilovich, Yulia Nefedova.
5021 Histopathologic and gene expression analysis in
mouse models of long-term chronic prostatic
inflammation using human prostate cancer-derived
bacterial isolates. Gretchen K. Hubbard, Shu-Han Yu, Debika
B. Shinohara, Ajay Vaghasia, William G. Nelson, Srinivasan
Yegnasubramanian, Angelo M. De Marzo, Karen S. Sfanos.
5022 Generation of T regulatory-cell specific RNA
aptamers. Suresh Veeramani, Sue E. Blackwell, William H.
Thiel, Paloma H. Giangrande, George J. Weiner.
5023 NSCLC PDX model for the evaluation of immunooncological treatment strategies. Eva Oswald, Kerstin
Klingner, Dorothee Lenhard, Gabriele Niedermann, Julia B.
Schüler.
April 18-22, 2015 • Philadelphia, PA
Poster
Board
16.
17.
18.
19.
20.
21.
22.
23.
24.
25.
26.
27.
28.
29.
Abstract
Number
5024 Implications of MAPK pathway inhibition on
monocytes and tumor-associated macrophages in
melanoma. Gabriela Gremel, Maria Romina Girotti, Amaya
Viros, Garry Ashton, Helen Bradley, Elena Galvani, Rebecca
Lee, Alberto Fusi, Paul Lorigan, Richard Marais.
5025 Immune expression profiling of MAPK inhibitor
resistant tumors based upon mechanisms of resistance.
James S. Wilmott, Hojabr Kakavand, Alexander M. Menzies,
Ricardo Vilain, Gulietta M. Pupo, John F. Thompson, Richard
F. Kefford, Matteo S. Carlino, Helen Rizos, Georgina V. Long,
Richard A. Scolyer.
5026 Tumor associated targeting with Manocept: HIV
associated Kaposi’s sarcoma as a model system. Rongzhen
Zhang, Frederick O. Cope, Paige M. Bracci, Michael S.
McGrath.
5027 Interleukin-17B promotes chemoresistance of
breast tumors through ERK1/2 anti-apoptotic pathway.
Emilie Laprevotte, Jeremy Bastid, Stéphanie Cochaud,
Jerôme Giustiniani, Marion Philippe, Kathryn A. Frewer,
Andrew J. Sanders, Wen G. Jiang, Armand Bensussan, Gilles
Alberici, Jean-François Eliaou, Nathalie Bonnefoy.
5028 CXCL10 within the tumor microenvironment
induces gemcitabine resistance in pancreatic cancer cells.
Daniel Delitto, Chelsey Perez, Brian S. Black, Heather L.
Sorenson, Andrea E. Knowlton, Song Han, Dongyu Zhang,
George A. Sarosi, Lyle L. Moldawer, Kevin E. Behrns, Chen Liu,
Thomas J. George, Ryan M. Thomas, Jose G. Trevino,
Shannon M. Wallet, Steven J. Hughes.
5029 Microglia differentiated from induced pluripotent
stem cells treat glioma tumors in mice. Hetal Pandya, David
M. Ichikawa, Michael J. Shen, Andrea B. Sedlock, Kory R.
Johnson, Dragan Maric, Dorian B. McGavern, Harry L. Malech,
John K. Park.
5030 Polarizing tumor associated macrophages (TAMs)
towards an anti-tumor phenotype with a novel compound
reveals a new subset of TAMs within breast tumors which
facilitate tumor regression. Alaba O. Sotayo, Jennnifer L.
Guerriero, Holly E. Ponichtera, Anthony G. Letai.
5031 A humanized mouse model for translational
assessment of targeted immune checkpoint blockade.
Gilson Baia, David Vasquez-Dunddel, Daniel Ciznadija, David
Sidransky, Amanda Katz, Keren Paz.
5032 Acute phase liver graft injury mobilizes regulating
B cells after transplantation for HCC patients through
TLR4/CXCL10/CXCR3 signaling. Kwan Man, Yan Shao,
Chang Xian Li, Chung Mau Lo.
5033 Azacitidine pretreatment sensitizes NSCLC cells to
interferon-␥. Kai He, Xin Zhang, Ludmila Danilova, Xiaoyu
Pan, Julie Brahmer, Drew Pardoll, Malcolm Brock, Stephen
Baylin, James Herman, John Wrangle.
5034 Imprime PGG decreases regulatory T cell
suppression and enhances T cell proliferation and
differentiation revealing additional mechanisms for its
anti-tumor activity. Steven M. Leonardo, Keith Gorden, Ross
Fulton, Lindsay Wurst.
5035 Effect of FXR agonist on colitis and colorectal
carcinogenesis in mice. Tsuneyuki Miyazaki, Takahiro Kochi,
Hiroyasu Sakai, Yohei Shirakami, Masahito Shimizu, Takuji
Tanaka, Hisataka Moriwaki.
5036 Tumor-induced activation of the Wnt/␤-catenin/
TCF4 pathway in dendritic cells promotes immune
tolerance. Yuan Hong, Indumathi Manoharan, Amol
Suryawanshi, Santhakumar Manicassamy.
5037 Immunotherapy meets epigenetics: GP96-Ig
cellular vaccine genetic signature is modulated by the
inhibition of histone modifications. George J. Fromm, Neal
Schilling, Taylor H. Schreiber.
11
11
587
POSTER SESSION
Poster Section 12 • Wednesday, 8:00 AM-12:00 PM
Endocrinology
Poster
:LJ[PVU
12
12
Molecular Endocrinology of Cancer 2
(not eligible for CME credit)
Poster
Board
1.
5038 Role of the short isoform of the progesterone
receptor in hormone-regulated invasiveness of breast
cancer cells at pre- and post-menopausal levels of
estrogen and progesterone. Thomas B. McFall, Mugdha
Patki, Rayna Rosati, Manohar Ratnam.
3.
5040 Calcium channels: Potential new therapeutic
targets for hormone independent and resistant breast
cancers. Kedra Cyrus, Mudit Kaushal, Zeina Sharawi, Glyn
Noguchi, Tiffany Chang, William Rydzewski, Fatima Gibrel,
William Yeguech, Bassam Haddad, Mary Beth Martin.
4.
5041 The ER␤ downregulation mediated by MTA1 in
salivary gland cancer cells. Kazufumi Ohshiro, Rakesh
Kumar.
5.
5042 Dynamic transcriptional regulation of ER␣
targets in prostate cancer. Kellie Cotter, Dimple
Chakravarty, Andrea Sboner, Mark A. Rubin.
6.
5043 ER␤ decreases the invasiveness of triplenegative breast cancer cells by regulating mutant p53
gain-of-function. Igor Bado, Fotis Nikolos, Gayani
Rajapaksa, Jan-Ake Gustafsson, Christoforos Thomas.
7.
5044 Reducing breast cancer risk with hormone
replacement therapy. Anna Dembo, Geoffrey Greene.
8.
5045 Characterization of estrogen receptor alpha
phosphorylation sites as a marker for tamoxifen resistant
breast cancer. Wayne A. Speckmann, Robert Brockett, Chun
Yang, Chandra Mohan, Kevin Long, Michele Hatler, Xiaoyi Xu.
9.
588
Abstract
Number
5046 Amphiregulin is a key effector of estrogen
receptor in breast cancer. Esther A. Peterson, Natasha
Chandiramani, Evelyn J. Aranda Jaque, E. C. Jenkins, Paraic
A. Kenny.
10.
5047 Role of estrogen receptors alpha and beta in the
balance between proliferation and surveillance. D. J. Jerry,
Karen A. Dunphy, Amy L. Roberts, Margarita Brown.
11.
5048 The cholesterol metabolite, 27hydroxycholesterol stimulates cell proliferation in prostate
epithelial cell lines via estrogen receptor beta. Shaneabbas
Raza, Jared Schommer, Megan Meyer, Bin Guo, Kimberly
Hammer, Othman Ghribi.
12.
5049 Checkpoint kinase 2 is a novel regulator of
prostate cancer cell growth. Huy Q. Ta, Melissa L. Ivey,
Henry F. Frierson, Mark R. Conaway, Jaroslaw Dziegielewski,
James M. Larner, Daniel Gioeli.
13.
5050 Proteome-based combined treatment strategies
synergizing antagonism of androgen receptor function in
prostate cancer. Joo Hyoung Lee, James A. Mobley,
Selvarangan Ponnazhagan.
Poster
Board
Abstract
Number
14.
5051 Androgen receptor-mediated regulation of
p14ARF transcription in prostate tumor cells. Maria Mudryj,
Salma Siddiqui, Stephen J. Libertini, Alan P. Lombard,
Benjamin Mooso, Leandro D’Abronzo, Frank Melgoza,
Alexander Borowsky, Christiana Drake, LiHong Qi, Paramita
M. Ghosh.
15.
5052 The association between estrogen receptor alpha
and platinum sensitivity in ovarian cancer cells. Sohei
Matsumura, Tsuyoshi Ohta, Toshifumi Takahashi, Kazuhiro
Takahashi, Satoru Nagase.
16.
5053 Discovery of GDC-0810 a novel, non-steroidal
selective estrogen receptor degrader with robust activity
in pre-clinical models of endocrine-resistant breast cancer.
James Joseph, Steven Govek, Beatrice Darimont, Daniel
Brigham, Anna Aparicio, Eric Bischoff, Mehmet Kahraman,
Michelle Nannini, Joshua Kaufman, Andily Lai, Kyoung-Jin
Lee, Jason Oeh, Nhin Lu, Wei Zhou, Michael Moon, Jing Qian,
John Sensintaffar, Gang Shao, Deepak Sampath, Lori S.
Friedman, Peter Rix, Richard A. Heyman, Nicholas Smith,
Jeffrey H. Hager.
17.
5054 Discerning the PARP-dependent AR cistrome/
transcriptome in prostate cancer. Matthew J. Schiewer,
Sumin Han, Joseph Evans, Michael A. Augello, Lisa BermanBooty, Theodore Parsons, Ruth Birbe, Adam P. Dicker,
William K. Kelly, Leonard G. Gomella, Felix Feng, Karen E.
Knudsen.
18.
5055 Role of insulin-like growth factor 1 receptor in
pancreatic cancer pathogenesis. Ramadevi Subramani
Reddy, Arunkumar Arumugam, Sushmita B. Nandy, Elizabeth
Gonzalez, Viviana Gonzalez, Sandrine Bonkoungou, Andrew
Ortega, Rajkumar Lakshmanaswamy.
19.
5056 PIM-1 kinase regulates vitamin D receptor
signaling in human renal carcinoma cells. Wei Luo, Yingyu
Ma, Carmen Baldino, Justin Caserta, Swathi Ramakrishnan,
Pili Roberto, Candace Johnson, Donald Trump.
20.
5057 Single-cell RNA-seq analysis of heterogeneous
populations within gastroenteropancreatic
neuroendocrine tumors: the role of Sox transcription
factors. Haydee Lara, Tamara Matysiak-Budnik, Scott T.
Magness.
21.
5058 Silencing of NOTCH signaling enhances the
sensitivity of ERG positive prostate cancer cells to AR
inhibitors. Ahmed A. Mohamed, Shyh-Han Tan, Shilpa Katta,
Charles P. Xavier, Lakshmi Ravindranath, Wei Huang, Hua Li,
Meera Srivastava, Shashwat Sharad, Taduru Sreenath,
Gyorgy Petrovics, Albert Dobi, Shiv Srivastava.
22.
5059 Androgenic signaling influences SOCS-3 in
prostate cancer cells. Florian Handle, Holger H. Erb, Birgit
Luef, Frédéric R. Santer, Zoran Culig.
AACR ANNUAL MEETING 2015
POSTER SESSION
Poster Section 14 • Wednesday, 8:00 AM-12:00 PM
Tumor Biology
Biomarkers and Clinical Implications of the Tumor Microenvironment
(not eligible for CME credit)
Poster
Board
1.
2.
3.
4.
5.
6.
7.
8.
9.
10.
11.
12.
13.
14.
15.
Abstract
Number
5060 Exosome transfer from ovarian cancer cells to
mesothelial cells promotes cell invasion by upregulating
MMP-9 secretion and increasing clearance of mesothelial
cells. Koji Nakamura, Kenjiro Sawada, Yasuto Kinose, Akihiko
Yoshimura, Erika Nakatsuka, Seiji Mabuchi, Tadashi Kimura.
5061 Astrocytes promote medulloblastoma
tumorigenesis via sonic hedgehog secretion. Larra W.
Yuelling, Fang Du, Eric Lee, Renata Muradimova, Peng Li,
Zeng-jie Yang.
5062 Ovarian cancer cells induce the
microenvironment changes and subsequently promote
disease propagation and dissemination through epithelialmesenchymal transition and enrichment of tumorigenic
cells. Nanni Huser, Zhengming Yan, Jing Yuan, Cathy C.
Zhang.
5063 Lysyl oxidase-like 2 (LOXL2) from cancerassociated fibroblasts stimulates the progression of
gastric carcinoma. Hiroaki Kasashima, Masakazu Yashiro,
Kisyu Kitayama, Go Masuda, Haruhito Kinoshita, Katsunobu
Sakurai, Takahiro Toyokawa, Naoshi Kubo, Hiroaki Tanaka,
Kazuya Muguruma, Masaichi Ohira, Kosei Hirakawa.
5064 EGFR and HER3 are important in the interaction
between lung cancer cells and fibroblasts. Christina
Demuth, Kristine R. Jakobsen, Peter Meldgaard, Anders L.
Nielsen, Boe S. Sorensen.
5065 Interleukin-1␤ secreted into the bone metastatic
niche by androgen receptor-negative prostate cancer cells
enables skeletal metastasis. Kristina S. Shahriari, Fei Shen,
QingXin Liu, Danielle L. Jernigan, Ramanpreet Kaur,
Alessandro Fatatis.
5066 Reprogramming the TGF-beta signaling in
cancer-associated fibroblasts inhibits ovarian cancer
progression. Tsz-Lun Yeung, Cecilia S. Leung, Kwong-Kwok
Wong, Samuel C. Mok.
5067 Preadipocyte exosomes promote early stage
breast cancer formation by enhancing cancer stem cell
renewal signaling. Benjamin Wolfson, Ramkishore
Gernapudi, Nadire Duru, Qun Zhou.
5068 Treatment with regorafenib inhibits the tumorpromoting effect of bone marrow-derived mesenchymal
stem cells in an orthotopic nude mice model of colon
cancer. Kei Shinagawa, Yasuhiko Kitadai, Ryo Yuge, Mieko
Onoyama, Shinji Tanaka, Wataru Yasui, Kazuaki Chayama.
5069 IL-33 secreted by cancer-associated fibroblasts
mediates epithelial-stromal interactions and promotes
gastric cancer invasion via ERK signaling pathway. Liping
Su, Quan Zhou, Chenchen Wang, Xiongyan Wu, Xiaofeng
Wang, Jianfang Li, Zhenggang Zhu, Bingya Liu.
5070 Inhibition of collagen receptor discoidin domain
receptor-1 (DDR1) reduces colon cancer cell migration and
metastasis. Ryo Yuge, Yasuhiko Kitadai, Kei Shinagawa, Mieko
Onoyama, Shinji Tanaka, Wataru Yasui, Kazuaki Chayama.
5071 Inhibition of Porcupine reduces Wnt-dependent
colony formation and/or proliferation in both autocrine
and paracrine cell models. Ben A. Thompson, Kate J.
Messenger, Emily Linnane, Sarah E. Coupland, Peter J. Calcraft.
5072 Mesenchymal stem cells promote osteogenesis
and the evolution of apoptosis resistant bone metastatic
prostate cancer. Jeremy J. McGuire, Leah Cook, Jeremy
Frieling, Conor Lynch.
5073 Role of TIMP-1 glycosylation in lung carcinoma.
Byung R. Lee, Ammar Kutiyanawalla, Sampa Ghosal-Gupta,
Amyn M. Rojiani, Mumtaz V. Rojiani.
5074 Activation of TGF ␤-IL6 axis mediates
chemoresistance in non-small cell lung cancer by
increasing epithelial-mesenchymal transition signaling.
Yasushi Shintani, Soichiro Funaki, Toru Kimura, Ayako
Fujiwara, Tomohiro Kawamura, Toshiya Bessho, Masayoshi
Inoue, Masato Minami, Meinoshin Okumura.
April 18-22, 2015 • Philadelphia, PA
Poster
Board
16.
17.
18.
19.
20.
21.
22.
23.
24.
25.
26.
27.
28.
29.
30.
Abstract
Number
5075 The composition and interactions in the
microenvironment of human prostate cancer. Monique
Melis, Bianca Cioni, Ekaterina Nevedomskaya, Johan van
Burgsteden, Emma Hodel, Annegien Broeks, Henk van der
Poel, Jeroen de Jong, Andre Bergman.
5076 Tumor cell-derived exosomes educate bone
marrow mesenchymal stromal cells toward a
protumorigenic function. Rie Nakata, Lucia Borriello, Muller
Fabbri, Hiroyuki Shimada, Yves A. Declerck.
5077 Metastasis suppressors regulate the tumor
microenvironment by blocking recruitment of prometastatic TAMs. Daniel C. Rabe, Casey Frankenberger,
Russell Bainer, Devipriya Sankarasharma, Kiran Chada,
Thomas Krausz, Yoav Gilad, Lev Becker, Marsha R. Rosner.
5078 Human breast carcinoma-associated
mesenchymal stem cells promote breast cancer cell
proliferation, irreversible EMT and invasion through
Collagen I. Maria E. Gonzalez, Emily E. Martin, Celina G. Kleer.
5079 Parasympathetic signaling suppresses pancreatic
cancer development. Bernhard W. Renz, Marina Macchini,
Yoku Hayakawa, C. B. Westphalen, Michael Churchill, Suchetak
Kar, Xiaowei Chen, Karan Nagar, Yagnesh Tailor, Daniel L.
Worthley, Alina C. Iuga, Ken P. Olive, Timothy C. Wang.
5080 HIF-1 is responsible for the induction of cancerassociated fibroblasts in hypoxic tumor
microenvironment. Koji Teramoto, Yoko Kataoka, Tomoyuki
Igarashi, Yasuhiko Ohshio, Jun Hanaoka, Yataro Daigo.
5081 The IGF axis regulates hepatic stellate cell
recruitment and activation during colorectal carcinoma
liver metastasis. Maria C. Fernandez, Roni F. Rayes, Jun Xu,
Tatiana Kisseleva, Shoshana Yakar, Pnina Brodt.
5082 Impact of HGF knockin microenvironment on
epithelial-mesenchymal transition and cancer stem cells in
a non-small cell lung cancer xenograft model. Tony Navas,
Thomas D. Pfister, Scott M. Lawrence, Apurva K. Srivastava,
Robert J. Kinders, Suzanne Borgel, Melinda G. Hollingshead,
Lindsay M. Dutko, Brad A. Gouker, Donna Butcher, Elinor
Ng-Eaton, Naoko Takebe, Ralph E. Parchment, Joseph E.
Tomaszewski, James H. Doroshow.
5083 Adipocytes promote pancreatic cancer cell
proliferation and progression. Roopali Roy, Marsha A.
Moses.
5084 A multifaceted role of the Hedgehog pathway in
modulating pancreatic ductal adenocarcinoma biology.
Dafydd H. Thomas, Albert Lee, Carmine Palermo, Stephen
Sastra, Raul Rabadan, Kenneth Olive.
5085 Acute myeloid leukemia cells induce osteogenic
differentiation in mesenchymal stem cells through bone
morphogenetic protein- and RUNX-2- mediated signaling.
Venkata Lokesh Battula, Phuong M. Le, Jeff Sun, Christopher
B. Benton, Teresa Mc.Queen, Elizabeth J. Shpall, Carlos E.
Bueso-Ramos, Marina Konopleva, Michael Andreeff.
5086 De-differentiation of CD45+ hematopoietic cells
to CD45- stromal cells in vitro. Yang Jo Chung, Suntae Kim,
Peter Aplan.
5087 Precise characterization of macrophage secretory
exosomes can lead to novel therapeutic approaches.
Robert B. Bednarczyk, Yuki Kitadai, Neha Y. Tuli, Elyse K.
Hanly, Ghada Benrahoma, Abraham Mittelman, Raj K. Tiwari.
5088 Glioblastoma stem cell-secreted exosomes can
induce a tumor supportive M2 response. Konrad
Gabrusiewicz, Yuuri Hashimoto, Jun Wei, Maiti Sourindra,
John Yu, Shinji Yamashita, Anna Zal, Tomasz Zal, Laurence
Cooper, Amy B. Heimberger.
5089 Desmoplastic stroma affects growth and invasion
of progressively mutated human pancreatic cancer cells in
vitro. Ruchi Malik, Tiffany Luong, Seda Karamil, Peter Lelkes,
Edna Cukierman.
Poster
:LJ[PVU
14
14
589
POSTER SESSION
Poster Section 15 • Wednesday, 8:00 AM-12:00 PM
Tumor Biology
Poster
:LJ[PVU
15
15
590
Factors Regulating Motility and Invasion
(not eligible for CME credit)
Poster
Board
Abstract
Number
Poster
Board
Abstract
Number
1.
5090 Targeting metastatic prostate cancer with
polyisoprenylated cysteinyl amides. Rosemary A. Poku,
Augustine Nkembo, Olufisayo Salako, Felix Amissah, Hernan
Flores-Rozas, Tryphon Mazu, Nazarius S. Lamango.
11.
5100 Aerobic glycolysis is the primary metabolic
pathway used for prostate cancer cell motility and
invasion processes regardless of androgen sensitivity.
James E. Verdone, Jelani C. Zarif, Kenneth J. Pienta.
2.
5091 Inhibiting endothelium directed tumor cell
streaming by targeting the HGF/C-Met and EGF/CSF-1
signaling pathways. Edison Leung, Yarong Wang, Bryan
Smith, Daniel Flynn, John Condeelis.
12.
5101 The control of migration and invasion processes
in colorectal adenocarcinoma is modulated by prion
protein and its ligand STI1/HOP. Tonielli S. Lacerda, Marcos
Vinicius S. Dias, Fernanda S. Giudice, Bianca Luise Teixeira,
Vilma Regina Martins.
3.
5092 Midkine as a potential target for combating drug
resistance and invasion in melanoma. Amanpreet Kaur,
Michael O’Connell, Marie Webster, Reeti Behera, Vanessa
Dang, Abibatou Ndoye, Ashani Weeraratna.
13.
4.
5093 Pre-clinical assessment of a novel anti-invasion
nanoparticle therapeutic in combination with
bevacizumab for the treatment of glioblastoma. David W.
Murray, Philip O’Halloran, Monika Jarzabek, Brian MacCarthy,
Jann N. Sarkaria, Raymond M. Schiffelers, Marc Symons,
Annette T. Byrne.
5102 Differential levels of mutated Kras drive lung
cancer cell motility and morphology via a hypoxiasensitive FAK/Erk/Myosin II signaling pathway. Anette C.
Schafer, Meghan Discoll, Ashwathi Mohan, Andrew Ludlow,
Wesley Burford, Jerry W. Shay, Gaudenz Danuser.
14.
5103 Loss of p27 upregulates MnSOD in a STAT3dependent manner, disrupts intracellular redox activity
and enhances cell migration. Jing An, Dongyun Zhang,
Chuanshu Huang.
15.
5104 Isorhapontigenin (ISO) inhibits cancer invasion
by enhancing FOXO1 transcription through targeting
STAT1 phosphorylation at Tyr701. Lei Xue, Guosong Jiang,
Jingxia Li, Chuanshu Huang.
16.
5105 The imprinted tumor suppressor gene NDN
inhibits cell motility in ovarian cancer by reactivating FAK
and RhoA. Hailing Yang, Partha Das, Weiqun Mao, Rebecca T.
Marquez, Zhen Lu, Robert C. Bast.
17.
5106 Influence of chloride flux on cell motility in head
and neck squamous cell carcinoma. Nayel Khan, Kevin
Steehler, Carolyn Kemp, Sucheta Kulkarni, Kara Davis,
Umamaheswar Duvvuri.
18.
5107 Divergent behaviors and underlying mechanisms
of cell migration and invasion in non-metastatic T24 and
its metastatic derivative T24T bladder cancer cell lines.
Honglei Jin, Jingxia Li, Chuanshu Huang.
5.
5094 Capsaicin inhibits invasion of human non-small
cell lung cancer cells in a TRPV1 receptor independent
manner. Matthew N. Eskew, Kathleen C. Brown, Piyali
Dasgupta.
6.
5095 1,25D3 inhibits migration and invasion through
miR-101-3p in human bladder cancer cells. Yingyu Ma, Wei
Luo, Rachel Pratt, Donald L. Trump, Candace S. Johnson.
7.
5096 ALIBI: a novel, truncated tubulin isotype in AML
and stem cells. Paul Basciano, Xi Li, Jason Matakas, Susanna
Liu, Silvana Di Giandomenico, Siddhartha Sen, Todd Evans,
Joseph Scandura, Monica Guzman, Paraskevi Giannakakou.
8.
5097 APE1/Ref-1 promotes cell adhesion and
migration in cervical cancer cells. Mihwa Kim, Ho J. You,
Dae J. Kim.
9.
5098 Participation of Crk-associated substrate (CAS) in
human pancreatic cancer cell migration, invasion and
metastatic processes. Hirotaka Okamoto, Hideki Fujii.
19.
5108 Oscillatory calcium signal drives melanoma
invasion and metastasis. Jianwei Sun, Fujian Lu, Huifang He,
Heping Cheng, Shengyu Yang.
10.
5099 Abrogation of cancer cell extravasation in renal
cell carcinoma PDX lines via invadopodia dysregulation
mediated by PAK1 inhibitors. Karla Williams, Clarisse
Mazzola, James Brugarolas, Nicholas Power, Ann Chambers,
Hon Leong.
20.
5109 The CARMA3-Bcl10-MALT1 signalosome mediates
NF-␬B activation and cellular invasion in AGTR1-positive
breast cancer. Prasanna Ekambaram, Nathaniel Hubel, JiaYing Lee, Linda Klei, Vincent Concel, Philip Delekta, Scott
Tomlins, Linda McAllister-Lucas, Peter Lucas.
AACR ANNUAL MEETING 2015
POSTER SESSION
Poster Section 16 • Wednesday, 8:00 AM-12:00 PM
Tumor Biology
Imaging of Molecular and Cellular Events in Tumors and Tumor Cells
(not eligible for CME credit)
Poster
Board
1.
2.
Abstract
Number
5110 Initial characterization of an optical reporter
myoblast cell line for non-invasive imaging in a cancer
cachexia model in mice. Paul T. Winnard, Marie-France
Penet, Yelena Mironchik, Flonne Wildes, Anirban Maitra,
Zaver M. Bhujwalla.
5111 Bio-distribution and tumor targeting of a Pcadherin x CD3 bi-specific redirected T-cell molecule using
fluorescence molecular tomography imaging. Anand
Giddabasappa, Vijay Gupta, Timothy S. Fisher, John David,
Norberg Rand, Allison Rohner, Justin Cohen, Tracey Clark,
Nahor Haddish-Berhane, Adam Root, Chad May.
3.
5112 In vivo molecular imaging of HIF-1␣ and septin 9
interaction by bimolecular fluorescence complementation.
Maya Golan, Nicola J. Mabjeesh.
4.
5113 Rapid cancer imaging by GGT-targeted
fluorescence probe for primary lung cancer. Haruaki Hino,
Mitsuaki Kawashima, Tomonori Murayama, Junji Ichinose,
Kentaro Kitano, Kazuhiro Nagayama, Jun-ichi Nitadori,
Masaki Anraku, Tomohiro Murakawa, Kasue Mizuno, Sayaka
Tanaka, Mako Kamiya, Nobuhiro Nishiyama, Kazunori
Kataoka, Kohei Miyazono, Yasuteru Urano, Jun Nakajima.
5.
6.
7.
8.
5114 Multispectral optoacoustic tomography (MSOT)
as a novel approach for dynamic, noninvasive assessment
of tumor therapy response and chronic inflammation.
Wouter H. Driessen, Neal Burton, Christian Schwöppe,
Wolfgang E. Berd, Toni Weinhage, Georg Varga, Christiane
Geyer.
5115 An orthotopic lung tumor model for imageguided microirradiation in rats. Zhang Zhang, Michelle
Wodzak, Olivier Belzile, Heling Zhou, Ralph Mason, Rolf
Brekken, Rajiv Chopra, Michael D. Story, Robert Timmerman,
Debabrata Saha.
5116 Detection of pancreatic cancer using acidic pH
targeted probes detected using multispectral optoacoustic
tomography. Matthew Zeiderman, Anil Khanal, Charles W.
Kimbrough, Jorge Gomez, William E. Grizzle, Kelly M.
McMasters, Lacey R. McNally.
5117 Fluorescence-guided surgery of liver metastasis
in orthotopic nude-mouse models. Takashi Murakami,
Yukihiko Hiroshima, Shinji Miwa, Yano Shuya, Makoto Toneri,
Mako Yamamoto, Masashi Momiyama, Takashi Chishima,
Kuniya Tanaka, Michael Bouvet, Satoshi Hasegawa, Itaru
Endo, Robert M. Hoffman.
April 18-22, 2015 • Philadelphia, PA
Poster
Board
Abstract
Number
9.
5118 In-vivo non-invasive mitochondrial evaluation of
3D human skin. Dimitra Pouli, Mihaela Balu, Bruce Tromberg,
Irene Georgakoudi.
10.
5119 Mechanisms associated with blood flow
modifying effects of electric pulses used for
electrochemotherapy on normal and tumor blood vessels.
Bostjan Markelc, Elisabeth Bellard, Gregor Sersa, Tanja
Dolinsek, Justin Teissie, Muriel Golzio, Maja Cemazar.
11.
5120 Using flow-proteometric platform to analyze
individual signaling complexes in tumor tissue. Chao-Kai
Chou, Heng-Huan Lee, Pei-Hsiang Tsou, Chun-Te Chen, JungMao Hsu, Hirohito Yamaguchi, Ying-Nai Wang, Jennifer L.
Hsu, Jin-Fong Lee, Jun Kameoka, Mien-Chie Hung.
12.
5121 Study of a synthetic peptide probe for apoptosis
imaging. Shen Yang, Jie Meng, Huike Liu, Chuan Wang,
Yanlian Yang, Hua Guo, Jian Liu, Chen Wang, Haiyan Xu.
13.
5122 In vivo imaging models of bone and brain
metastases and pleural carcinomatosis developed using a
novel human EML4-ALK lung cancer cell line, A925LPE3.
Shigeki Nanjo, Shinji Takeuchi, Kenji Kita, Koji Fukuda,
Mitsutoshi Nakada, Hiroshi Nishihara, Seiji Yano.
14.
5123 Curative fluorescence-guided surgery of
pancreatic cancer in combination with UVC irradiation in
orthotopic mouse models. Yukihiko Hiroshima, Ali Maawy,
Yong Zhang, Sho Sato, Takashi Murakami, Mako Yamamoto,
Fuminari Uehara, Shinji Miwa, Shuya Yano, Masashi
Momiyama, Takashi Chishima, Kuniya Tanaka, Michael
Bouvet, Itaru Endo, Robert M. Hoffman.
15.
5124 Molecular imaging of tumor energy metabolism
as an early indicator of anticancer drug efficacy in small
animal models. Jen-Chieh Tseng, Jeffrey Peterson.
16.
5125 Imaging the tumor microenvironment of
metastasis reveals the mechanism of transient blood
vessel permeability and tumor cell intravasation. Allison S.
Harney, Esther N. Arwert, David Entenberg, Yarong Wang,
Peng Guo, Bin-Zhi Qian, Bryan D. Smith, Jeffrey W. Pollard,
Joan G. Jones, Daniel L. Flynn, John S. Condeelis.
Poster
:LJ[PVU
16
16
591
POSTER SESSION
Poster Section 17 • Wednesday, 8:00 AM-12:00 PM
Tumor Biology
Poster
:LJ[PVU
17
17
Other Animal Species and Cell Models of Cancer
(not eligible for CME credit)
Poster
Board
1.
2.
3.
4.
5.
6.
7.
8.
9.
10.
11.
12.
13.
14.
592
Abstract
Number
5126 Establishment of an esophageal small
cell carcinoma cell line (TYUC-1). Yutaka Shimada,
Tomoyuki Okumura, Yoshinori Takei, Kazuaki Watanabe,
Akira Hirasawa, Arito Yamane, Masahiko Nishiyama,
Takuya Nagata, Kazuhiro Tsukada, Kazuharu Shimizu.
5127 The most common mistakes in cancer cell
pharmacology. Guido Lenz, Andrew O. Silva.
5128 Changes in mitochondrial background affect
nuclear DNA methylation. Carolyn J. Vivian, Amanda E.
Brinker, Gerald C. Gooden, Christophe Legendre, Bodour
Salhia, Danny R. Welch.
5129 Model osteosarcoma by Li-Fraumeni syndrome
patient-specific induced pluripotent stem cells. Dung-Fang
Lee, Jie Su, Huen Suk Kim, Betty Chang, Ruiying Zhao, Dmitri
Papatsenko, Ye Yuan, Julian Gingold, Weiya Xia, Henia Darr,
Christoph Schaniel, Razmik Mirzayans, Mien-Chie Hung, Ihor
R. Lemischka.
5130 Assessment of the antitumor activity of leech
(huridinaria manillensis) saliva extract in prostate cancer.
Amr E. Ammar, Mohamed H. Hassona, Gray R. Meckling,
Leslie G. Chan, Mei Y. Chin, Abdulrahman Abdualkader,
Mohamed Alaama, Ahmed Merzouk, Abulbashar Helaluddin,
Abbas Ghawi, Omer Kucuk, Emma S. Guns.
5131 Establishment of uterine carcinosarcoma
primary cell lines for chemosensitivity testing and
evaluation of targeted therapy. Jurriaan Brouwer-Visser,
Eirwen Scott, Shijun Mi, Maria J. Cossio, Tiffany Hebert,
Gloria S. Huang.
5132 Evaluation of multi-marker in tissue-derived
cancer cells from patients with epithelial ovarian
carcinoma. Shin-Wha Lee, Sang-Eun Lee, Ha-Young Lee,
Dae-Yeon Kim, Jong-Hyeok Kim, Yong-Man Kim, Young-Tak
Kim, Joo-Hyun Nam.
5133 The RNA-binding protein HuR facilitates
proliferation and metastasis in human pancreatic ductal
adenocarcinoma. Masaya Jimbo, Fernando F. Blanco, Brad
Screnci, Gabriela Cosma, Vitali Alexeev, Yu-Hung Huang,
Jordan M. Winter, Charles J. Yeo, Janet A. Sawicki, Jonathan
R. Brody.
5134 Pharmaceutical effect of vitamin C (ascorbate) on
B16 melanoma in vitro and in vivo. Pierre-Christian Violet,
Nermi L. Parrow, Serrano L. Oscar, Jacqueline Yang, Mark A.
Levine.
5135 Study of a new splice variant of Neuropilin-1:
Antagonistic functions in the regulation of tumor
progression. Céline Hendricks, Lauriane Janssen, Romain
Delcombel, Johanne Dubail, Christophe Deroanne, Alain
Colige.
5136 The Flint Animal Cancer Center (FACC) canine
tumor cell line panel: A resource for comparative and
translational oncology. Daniel L. Gustafson, Jared S.
Fowles, Douglas H. Thamm, Rodney L. Page, Dawn L.
Duval.
5137 IQGAP1, an ERK1/2 MAPK scaffold, is an
oncogenic target in canine melanoma. Ashley Zehnder,
Becky Lee, Poornima Neela, Paul Khavari.
5138 New technique generates cell cultures from rare
adenoid cystic carcinomas of the salivary gland. Chen
Chen, Sujata Choudhury, Xuefeng Liu, Richard Schlegel,
Seema Agarwal.
5139 Cell sorting strategies for the isolation of cancer
cells and associated fibroblasts from tumor biopsies,
surgical resections, and patient-derived xenografts. Luke
H. Stockwin, Michael Mullendore, Carrie Bonomi, Kelly
Dougherty, James H. Doroshaw, Melinda G. Hollingshead,
Dianne L. Newton.
Poster
Board
15.
16.
17.
18.
19.
20.
21.
22.
23.
24.
25.
26.
27.
28.
Abstract
Number
5140 TALEN mediated mutation of apc and ␤-catenin
in Xenopus tropicalis as powerful models for Wnt driven
cancer and Familial Adenomatous Polyposis (FAP). Tom
Van Nieuwenhuysen, Thomas Naert, David Creytens, Frans
Van Roy, Kris Vleminckx.
5141 A comprehensive system of congenic mouse
melanoma models for evaluation of immune therapies.
Katrina M. Meeth, William E. Damsky, Marcus Bosenberg.
5142 A naturally occurring model for gastric cancer.
Manar A. AbdelMageed, Monica Betancur-Boissel, Parthena
Foltopoulou, Sureshkumar Muthupalani, James G. Fox,
Elizabeth A. McNiel.
5143 Rats heterozygous for Pten develop
fibroadenoma and adenocarcinoma arising from the
mammary gland. Aaron M. McCoy, Bala Manickam, Lara
Reid, Edward Weinstein, Xiaoxia Cui.
5144 Low dose sorafenib delays hepatocellular cancer
(HCC) development in the woodchuck model of hepatitis B
related HCC. Renuka V. Iyer, Sandra Sexton, Leslie Curtin,
Gerald Fetterly, Orla Maguire, Hans Minderman, Ilia Toshkov,
Bud Tennant, Alan Hutson, Donald L. Trump, Candace
Johnson.
5145 Y-27632 inhibits Myc-induced apoptosis and
cooperates with Myc to immortalize human keratinocytes.
Aleksandra Dakic, Kyle Divito, Shuang Fang, Nancy PalechorCeron, Vera Simic, Sujata Choudhury, Songtao Yu, Cynthia M.
Simbulan-Rosenthal, Dean Rosenthal, Richard Schlegel,
Xuefeng Liu.
5146 Establishment of an orthotopic bladder cancer
model to evaluate continuous intravesical delivery of small
molecule inhibitors in the nude rat. Leigh J. Williams,
Stephanie K. Klein, Danielle Greenawalt, Dawn Trueman,
Helen Musgrove, Helen Jones, Linette Ruston, Barry R.
Davies.
5147 Canine spontaneous head and neck squamous cell
carcinomas represent their human counterparts at the
molecular level. Deli Liu, Huan Xiong, Angela E. Ellis, Nicole
C. Northrup, Dong M. Shin, Shaying Zhao.
5148 NR5A2 is essential for pancreas development
and affects pancreas carcinogenesis. Sahar Nissim, Olivia
Weeks, John Hedgepeth, Julia Wucherpfennig, Xiao-Xu
Wang, Alec Kimmelman, Wolfram Goessling.
5149 An orthotopic model of human chordoma in rats.
Rachel Sarabia-Estrada, Alejandro Ruiz-Valls, Courtney R.
Goodwin, Sagar Sha, Alfredo Quiñones-Hinojosa, Ziya L.
Gokaslan, Daniel M. Sciubba.
5150 Drosophila models of Ret fusions in papillary
thyroid carcinoma. Sarah Levinson, Ross Cagan.
5151 Yap reprograms glutamine metabolism and
supports growth during liver development and
tumorigenesis. Andrew G. Cox, Katie L. Hwang, Kimberley
Evason, Kristin K. Brown, Sebastian Beltz, Keelin O’Connor,
Giorgio G. Galli, Dean Yimlamai, Sagar Chhangawala, Evan
Lien, Fernando D. Camargo, John Asara, Yariv Houvras, Didier
Y. Stainier, Wolfram Goessling.
5152 Zebrafish models of myeloid malignancies
produced through tet2 and asxl1 genomic editing. Evisa
Gjini, Marc Mansour, Jeffry Sander, Shuning He, Myunggon
Ko, Yi Zhou, Scott Rodig, Keith Joung, Leonard Zon, Anjana
Rao, Thomas Look.
5153 Myogenic regulatory factors and their role in
embryonal rhabdomyosarcoma. Ines M. Tenente, Myron
Ignatius, Eleanor Chen, Madeline Hayes, David M.
Langenau.
AACR ANNUAL MEETING 2015
POSTER SESSION
Poster Section 18 • Wednesday, 8:00 AM-12:00 PM
Tumor Biology
Predicting, Profiling, and Imaging Prospective and Established Metastases
(not eligible for CME credit)
Poster
Board
1.
2.
3.
4.
5.
6.
8.
9.
10.
11.
12.
13.
15.
16.
Abstract
Number
5154 Diagnostic serum markers for metastatic brain
tumors identified by cross-species hybridization of
microarrays in animal models. Ho Jeong Lee, Sun Jin Kim,
Hyun Kyung Yu, Seung Wook Kim, Qiuyu Wu, Junqin He,
Isaiah J. Fidler.
5155 Status and clinical relavence of G1/S cell cycle
regulatory proteins in Ocular Surface Squamous Neoplasia.
Sheetal Chauhan, Seema Sen, Anjana Sharma, Seema
Kashyap, M. Vanathi, Neelam Pushker, Radhika Tandon.
5156 Establishment of a FISH based analysis for
individual risk assessment of ccRCC patients on tissue
microarrays. Julia Grimm, Arndt Hartmann, Christine Stoehr,
Martin Janssen, Frank Kunath, Michael Stöckle, Kerstin
Junker.
5157 Elevated uptake of free fatty acids via CD36
promotes epithelial-mesenchymal transition in
hepatocellular carcinoma. Aritro Nath, Irene Li, Christina
Chan.
5158 CD44 cleavage promotes anoikis resistance and
metastasis in Ewing sarcoma. Nikolina Dioufa, Guang Li,
Maria Tsokos.
5159 Identification of ARv567es expression profile in
the prostate cancer clinical samples with a newly
developed antibody. Gang Liu, Aihua Li, Shihua Sun, Cynthia
Sprenger, Eva Corey, Colm Morrisey, Scott Dehm, Stephen
Plymate.
5161 Discovery of a matrix metalloproteinase MMP10
as a clinically relevant biomarker to predict lymph node
metastasis in tongue squamous cell carcinoma. Pawan
Upadhyay, Nilesh L. Gardi, Hemant R. Dhamne, Kavitha
Sonawane, Anil D’Cruz, Sudhir Nair, Amit Dutt.
5162 Phosphatidylinositol 4-Kinase type IIIa (PI4KA)
expression in prostate cancer. Diego Sbrissa, Louie Semaan,
Li Yanfeng, Assia Shisheva, Sreenivasa R. Chinni.
5163 A high level of circulating CXCL10 at initial
diagnosis is associated with poor prognosis of
osteosarcoma patients. Ricardo J. Flores, Aaron J. Kelly,
Yiting Li, Manjula Nakka, Ching C. Lau, John Hicks, Tsz-Kwong
Man.
5164 Primary tumor subclones carry somatic mutation
signatures of metastasis. Noemi Andor, Hanlee P. Ji.
5165 Cancer associated macrophage-like cells as a
blood-based biomarker for the screening of solid tumors.
Daniel Adams, Katherine Alpaugh, Massimo Cristofanilli,
Stuart Martin, Saranya Chumsri, Raymond C. Bergen, Susan
Tsai, Martin Edelman, Peixuan Zhu, Shuhong Li, Olga V.
Makarova, Platte T. Amstutz, Cha-Mei Tang, Jeffrey R. Marks.
5166 The Wnt signaling pathway in the ovarian
carcinoma. Michal Chehover, Claes Tropé, Reuven Reich, Ben
Davidson.
5168 Tumor metabolism as a driver of lethal prostate
cancer. Rachel S. Kelly, Jennifer A. Sinnott, Jennifer R. Rider,
Ericka Ebot, Travis Gerke, Kathryn Penney, Michaela Bowden,
Massimo Loda, Philip W. Kantoff, Neil E. Martin, Edward L.
Giovannucci, Andreas Pettersson Pettersson, Svitlana
Tyekucheva, Kathryn M. Wilson, Matthew Vander Heiden,
Lorelei A. Mucci.
5169 Omics approach to identify driver genes for
peritoneal dissemination of gastric cancer cells. Sho
Nambara, Junji Kurashige, Tomoko Saito, Hisateru Komatsu,
Masami Ueda, Shotaro Sakimura, Hidenari Hirata, Ryutaro
Uchi, Yuki Takano, Yoshiaki Shinden, Tomohiro Iguchi,
Hidetoshi Eguchi, Keishi Sugimachi, Yoshihiko Maehara, Koshi
Mimori.
April 18-22, 2015 • Philadelphia, PA
Poster
Board
17.
18.
19.
20.
21.
22.
23.
24.
25.
26.
27.
29.
30.
Abstract
Number
5170 The autotaxin-lysophosphatidic acid signaling
pathways in ovarian carcinoma. Hadil Onalla, Claes Tropé,
Reuven Reich, Ben Davidson.
5171 EpCAM expression governs tumor growth or
distant metastasis of human endometrial cancer: grow or
go theory. Kuo-Chang Wen, Peng-Hui Wang, Pi-Lin Sung,
Mong-Hong Lee, Cheng-Wen Wu.
5172 Developing a lung metastasis gene signature
using a lung tropism model in melanoma. Yu Wen, Maung
Naing Lin Shan, Jiadong Li, James Goydos.
5173 Androgen receptor status is highly conserved
during tumor progression of breast cancer. André Grogg,
Katrin Pfaltz, Claudia Lädrach, Nikola Cihoric, Martin Zweifel,
Coya F. Tapia.
5174 Imaging of tissue factor expression in an
orthotopic pancreatic tumor mouse model using small
animal PET/CT and MRI. Carsten H. Nielsen, Troels E.
Jeppesen, Lotte K. Kristensen, Laura H. Larsen, Jacob
Madsen, Bo Wiinberg, Lars C. Petersen, Andreas Kjaer.
5175 Preclinical monitoring of prostate cancer lesions
in bone by intravital multiphoton microscopy. Eleonora
Dondossola, Stephanie Alexander, Steve Alexander, Boris
Holzapfel, Christopher Logothetis, Dietmar Hutmacher, Peter
Friedl.
5176 Chemotherapy alters the natural history of
metastatic progression. Nicole M. Aiello, David L. Bajor,
Minh N. Pham, Robert H. Vonderheide, Ben Z. Stanger.
5177 Heterogeneity of pancreatic ductal
adenocarcinoma visualized. Veronique Veenstra, Helene
Damhofer, Tom van Leusden, Jan Kessler, Jan Paul Medema,
Hanneke van Laarhoven, Louis Vermeulen, Maarten Bijlsma.
5178 Chitinase-3-like-1 (CHI3L1) expressed during
allergic pulmonary inflammation alters lung
microenvironment accelerating breast cancer metastasis.
Nathalia Gazaniga, Camilla S. Castro, Stephania Libreros,
Ramon Garcia-Areas, Vijaya Iragavarapu-Charyulu.
5179 An endothelial-mesenchymal transition of brain
endothelial cells is required for metastatic extravasation.
Istvan A. Krizbai, Akos Gasparics, Peter Nagyoszi, Csilla
Fazakas, Imola Wilhelm, Rita Bencs, Laszlo Rosivall, Attila
Sebe.
5180 Allergic pulmonary inflammation accelerates
breast cancer metastasis via increase of MDSCs in the lung
microenvironment. Stephania Libreros, Ramon GarciaAreas, Nathalia Gazaniga, Philip Robinson, Vijaya
Iragavarapu-Charyulu.
5182 Characterization of miRNA expression pattern
from in-vitro obtained exosomes of different urinary
bladder cancer cell lines. Sophie Baumgart, Joana
Heinzelmann, Michael Stoeckle, Marie Stampe Ostenfeld,
Kerstin Junker.
5183 Identification and characterization of wild type
kinases driving prostate cancer metastasis. Claire
Faltermeier, Justin Drake, Peter Clark, Bryan Smith, Colleen
Mathis, Yang Zong, Carmen Volpe, Owen Witte.
Poster
:LJ[PVU
18
18
593
POSTER SESSION
Poster Section 19 • Wednesday, 8:00 AM-12:00 PM
Tumor Biology
Poster
:LJ[PVU
19
19
Tumor Metastasis
(not eligible for CME credit)
Poster
Board
1.
5184 Synaptonemal complex protein 3 is associated
with lymphangiogenesis in non-small cell lung cancer.
Haruhisa Kitano, Joon-Yong Chung, Jun Hanaoka, Shuhei
Inoue, Doki Yoshinori, Junya Fukuoka, Stephen M. Hewitt.
2.
5185 Identification of BRIP1 as a novel marker of
breast tumor malignancy in the Omani population. Ishita
Gupta, Allal Ouhtit, Marwa Al-Riyami, Adil Al Ajmi.
3.
4.
5.
5186 Label-free imaging identification of white blood
cells using quantitative phase microscopy for negative
selection of circulating tumor cells. Yusuke Ozaki, Hidenao
Iwai, Hirotoshi Kikuchi, Tomohiro Matsumoto, Shinichiro
Miyazaki, Toshiki Kawabata, Yoshihiro Hiramatsu, Manabu
Ohta, Kinji Kamiya, Megumi Baba, Kentaro Goto, Toyohiko
Yamauchi, Yukio Ueda, Shigetoshi Okazaki, Hiroyuki Konno.
5187 Expression of metastasis-related miRNAs in
EpCAM-positive CTC fraction in corresponding plasma and
FFPEs of breast cancer patients with verified metastasis.
Athina Markou, Martha Zavridou, Ioanna Sourvinou, Nikos
Malamos, Vasilis Georgoulias, Evi S. Lianidou.
5188 Immunostaining of MRP-1 protein in circulating
tumor cells predicts shorter progression free survival in
metastatic colorectal cancer patients. Emne A. Abdallah,
Ludmilla T. Chinen, Virgílio S. Silva, Natalia B. Mingues,
Marcelo C. Machado Netto, José Luiz Gasparini Júnior, Bruna
M. Rocha, Juliana V. Romero, Marcilei E. Buim, Mitzi Brentani,
Marcello F. Fanelli.
Poster
Board
Abstract
Number
12.
5195 A novel, multimodal theranostic nanoprobe is
effectively incorporated into melanoma brain metastatic
cells. Synnøve N. Aasen, Tilo W. Eichler, Martin Hruby, Aneta
Pospisilova, Petr Stepanek, Endy Spriet, Daniel Jirak, Kai Ove
Skaftnesmo, Frits Thorsen.
13.
5196 Histologic and whole slide quantitative image
analysis of lung metastases in a mouse breast cancer
model using carboplatin and Nutlin 3A alone and in
combination. Margaret Strack, Eva Tonsing-Carter, Tony
Sinn, Tiaishia Spragin, Kacie Peterson, Barbara Bailey, Karen
Pollok, George Sandusky.
14.
5197 Claudin-1 enhances tumor proliferation and
metastasis by regulating cell anoikisin gastric cancer.
Jiangfang Li, Jie Huang, Bingya Liu, Zhenggang Zhu.
15.
5198 Contribution of inflammatory cytokines to CD44mediated breast cancer metastatic potential. Hunter
Covert, Liliana Mellor.
16.
5199 A second round for concomitant resistance in
human cancer: A restraint upon metastasis. Geraldine
Gueron, Nicolás Anselmino, Damian Manchuca, Emiliano G.
Ortiz, Maria Noelia Carabelos, Federico Schuster, Paula
Chiarella, Alejandra Paez, Felipe M. Jaworski, Javier
Cotignola, Roberto Meiss, Raul Ruggiero, Elba S. Vazquez.
17.
5200 Significance of SPARC expression as the predict
factor of the therapeutic effect of nab-PTX in gastric
cancer. Yuki Kiyozumi, Junji Kurashige, Shiro Iwagami,
Kenichi Nakamura, Mayuko Ohuchi, Daisuke Izumi, Keisuke
Kosumi, Kazuto Harada, Ryuma Tokunaga, Yukiharu Hiyoshi,
Yoshifumi Baba, Yasuo Sakamoto, Yuji Sakamoto, Naoya
Yoshida, Hideo Baba.
6.
5189 Inhibitory effect of phytochemicals on
oncostatin-M-induced tumor invasion and migration in
human esophageal carcinoma. Eijin Naka, Yuko Takahashi,
Hisahiro Matsubara, Kazunori Kato.
7.
5190 CCR6-mediated molecular mechanisms involved
in colon cancer. Neeraj Kapur, Hina Mir, Rajesh Singh,
Shailesh Singh.
18.
8.
5191 Missense mutants of p53 tumor suppressor
contributes to drug-resistance and epithelialmesenchymal transition in colon cancer cells. Salman B.
Hosain, Yong Y. Liu.
5201 Antimetastatic effect of a Dializable Leucocyte
Extract in a murine model of prostate cancer. Miguel A.
Hernandez-Esquivel, Sonia M. Perez-Tapia, Richard G. Pestell,
Marco A. Velasco-Velazquez.
19.
5192 TGM-2 mediated downregulation of fibronectin
during TGFb-induced epithelial-mesenchymal transition in
lung cancer NCI-H358 cells. Thung S. Lai, Pin-Tsen Lin,
Charles S. Greenberg, Harry A. Drabkin, Robert Gemmill.
5202 Magnolin suppresses cell migration by abrogation
of ERK-mediated RSK2/NF-␬B signaling pathway. CheolJung Lee, Mee-Hyun Lee, Ji-Hong Song, Sun-Mi Yoo, YongYeon Cho.
20.
5203 Differential response to retinoid treatment in
mouse and human mammary tumor cell lines with
alterations in protein kinase C (PKC) expression. Maria I.
Diaz Bessone.
21.
5204 Parameters associated with metastatic
dissemination are differentially modulated by specific
isotypes of the retinoic acid receptor. Carolina Flumian,
Damián E. Berardi, Stefano M. Cirigliano, María I. Díaz
Bessone, Elisa D. Bal de Kier Joffé, Alejandro J. Urtreger,
Laura B. Todaro.
9.
10.
594
Abstract
Number
5193 Ataxia telangiectasia mutated relates to
epithelial-mesenchymal transition in colorectal cancer.
Hidena Takahashi, Masashi Tsuruta, Hirotoshi Hasegawa, Koji
Okabayashi, Ryo Seishima, Shimpei Matsui, Toru Yamada,
Takayuki Kondo, Takehiro Shimada, Mutsuhito Matsuda,
Masashi Yahagi, Yusuke Yoshikawa, Yusuke Asada, Kiyoaki
Sugiura, Yoshiyuki Suzuki, Yuki Tajima, Junpei Nakadai, Yuko
Kitagawa.
AACR ANNUAL MEETING 2015
POSTER SESSION
Poster Section 20 • Wednesday, 8:00 AM-12:00 PM
Tumor Biology
Tumor-Host Interactions
Poster
:LJ[PVU
(not eligible for CME credit)
Poster
Board
Abstract
Number
1.
5205 Docosahexaenoic acid (DHA) alters breast cancer
exosome-mediated microRNA signaling. Bethany N.
Hannafon, Karla Carpenter, William Berry, Ralf Janknecht,
William Dooley, Wei-Qun Ding.
3.
5207 Vascular remodeling is associated with increased
permeability of experimental brain metastases of breast
cancer. Kaci A. Bohn, Tori B. Terrell-Hall, Chris E. Adkins,
Rajendar K. Mittapalli, Mohamed I. Nounou, Afroz S.
Mohammad, Paul R. Lockman.
4.
5208 Neovascularization in brain metastasis is through
both angiogenesis and vasculogenesis. Stephanie Mok,
Lee-Cyn Ang, Christopher J. Howlett, Zia A. Khan.
5.
5209 Non-tumoral autotaxin stored into platelet ␣granules promotes breast cancer cell metastasis. Raphael
Leblanc, Sue-Chin Lee, Dereck Norman, Johnny Ribeiro,
Gabor Tigyi, Olivier Peyruchaud.
6.
5210 Creation of endothelial-targeted adenoviral
vectors for genetic engineering of the metastatic tumor
microenvironment. Zhi Hong Lu, Sergey Kaliberov, Lyudmila
Kaliberova, Rebecca E. Sohn, Yingqui Du, David T. Curiel,
Jeffrey M. Arbeit.
7.
5211 In vivo fluorescence and spectral microscopy of
the effects of aerobic exercise on tumor oxygenation and
perfusion in breast cancer. Jennifer A. Lee, Jennifer M.
Wiggins, Lori P. Rice, Dietmar W. Siemann.
8.
5212 GM-CSF and MMP9, targets of metformin, are
crucial mediators of the tumor-promoting role of adipose
tissue cells in breast cancer. Francesca Reggiani, Patrizia
Mancuso, Cristina Rabascio, Stefania Orecchioni, Giovanna
Talarico, Cinzia Massaro, Valentina Labanca, Angelica Calleri,
Francesco Bertolini.
9.
5213 RUNX2 modulates the angiogenic potential of
human neuroblastoma cells. Manu Gnanamony, Indra
Mohanam, Sanjeeva Mohanam.
10.
5214 Synergistic activity of aspirin, atenolol and
metformin in the inhibition of angiogenesis, local and
metastatic growth of breast cancer by targeting both
neoplastic and microenvironment cells. Giovanna Talarico,
Francesca Reggiani, Stefania Orecchioni, Patrizia Mancuso,
Angelica Calleri, Giuliana Gregato, Valentina Labanca,
Douglas M. Noonan, Katiuscia Dallaglio, Adriana Albini,
Francesco Bertolini.
Poster
Board
Abstract
Number
15.
5219 Circulating hTERT (human telomerase) mRNA:
mechanism of action and potential use for early diagnosis
of malignancy. Orit Uziel, Anna Gutkin, Einat Beery, Jardena
Nordenberg, Hadar Goldvaser, Yair Zloof, Steven Henick, Meir
Lahav.
16.
5220 Inflamed and wound recovered tumor
microenvironment contributions to lymphatic-mediated
metastasis. Darci M. Fink, Alicia L. Connor, Philip M. Kelley,
Richard M. Tempero, Michael A. Hollingsworth.
17.
5221 Mammary tumor aggressiveness is exacerbated
by endothelial HoxA5 expression. Josette Northcott, Hans
Layman, Nancy Boudreau.
18.
5222 Endothelial plasticity generates aberrant
angiogenesis and therapy resistance in glioblastoma.
Menggui Huang, Yi Fan.
19.
5223 A novel pro-angiogenic role for IDO1 in
inflammatory tumor promotion. Arpita Mondal, James B.
DuHadaway, Erika Sutanto-Ward, Courtney Smith, George C.
Prendergast, Arturo Bravo-Nuevo, Alexander J. Muller.
20.
5224 Non-canonical activity of threonyl-tRNA
synthetase promotes angiogenesis and invasion in a
mouse model of ovarian cancer. Peibin Wo, Theresa
Wellman, Alan Howe, Christopher Francklyn, Karen M.
Lounsbury.
21.
5225 Endothelial-specific Jagged1 blockade prevents
solid tumor growth in pre-clinical models. Antonio Duarte,
Ana-Rita Pedrosa, Alexandre Trindade, Catarina Carvalho,
José Graça, Sandra Carvalho, Maria C. Peleteiro, Ralf H.
Adams.
22.
5226 Glioma stem cells internalize perivascular
bevacizumab via a non-canonical pathway and target it for
recycling or degradation. Gaelle Muller-Greven, Cathleen
Carlin, Justin Lathia, Richard Prayson, Manmeet Ahluwalia,
Steven Toms, Markus Bredel, Jeremy Rich, Petra Hamerlik,
Candece L. Gladson.
23.
5227 Endothelial-targeted fumagillin nanoparticles
and zoledronic acid additively reduce tumor angiogenesis.
Alison Esser, Anne Schmieder, Jingyu Xiang, Michael Ross,
Xinming Su, Huiying Zhang, Grace Cui, Stacy Allen, XiaoXia
Yang, Dipanjan Pan, Greg Lanza, Kathy Weilbaecher.
11.
5215 Loss of Rpl22 promotes tumor progression
through regulation of angiogenesis. Shuyun Rao, Jason E.
Stadanlick, Kathy Q. Cai, David L. Wiest.
24.
5228 mTORC2 mediates SDF-1␣/CXCL12-induced
angiogenesis. Mary E. Ziegler, Michaela M. Hatch,
Christopher C. Hughes.
12.
5216 Potential use of saliva and hair samples to
identify genetic markers for anti-VEGF therapy. Gloria R.
Xue, Crystal R. Xue, Fei Shen, Bryan P. Schneider.
25.
13.
5217 Microenvironmental influences on glioma stem
cell migration. Monica J. Chau, Myles R. McCrary, Subhas
Mukherjee, Daniel J. Brat.
5229 Disruption of the acetylcholine signaling pathway
suppresses the growth and angiogenesis of human lung
cancers. Piyali Dasgupta, Kathleen C. Brown, Jamie K. Lau,
Aaron M. Dom, Brent A. Thornhill, Clayton M. Crabtree,
Theodore R. Witte, W. E. Hardman, Cody A. Stover, A. B.
Carpenter, Yi C. Chen.
April 18-22, 2015 • Philadelphia, PA
20
20
595
POSTER SESSION
Poster Section 22 • Wednesday, 8:00 AM-12:00 PM
Clinical Research
Poster
:LJ[PVU
22
22
Circulating Free DNA 2
(not eligible for CME credit)
Poster
Board
1.
2.
3.
4.
5.
6.
7.
8.
9.
10.
11.
596
Abstract
Number
5230 Circulating tumor DNA as a ‘liquid biopsy’ in head
and neck cancer. Sandra Perdomo, Devasena
Anantharaman, James Mckay, Paul Brennan.
5231 Plasma genetic and genomic abnormalities
predict treatment response and clinical outcome in
advanced prostate cancer. Liang Wang, Shu Xia, Meijun Du,
Rachel Ditmar, Tiezheng Yuan, Yongchen Guo, Yuan Wang,
Adam Lee, Michael Tschannen, Elizabeth Worthey, Howard
Jacobs, Chiang-Ching Huang, Manish Kohli.
5232 Changes in plasma circulating DNA composition
during focal ablative therapy for liver cancer. Maarit I.
Tiirikainen, Karolina Peplowska, Min-Ae Song, Kyle Miyazaki,
Linda L. Wong, Sandi A. Kwee.
5233 Prediction and response evaluation of EGFR
blockade for colorectal cancer by using circulating cellfree DNA. Takuma Iwai, Takeshi Yamada, Hatato Kan,
Michihiro Koizumi, Seiichi Shinji, Goro Takahashi, Atushi
Watanabe, Satoshi Matumoto, Akihisa Matuda, Aya
Yamagishi, Yasuyuki Yokoyama, Eiji Uchida.
5234 Tumor-unique mutation detection in cell-free
DNA to monitor colorectal tumor burden using a cancerassociated gene sequencing panel. Kei A. Sato, Satoshi S.
Nishizuka, Takeshi Iwaya, Kohei Kume, Koki Otsuka, Go
Wakabayashi.
5235 Circulating tumor DNA as a prognostic marker in
colorectal cancer: Preliminary results of a prospective
trial. Pierre Laurent-Puig, Olivier Bouché, Ralph Niarra,
Pascaline Aucouturier, Leonor Benhaim, Bruno Landi, Anne
Berger, Thierry Lecomte, Corinne Normand, Delphine Le
Corre, Audrey Didelot, Karine Mallet, Karla Perez Toralla,
Thevy Hor, Zakaria El Harrak, Gilles Chatellier, Brian
Hutchison, Darren Link, Valerie Taly.
5236 Prospective clinical application of circulating
cell-free DNA sequencing in metastatic colorectal cancer.
Maria Pia Morelli, Michael Overman, Eduardo Vilar, Van
Morris, David Fogelman, Imad Shureiqi, Chris Garret, Raghav
Kanwal, Cathy Eng, Brian Kee, Shanequa Manuel, Robert
Wolff, Dragon Sebisanovic, LaiMun Sew, Aubey Zapanta, Ben
Shiller, Gangwu Mei, Helmy Eltoukhy, AmirAli Talasaz, Scott
Kopetz.
5237 Monitoring minimal residual disease by urinary or
plasma circulating tumor DNA of KRAS mutation burden in
colorectal cancer patients with resectable liver
metastases. Vlada Melnikova, Jason C. Poole, Cecile Rose T.
Vibat, Lucie Benesova, Barbora Belsanova, Saege Hancock,
Latifa Hassaine, Errin Samuelsz, Timothy T. Lu, Mark G.
Erlander, Marek Minarik.
5238 Methodology for single copy detection and
quantitative monitoring of clinically actionable circulating
tumor DNA mutations in urine from cancer patients.
Karena Kosco, Jason C. Poole, Saege Hancock, Errin
Samuelsz, Timothy T. Lu, Erin Clark, Latifa Hassaine, Shiloh
Guerrero, Cecile Rose T. Vibat, Vlada Melnikova, Mark G.
Erlander.
5239 KRAS wild-type status as detected by circulating
tumor DNA analysis may be a prognostic or predictive
factor for clinical benefit in patients with unresectable,
locally advanced or metastatic pancreatic cancer (PC)
treated with the MEK inhibitor refametinib (BAY 86-9766)
and gemcitabine. Michael Teufel, Jean-Luc Van Laethem,
Hanno Riess, Marius Giurescu, Vittorio L. Garosi, Anke Schulz,
Richardus Vonk, Henrik Seidel, Joachim Reischl, Barrett H.
Childs.
5240 Comparative levels of KRAS mutations circulating
tumor DNA for association with overall survival in patients
with non-resectable pancreatic cancer. Julia S. Johansen,
Cecile Rose T. Vibat, Saege Hancock, Latifa Hassaine, Errin
Samuelsz, Inna Chen, Eric A. Collisson, Dan Calatayud, Benny
V. Jensen, Jane P. Hasselby, Timothy T. Lu, Jason C. Poole,
Vlada Melnikova, Mark G. Erlander.
Poster
Board
12.
13.
14.
15.
16.
17.
18.
19.
20.
21.
22.
23.
Abstract
Number
5241 Clinical relevance of circulating tumor DNA in
plasma from pancreatic cancer patients. Kjersti Tjensvoll,
Morten Lapin, Tove Buhl, Satu Oltedal, Katrine S. Berry,
Bjørnar Gilje, Jon Arne Søreide, Millind Javle, Oddmund
Nordgård, Rune Smaaland.
5242 Utilization of next-generation sequencing to
identify clinically-relevant mutations in cell-free
circulating tumor DNA from patients with advanced
pancreatic cancer. Clifford G. Tepper, Ryan R. Davis,
Stephenie Y. Liu, Rebekah A. Tsai, Irene M. Hutchins, Philip C.
Mack, Thomas J. Semrad.
5243 Copy number variation in cell free DNA in
pancreatic cancer patients undergoing neoadjuvant
therapy. Karthika Divakaran, Xia Shu, Rachel L. Dittmar,
Jenny Grewal, Kathleen K. Christians, Fabian M. Johnston,
Douglas B. Evans, Spencer Huang, Liang Wang, Susan Tsai.
5244 Next-generation sequence analysis of cell-free
DNA in patients with chemotherapy-refractory advanced
pancreatic adenocarcinoma (PDAC) treated with
selumetinib (AZD6244) and erlotinib. Andrew H. Ko, Tanios
Bekaii-Saab, Ryan Courtin, Olga K. Mirzoeva, Sharvina Ziyeh,
Robin K. Kelley, Elizabeth Ditto, Anna Ong, Regina
Linetskaya, Margaret Tempero, Alan P. Venook, Amirali
Talasaz, Wolfgang M. Korn.
5245 Identification and quantification of somatic
structural variations in tumor, urine and plasma from
bladder cancer patients. Karin Birkenkamp-Demtröder, Iver
Nordentoft, Emil Christensen, Søren Hoyer, Thomas Reinert,
Søren Vang, Jørgen Bjerggaard Jensen, Torben F. Ørntoft,
Lars Dyrskjøt.
5246 Noninvasive detection of MET gene amplification
in the circulation of cancer patients. Mark Sausen, Samuel
V. Angiuoli, Bryan Chesnick, Kevin Galens, Siân Jones, Maura
Kadan, Lisa Kann, Karli Lytle, Derek Murphy, Monica
Nesselbush, Sonya Parpart-Li, David Riley, Manish Shukla,
Theresa Zhang, Victor E. Velculescu, Luis A. Diaz.
5247 Predominance of EGFR mutations responsible for
resistance to tyrosine kinase inhibitors among tumor DNAs
assessed by picoliter droplet digital PCR analysis of cellfree plasma DNAs. Yoshitaka Seki, Yutaka Fujiwara, Takashi
Kohno, Erina Takai, Kuniko Sunami, Hidehito Horinouchi,
Shintaro Kanda, Hiroshi Nokihara, Noboru Yamamoto, Shunichi Watanabe, Kazuyoshi Kuwano, Yuichiro Ohe.
5248 Non-invasive EGFR T790M detection using
droplet digital PCR system. Shinsuke Hashida, Kadoaki
Ohashi, Takehiro Matsubara, Tomoaki Ohtsuka, Mototsugu
Watanabe, Ken Suzawa, Yuho Maki, Hiromasa Yamamoto,
Junichi Soh, Hiroaki Asano, Kazunori Tsukuda, Shinichiro
Miyoshi, Katsuyuki Kiura, Shinichi Toyooka.
5249 Intratumor heterogeneity and the detection of
potential driver mutations in cfDNA in a NSCLC cohort
using UltraSEEKTM. Mariam Jamal-Hanjani, Elza De Bruin,
Gareth Wilson, Nicholas McGranahan, Andrew Rowan,
Michael Mosko, Heath Metzler, Anders Nygren, Charles
Swanton.
5250 Analysis of circulating plasma DNA on metastatic
animal model using human lung cancer cell lines. Naoko
Aragane, Akemi Sato, Naomi Kobayashi, Eisaburo Sueoka,
Seiji Okada, Shinya Kimura.
5251 TaqMan® rare mutation assays for QuantStudio®
3D digital PCR system. Marion Laig, Brian Ho, Nivedita S.
Majumdar, Le T. Lac, Frances Chan, Ramesh Sathiyaa, Iain Russel,
Paco Cifuentes, Ted Straub, Kamini Varma, David Keys.
5252 Liquid biopsies to prospectively select patients
with KRAS or NRAS mutant hepatocellular carcinoma
(HCC) in two phase II studies with Refametinib. Heiko
Krissel, Andrea Hennig, Danny Zhang, Rodrigo Ito, Christine
Gonschorek, Fabricio Souza, Martina Poethig, Kathleen
Schostack, Joachim Reischl, Philipp Angenendt, Barrett H.
Childs, Michael Teufel.
AACR ANNUAL MEETING 2015
POSTER SESSION
Poster Section 23 • Wednesday, 8:00 AM-12:00 PM
Clinical Research
Genomics in the Clinic 2
Poster
:LJ[PVU
(not eligible for CME credit)
Poster
Board
Abstract
Number
Poster
Board
Abstract
Number
1.
5253 LT␤ receptor and NIK signaling activates the
alternative NF-kB pathway in head and neck squamous
cell carcinoma. Rita Das, Tsu-Fang Cheng, Jamie coupar,
Anthony Saleh, Xingping Yang, jialing Zhang, shaleeka
Cornelius, Carter Van Waes, zhong Chen.
18.
5270 IDH mutation status and role of WHO grade and mitotic
index in overall survival in grade II-III diffuse gliomas. Adriana Olar,
Khalida Wani, Kristin Diefes, Lindsey Heathcock, Hinke van Thuijl, Mark
Gilbert, Terri Armstrong, Erik Sulman, Daniel Cahill, Jaap Reijneveld, Bauke
Ylstra, Pieter Wesseling, Kenneth Aldape.
2.
5254 Sentinel lymph node detection and in vivo/ex
vivo assessment of melanin distribution by means of
multispectral optoacoustic tomography (MSOT) in
patients with malignant melanoma. Stefan Morscher, Ingo
Stoffels, Neal C. Burton, Jing Claussen, Thomas Sardella, Iris
Helfrich, Uwe Hillen, Julia Leyh, Dirk Schadendorf, Matthias
Gunzer, Joachim Klode.
19.
5271 Hepatic hypoxia-activated intra-arterial therapy: effect of
selective targeting of hypoxia in a rabbit liver tumor model. Rafael
Duran, Sahar Mirpour, Vasily Pekurovsky, Shanmugasundaram GanapathyKanniappan, Cory F. Brayton, Toby C. Cornish, Boris Gorodetski, Julius
Chapiro, Rüdiger Schernthaner, Constantine Frangakis, MingDe Lin, Jessica
D. Sun, Charles P. Hart, Jean-François H. Geschwind.
20.
5272 The correlation between the change of future remnant liver
volume and functional capacity in ALPPS (associating liver partition
and portal vein ligation for staged hepatectomy), and establishment of
ALPPS model in rats. Daisuke Kawaguchi, Yukihiko Hiroshima, Takashi
Murakami, Kenichi Matsuo, Chihiro Kosugi, Kiyohiko Syuto, Akimitsu
Yamada, Itaru Endo, Keiji Koda, Kuniya Tanaka.
21.
5273 Role of methylation of Wnt target genes in tumorigenesis
and effect of re-expression with demethylating agent decitabine in
colon cancer. Janneke Linnekamp, Raju Kandimalla, Louis Vermeulen,
Hanneke van Laarhoven, Jan Paul Medema.
22.
5274 MSI, 18q LOH, and clinicopathological features in stage II
sporadic colon cancers: Biomarker study in a phase III study of
postoperative adjuvant chemotherapy for stage II colon cancer
(SACURA trial). Toshiaki Ishikawa, Hiroyuki Uetake, Megumi Ishiguro,
Kenta Murotani, Hideki Ueno, Shigeyuki Matsui, Kenichi Sugihara, Naohiro
Tomita, SACURA study group.
23.
5275 Association of TERT polymorphism with acute myeloid
leukemia risk and prognosis. Kourosh Lotfi, Mohamed Ali Mosrati, Kerstin
Willander, Ingrid Jakobsen Falk, Monica Hermanson, Martin Höglund, Dick
Stockelberg, Yuan Wei, Peter Söderkvist.
24.
5276 Epithelial mesenchymal transition may contribute to
anaplastic change of pancreatic ductal adenocarcinoma. Kotaro Miura,
Kenjiro Kimura, Ryosuke Amano, Sadaaki Yamazoe, Go Ohira, Kohei Nishio,
Masatsune Shibutani, Katsunobu Sakurai, Hisashi Nagahara, Takahiro Toyokawa,
Naoshi Kubo, Hiroaki Tanaka, Kazuya Muguruma, Hiroshi Otani, Masakazu Yashiro,
Kiyoshi Maeda, Masaichi Ohira, Kosei Hirakawa.
25.
5277 ERG-based stratification of prostate cancer highlights
ethnicity associated biological differences. Albert Dobi, Michael Degon,
James Farrell, Wagner Baptiste, Denise Young, Yongmei Chen, Gyorgy
Petrovics, Jennifer Cullen, Jacob Kagan, Sudir Srivastava, Inger Rosner,
David G. McLeod, Shiv Srivastava, Isabell Sesterhenn.
26.
5278 Mutation in protein tyrosine phosphatase receptor type K
(PTPRK) enhances progression of colon cancer through WNT signaling.
Masayuki Tojo, Kazuo Konishi, Keiko Shinjo, Fumiharu Ohka, Keisuke
Katushima, Akira Hatanaka, Norihisa Ichimura, Hisako Nozawa, Tomoe
Shimazaki, Hitoshi Yoshida, Yutaka Kondo.
27.
5279 Establishing robust pharmacodynamic (PD)
immunofluorescence assays of clinical biopsies at the National Cancer
Institute: Optimized quality control procedures for the evaluation of
DNA damage response and epithelial-mesenchymal transition (EMT)
biomarkers. Katherine V. Ferry-Galow, Scott M. Lawrence, Tony Navas,
Hala R. Makhlouf, Donna O. Butcher, Brad A. Gouker, William H. Yutzy,
Jiuping Ji, Robert Kinders, Ralph E. Parchment, Shivaani Kummar, Joseph
E. Tomaszewski, James H. Doroshow.
28.
5280 A polymorphism of VEGFA is associated with susceptibility
to extrathyroidal invasion of papillary thyroid cancer. Young Gyu Eun,
Young Chan Lee, Jung-Woo Lee.
29.
5281 Prognostic biomarkers for progression-free survival in
glioblastoma multiforme: quantitative imaging and gene expressions.
Kelvin K. Wong, Stephen T. Wong.
3.
5255 miR-21 expression in HER2-positive breast cancer and
prediction of resistance to adjuvant trastuzumab. Boye S. Nielsen, Eva
Balslev, Tim S. Poulsen, Dorte Nielsen, Trine S. Moller, Christiane E. Mortensen, Kim
S. Holmstrom, Estrid Hoegdall.
4.
5256 MiRNA-31-5p expression in glioblastoma tissue and effects
of its replacement in glioblastoma cells. Jiri Sana, Andrej Besse, Jakub
Ondracek, Marek Vecera, Pavel Fadrus, Leos Kren, Hana Mlcochova,
Robert Illiev, Jitka Mlcochova, Petra Vychytilova, Renata Hezova, Jaroslav
Juracek, Ondrej Slaby.
5.
5257 Immunohistochemical analysis and comprehensive hormone
receptor profiling of uterine adenosarcomas at a single institution.
Jenna R. Zechmeister, Gloria S. Huang, Rouzan Karabakhtsian, Melissa
Schwartz, Eric R. Prossnitz, Gary L. Goldberg, Merieme Klobocista.
6.
5258 Expression analysis of STEAP1 in breast cancer patients as
therapeutic target. Chidananda Mudalagiriyappa, Sreeraj Pillai, Mark
Watson, Rebecca Aft.
8.
5260 Mitochondrial DNA phylogenetic analysis for local
recurrences and second primary tumors from patients with oral cavity
squamous cell carcinoma. Chih-Hsiung Lai.
9.
5261 Prognosis of baseline absolute lymphocyte count (ALC) and
neutrophil to lymphocyte ratio (NLR) in patients with pancreatic
adenocarcinoma. Kartik Anand, Erkut Borazanci, Sachin Pai, Runhua Shi, Syed H.
Jafri, Glenn Mills.
10.
5262 Specific mtDNA variants and colorectal adenopolyps.
LaShanale M. Wallace, Sharifeh Mehrabi, Xuebiao Yao, Felix O.
Aikhionbare.
11.
5263 Assessment and targeting of the MDM2-p53 network in CLL.
Laura Woodhouse, Clark Crawford, Scott Marshall, Nick Bown, Jonathan
Wallis, Geoffrey Summerfield, Elaine Willmore, John Lunec.
12.
5264 A novel strategy for accuurate and unambiguous mutation
detection of the highly homologous PMS2 gene. Jianli Li, Hongzheng
Dai, Yangming Feng, Jia Tang, Stella Chen, Xia Tian, Elizabeth Gorman, Eric
S. Schmitt, Jing Wang, Victor W. Zhang, Lee-Jun Wong.
14.
5266 RYBP expression predicts survival of patients with
hepatocellular carcinoma, and regulates response to chemotherapy.
Wei Wang, Jianwen Cheng, Jiang-Jiang Qin, Sukesh Voruganti, Subhasree Nag, Jia
Fan, Qiang Gao, Ruiwen Zhang.
15.
5267 Comorbidity and cause of death in patients with chronic
lymphocytic leukemia (CLL). Paolo Strati, Kari Chaffe, Sara Achenbach,
Timothy Call, Neil Kay, James Cerhan, Susan Slager, Tait Shanafelt.
16.
5268 Differences in ERG and ANXA2 expression between
Caucasian Americans and African Americans highlight distinct
pathologic features of prostate cancer progression. Shyh-Han Tan,
Denise Young, Yongmei Chen, Albert Dobi, Jennifer Cullen, Gyorgy
Petrovics, Isabell A. Sesterhenn, Shiv Srivastava.
17.
5269 Myxofibrosarcoma: A move toward Precision Medicine.
Chantal Pauli, Jonathan Pauwels, Theresa Y. MacDonald, Juan Miguel
Mosquera, Andrea Sboner, Olivier Elemento, Francesca Demichelis, Davide
Prandi, David Rickman, Beata Bode, Himisha Beltran, Mark A. Rubin.
April 18-22, 2015 • Philadelphia, PA
23
23
597
POSTER SESSION
Poster Section 24 • Wednesday, 8:00 AM-12:00 PM
Clinical Research
Poster
:LJ[PVU
24
24
Prognostic Biomarkers 3: Breast, Central Nervous System, Gynecological, and
Hematological Cancer
(not eligible for CME credit)
Poster
Board
1.
5282 A 3q amplification gene signature associated with triple
negative breast cancer lung-specific metastasis. Jun Qian, Heidi Chen,
Pierre P. Massion.
2.
5283 Vav2 oncoprotein up regulation may predict the aggressive
subtype of ductal carcinoma in situ. Marina A. Guvakova, Yun Qing Jiang,
Indira Prabakaran, Fei Wan, Nandita Mitra, Paul J. Zhang, Douglas L.
Fraker.
3.
4.
598
Abstract
Number
5284 Triple-negative breast cancer in Algerian population:
clinicopathological and molecular study. Farid Cherbal, Hadjer Gaceb,
Chiraz Mehemmai, Insaf Saiah, Rabah Bakour, Abdelhalim Ould-Rouis,
Tarek Touahria, Hassen Mahfouf, Samia Daoudi, Wassila Benbrahim, Kada
Boualga.
5285 Ki-67 expression and mitotic count in lymph node
metastasis and their association with clinico-pathologic features and
survival in aggressive breast carcinoma. Sura M. Aziz, Elisabeth Wik, Gøril
Knutsvik, Karin Collett, Lars A. Akslen.
Poster
Board
Abstract
Number
17.
5298 Serum angiogenic factors may predict prognosis in patients
with epithelial ovarian cancer. HIROAKI KOMATSU, Tetsuro Oishi, Hiroaki
Itamochi, Akiko Kudoh, Michiko Nonaka, Seiya Sato, Jun Chikumi, Shinya
Sato, Muneaki Shimada, Junzo Kigawa, Tasuku Harada.
18.
5299 Monitoring of ovarian cancer recurrence and progression via
Lumipulse G CA125II assay. Rachel R. Radwan, Savitha S. Raju, Sara J.
Gannon, John Le, Sharee D. Jones, Catherine Peacock, Katherine Falcone,
Julianna T. Young, Zhong-Qian Li, Diana L. Dickson.
19.
5300 Loss of function of two closely linked tumor suppressors
contributes to biologic aggressiveness in endometrial cancers: Comutation of CTCF and ZFHX3. Christopher J. Walker, Mario A. Miranda,
Matthew O’Hern, Kevin Coombes, Ralf Bundschuh, David G. Mutch, Paul J.
Goodfellow.
20.
5301 Integrative protein-marker prognostic model for early-stage
endometrioid endometrial carcinoma. Han Liang, UT MD Anderson
RPPA/TCGA working group.
21.
5302 Genome-wide methylation analysis reveals multiple
epigenetic subtypes of acute myeloid leukemia. Andrew D. Kelly, Heike
Kroeger, Jumpei Yamazaki, Rodolphe Taby, Frank Neumann, Justin T. Lee,
Rong He, Shoudan Liang, Yue Lu, Matteo Cesaroni, Sherry A. Pierce,
Steven M. Kornblau, Carlos E. Bueso-Ramos, Farhad Ravandi, Hagop M.
Kantarjian, Jaroslav Jelinek, Jean-Pierre J. Issa.
22.
5303 Correlative results from PRELUDE, a phase III study of
enzastaurin (ENZA) vs placebo (PBO) in patients (pts) with high-risk
diffuse large B-cell lymphoma (DLBCL) following a response to R-CHOP
therapy. Eric D. Hsi, Kerry J. Savage, Sonali M. Smith, Fritz Offner, Scott P.
Myrand, Thomas M. Habermann, Donald E. Thornton, Boris K. Lin, Tuan S.
Nguyen, Oday Hamid, Michael Crump.
23.
5304 A serum protein test for improved prognostic stratification
of patients with myelodysplastic syndrome (MDS). Joanna Roder, Judith
Löffler-Ragg, Reinhard Stauder, Ulrich Germing, Wolfgang R. Sperr, Peter
Valent, Heinrich Roder, Arni Steingrimsson, Heinz Zwierzina.
5.
5286 Expression of cancer type amino acid transporter LAT1 is a
prognosis prediction factor in breast carcinoma: comparison between
triple-negative and non-triple-negative types. Masaaki Ichinoe, Tetsuo
Mikami, Kiyomi Hana, Nobuyuki Yanagisawa, Hitoshi Endou, Isao Okayasu,
Yoshiki Murakumo.
6.
5287 RNA DNA divergences: An unsuspected marker of cancer
genomic instability accurately predicts triple-negative breast cancer
severity. Bernard E. Bihain, Stéphane Verdun, Julie Tomasina, Benoit
Hilselberger, Marie Brulliard, Lionel Bonnard, Marina Trarbach, Olivier
Roitel, Sandrine Jacquenet, Virginie Ogier, Jean-Pierre Armand, Benoit
Thouvenot.
8.
5289 The role of the immune system in lymph node positive ER+
breast cancer. Jessica G. Cockburn, Amy Gillgrass, Anita Bane.
9.
5290 Identification of novel prognostic genes associated with risk
of recurrence in early breast cancer patients. Mi Jeong Kwon.
10.
5291 Prognosis within different breast cancer subtypes using
functional activity of signaling pathways. Henk van Ooijen, Márcia A.
Inda, Ralf Hoffmann, Paul van de Wiel, Anja van de Stolpe, Wim Verhaegh.
24.
5305 Predicting relapse using CD138-independent strategy to
detect residual myeloma plasma cells. Barbara Muz, Feda Azab, Pilar de
la Puente, Justin King, Micah Luderer, Ravi Vij, Abdel Kareem Azab.
11.
5292 Determination of the receptor for advanced glycation endproducts in breast cancer patients previous chemotherapy. Jorge A.
Guadarrama-Orozco, Erika B. Ruiz-García, Hector A. Maldonado-Martinez, Lilia
P. Barron-Rodríguez, Fernando Mainero-Ratchelous, Horacio AstudillodelaVega.
25.
5306 Microparticles as novel prognostic markers in multiple
myeloma. Sabna Rajeev Krishnan, Mary Bebawy, Ross D. Brown, Frederick
Luk, Yiulam Kwan.
26.
5307 Analysis of telomere length in classic and variant hairy cell
leukemia. Daniel C. Edelman, Evgeny Arons, Holly Stevenson, Allison Gomez,
David Petersen, Hong Zhou, Yonghong Wang, Joshua J. Waterfall, Paul S.
Meltzer, Robert Kreitman.
27.
5308 Distinct expression, activity, regulation and gene expression
signature of NF-␬B subunit c-Rel and the prognostic impact of
crosstalk between p53, p63 and c-Rel in different subsets of diffuse
large B-cell lymphoma. Zijun Y. Xu-Monette, Ken H. Young.
28.
5309 The role of aquaporin-1 as the prognostic factor for triple
negative breast cancer. Young Ah Lim, Lee-Su Kim.
29.
5310 Prognostic and predictive biomarkers of clinical response to
Bevacizumab in recurrent WHO grade 3 malignant glioma patients.
Anders Toft, Thomas Urup, Kirsten Grunnet, Ib J. Christensen, Signe R.
Michaelsen, Helle Broholm, Vibeke A. Larsen, Michael Kosteljanetz, Ulrik
Lassen, Hans S. Poulsen.
30.
5311 Studies of co-expression of cancer stem cell markers and
growth factor receptors in human ovarian cancer cells and their
responses to treatment with various tyrosine kinase inhibitors. Soozana
Puvanenthiran, Sharadah essapen, Alan M. Seddon, Helmout Modjtahedi.
12.
5293 Redox imaging biomarkers for breast cancer
diagnosis/prognosis: a pilot study. He N. Xu, Julia Tchou, Min Feng,
Huaqing Zhao, Nannan Sun, Sophia Zhang, Lily Moon, Lin Z. Li.
13.
5294
Biomarkers in residual disease after neoadjuvant
chemotherapy of breast cancer predict long-term outcome. Richard
Buus, Marie Klintman, Amna Sheri, Maggie Cheang, Mitch Dowsett.
14.
5295 Latent class longitudinal modeling of CTCs in ER+ metastatic
breast cancer patients. Terry Hyslop, Xuechan Li, Rui Duan, Mario
Giuliano, Antonio Giordano, Marlana Orloff, Hallgeir Rui, James M. Reuben,
Massimo Cristofanilli.
15.
5296 FOXP1 expression is associated with tumor progression and
poor prognosis in cervical cancer. Hanbyoul Cho, Woo Kyeom Yang, Sol
Kim, Ha-Yeon Shin, Eun Ju Lee, Jae-Hoon Kim.
16.
5297 Chromosomal instability as a prognostic marker in cervical
cancer. Christine How, Jeff Bruce, Jonathan So, Melania Pintilie, Benjamin
Haibe-Kains, Angela Hui, Blaise Clarke, David Hedley, Richard Hill, Michael
Milosevic, Anthony Fyles, Kenneth W. Yip, Fei-Fei Liu.
AACR ANNUAL MEETING 2015
POSTER SESSION
Poster Section 27 • Wednesday, 8:00 AM-12:00 PM
Experimental and Molecular Therapeutics
Apoptosis: Therapeutic Manipulation
Poster
:LJ[PVU
(not eligible for CME credit)
Poster
Board
1.
2.
3.
4.
5.
6.
7.
8.
9.
10.
11.
12.
13.
14.
15.
Abstract
Number
5312 Biobran/MGN-3, arabinoxylan from rice bran,
sensitizes breast adenocarcinoma tumor cells to paclitaxol
in mice. Nariman K. Badr El-Din, Doaa A. Ali, Mai Alaa ElDein, Mamdooh Ghoneum.
5313 The anticancer effect of Vernonia amygdalina in
the MMTV-PyVT transgenic mouse model. Clement G.
Yedjou, Paul B. Tchounwou, Lucio Miele, Ifedayo V. Ogungbe,
Robert J. Brown, Marinelle Payton.
5314 Evaluation of C-phycocyanin and anticancer
drug combination for inducing apoptosis in LNCaP
prostate cancer cells. Amal Khallouki, Hasan Azad,
Sivanesan Dhandayuthapani, Miroslav Gantar, Appu
Rathinavelu.
5315 Hydroxychloroquine inhibits proliferation and S6
phosphorylation in human renal carcinoma cells. Hyung-Ok
Lee, Aladdin Mustafa, Gary R. Hudes, Warren D. Kruger.
5316 Check point kinase 1 (Chk1) targeting as a novel
therapeutic strategy in small cell lung cancer (SCLC). Aly
A. Valliani, Triparna Sen, Fatehmeh Masrorpour, Lixia Diao,
Robert J. Cardnell, Jing Wang, Bonnie S. Glisson, Helen
Piwnica-Worms, Don L. Gibbons, Lauren A. Byers.
5317 Preclinical evaluation of IQS019, a novel BCR
kinase inhibitor, in in vitro and in vivo models of nonHodgkin lymphoma. Patricia Balsas, Jocabed Roldan, Laura
Jimenez, Vanina Rodriguez, Raimon Puig de la Bellacasa,
Jordi Teixido, Alba Matas-Cespedes, Alexandra Moros,
Antonio Martinez, Elias Campo, Jose I. Borrell, Patricia PerezGalan, Dolors Colomer, Gael Roue.
5318 Effect of C-phycocyanin on the anticancer
properties of taxol and topotecan in lung cancer implanted
athymic nude mice. Sivanesan Dhandayuthapani, Miroslav
Gantar, Thanigaivelan Kanagasabai, Manasa Subbarao, Appu
Rathinavelu.
5319 Apoptotic properties of platinum antitumor
agents phosphaplatins. Homa Dezvareh.
5320 Targeting HER3 and EGFR in NRG1 positive and
HER3 mutated lung squamous cell carcinoma. Maria C.
Pinzon-Ortiz, Xianhui Rong, Richard Versace, Qing Sheng, Z.
Alexander Cao.
5321 Preclinical validation for treatment with RG7787
in ovarian cancer. Gwendlyn Kollmorgen, Klara Palme,
Annette Seidl, Stefan Scheiblich, Christian Clemens, Edgar
Voss, Martin Kaufmann, Klaus Hirzel, Pamela Wilfert, Moritz
Marcinowski, Bernd Satzinger, Frank Herting, Gerhard
Niederfellner.
5322 Englerin-A prevents invasive phenotypes of renal
cell carcinoma by reprogramming mesenchymal to
epithelial transition: A key mechanism of its anticancer
properties . Inamul Haque, Snigdha Banerjee, John A.
Beutler, Sushanta K. Banerjee.
5323 Targeting PIM1 and CDK4/6 kinases in renal cell
carcinoma. Jeffery S. Small, Sheldon L. Holder.
5324 Selective Inhibition of HDAC6 regulates
preferential cytotoxicity in cancer cells by modulating p53
and Hsp90 stability. So Hee Kwon.
5325 A c-Kit targeting antibody-drug conjugate is
efficiently metabolized and activated inside cancer cell
lines and xenograft tumors. Erica Hong, Qifeng Qiu, Rui Wu,
Alan Wilhelm, Kathleen Whiteman, Jan Pinkas, Hans
Erickson, Tinya Abrams, Siew Schleyer.
5326 Intracellular bacterial delivery of a NIPP1-peptide
kills tumor cells. Nele Van Dessel, Neil S. Forbes.
April 18-22, 2015 • Philadelphia, PA
Poster
Board
16.
17.
18.
19.
20.
21.
22.
23.
24.
25.
26.
27.
28.
29.
Abstract
Number
5327 Simultaneous inhibition of ATR and PARP greatly
sensitizes colon cancer cell lines to irinotecan. David
Davidson, Atlal Abu-Sanad, Yunzhe Wang, Fatemeh
Hasheminasab, Justin Panasci, Raquel Aloyz, Lawrence
Panasci.
5328 Protein phosphatase 2A activity is a major
determinant of therapy response in cancer cells. Otto
Kauko, Susumu Imanishi, Amanpreet Kaur, Daniel Laajala,
Evgeny Kulesskiy, Mikael Jumppanen, Garry Corthals, Tero
Aittokallio, Krister Wennerberg, Jukka Westermarck.
5329 Development of small molecule activators of
protein phosphatase 2A for the treatment of lung cancer.
Jaya Sangodkar, Sudeh Izadmehr, Sahar Mahzar, Divya Hoon,
Shen Yao, David Kastrinsky, Daniela Schlatzer, Neelesh
Sharma, Alain C. Borczuk, Michael Ohlmeyer, Yiannis
Ioannou, Goutham Narla.
5330 Methioninase-loaded erythrocytes: a promising
drug for L-methionine restriction therapy in cancer. Fabien
Gay, Julie Bes, Vanessa Bourgeaux, Yann Godfrin.
5331 Targeting CA125 negative high grade serous
ovarian cancer stem cells can result in a dramatic
reduction in tumor burden. Deanna Janzen, Ekaterian
Tiourin, Justin Salehi, Jing Lu, Matteo Pellegrini, Sanaz
Memarzadeh.
5332 The Pim kinase inhibitor AZD1208 sensitizes acute
myeloid leukemia cells with fms-like tyrosine kinase 3
internal tandem duplication (FLT3-ITD) to cytotoxic
effects of chemotherapy drugs. Kshama A. Doshi, Karthika
Natarajan, Benjamin Wolfson, Dennis Huszar, Maria R. Baer.
5333 TH-302 potentiates the antitumor activity of
topotecan in neuroblastoma and rhabdomyosarcoma
preclinical models. Libo Zhang, Bing Wu, Paula Marrano,
Paul Thorner, Sylvain Baruchel.
5334 Oncolytic Newcastle disease virus: armed but not
dangerous. Danielle K. Carroll, James Harper, Shannon
Burke, Jon Travers, Ruth Franks, Christel Navarro, Xing
Cheng, Robert W. Wilkinson, Hong Jin.
5335 Discovery and validation of new kinase targets for
therapy in ovarian clear cell cancer. Joseph J. Caumanns,
Steven de Jong, G. Bea A. Wisman, Pieter Van der Vlies, Roel
J.C. Kluin, Lorenza Mittempergher, Katrien Berns, René
Bernards, Ate G.J. Van der Zee, The ovarian clear cell cancer
consortium.
5336 Improved antitumor effect of combining WNT/
beta-catenin inhibition with sorafenib in hepatocellular
carcinoma. Hsiao-Hui Lin, Wen-Chi Feng, Li-Chun Lu, Yu-Yun
Shao, Ann-Lii Cheng, Chih-Hung Hsu.
5337 An in silico platform for characterizing ADC
bystander effects. Jackson Burton, Shu-Wen Teng,
Christopher J. Zopf, Ryan Nolan, Arijit Chakravarty.
5338 Preclinical study of telomerase-specific p53
tumor suppressor gene overexpression in human scirrhous
gastric cancer cells with different p53 status. Naoto Hori,
Hiroshi Tazawa, Masahiko Nishizaki, Satoru Kikuchi, Shuya
Yano, Michihiro Ishida, Megumi Watanabe, Yasuo Urata,
Shunsuke Kagawa, Toshiyoshi Fujiwara.
5339 Cytotoxic genes from traditional Chinese
medicine inhibit tumor growth both in vitro and in vivo.
Yuanhui Zhang, Yuan Wang, Lina Wang, George Aslanidi,
Arun Srivastava, Changquan Ling, Chen Ling.
5340 Dual PI3K and Wnt pathway inhibition is a
synergistic combination against triple-negative breast
cancer. Jeffrey P. Solzak, Rutuja Atale, Brad Hancock, Milan
Radovich.
27
27
599
POSTER SESSION
Poster Section 28 • Wednesday, 8:00 AM-12:00 PM
Experimental and Molecular Therapeutics
Poster
:LJ[PVU
28
28
600
Drug Discovery
(not eligible for CME credit)
Poster
Board
Abstract
Number
1.
5341 Bifunctional integrated molecules with combined retinoic
acid receptor agonist/protein deacetylase inhibitory activities as
therapeutic agents for breast cancer and neuroblastoma. David CotnoirWhite, Angela Miller, Bin Zhao, Isroel Weiss, James Gleason, David
Bettoun, Sylvie Mader.
2.
5342
Xanthohumol induces apoptosis and reduces notch in
neuroblastoma. Mariappan Balamurugan, Selvi Kunnimalaiyaan, T.Clark
Gamblin, Muthusamy Kunnimalaiyaan.
3.
5343 The effect of horizontal and vertical inhibition of nodes
within the MAPK and PI3K-AKT pathways in NSCLC models. Sophie
Broutin, Adam Stewart, Parames Thavasu, Angelo Paci, Jean-Michel
Bidart, Udai Banerji.
4.
5344 Novel thioxodihydroquinazolinone small molecules for
combination with platinum drugs to reverse platinum resistance
through inducing mitochondrial apoptosis independent of Bax and Bak.
Wei Qian, Joseph Salamoun, Jingnan Wang, Vera Roginskaya, Bennett
Van Houten, Peter Wipf.
5.
5345 Enhanced inhibition of PC-3 xenograft prostate tumor
growth by combination of green tea and quercetin with docetaxel.
Piwen Wang, Susanne Henning, David Heber, Jaydutt Vadgama.
6.
5346
Notch3-mediated squamous cell differentiation shows antitumor effect on esophageal squamous cell carcinoma as well as
reduces its resistance to 5-Fluorouracil. Osamu Kikuchi, Shinya Ohashi,
Yukie Nakai, Yusuke Amanuma, Masahiro Yoshioka, Shin’ichi Miyamoto,
Mitsuteru Natsuizaka, Hiroshi Nakagawa, Tsutomu Chiba, Manabu Muto.
7.
5347
SK053, a small molecule inhibitor of enzymes involved in
allosteric disulfide bonds formation, shows potent anti-leukemic
effects and induces differentiation of human AML cells. Dominika Nowis,
Justyna Chlebowska, Pawel Gaj, Michal Lazniewski, Malgorzata Firczuk,
Karolina Furs, Radoslaw Sadowski, Pawel Leszczynski, Piotr Stawinski,
Szymon Klossowski, Ryszard Ostaszewski, Krzysztof Giannopoulos, Rafal
Ploski, Dariusz Plewczynski, Jakub Golab.
8.
5348 The extracellular domain of thrombomodulin induces
erythroid differentiation and hampers proliferation of human leukemia
cells in vitro and in vivo. Takayuki Ikezoe, Jing Yang, Chie Nishioka,
Goichi Honda, Akihito Yokoyama.
9.
5349 Discovery of retinoic acids as low affinity inhibitors of the
leukemia stem cell target NR2F6. Christine V. Ichim, Lap Shu A. Chan,
Dzana Dervovic, David Koos, Richard A. Wells, Thomas Ichim.
10.
5350 Targeting Heparan Sulfated Proteoglycans by branched
peptides for selective cancer imaging and therapy. Jlenia Brunetti,
Lorenzo Depau, Chiara Falciani, Elisabetta Mandarini, Giulia Riolo, Giulia
Roscia, Alessandro Pini, Luisa Bracci.
11.
5351
Oral delivery of doxorubicin using bile enhancer for
metronomic maintenance chemotherapy. Seho Kweon, Foyez K.A.
Mahmud, Hyo Won Chang, Have Yoon Nam, Mi Ra Kim, Jung Je Park,
Youngro Byun, Sang Yoon Kim.
12.
5352
Mesenchymal stem cell as delivery carrier for prodrug gene
therapy against colorectal cancer cell. Nasrin Salehi, Ching-An Peng.
13.
5353 Efficacy of an innovative, enzyme-activated doxorubicin
prodrug in patient-derived dedifferentiated liposarcoma and synovial
sarcoma xenograft models. Jasmien Cornillie, Agnieszka Wozniak, Lise
Vreys, Haifu Li, Thomas Van Looy, Jasmien Wellens, Ulla Vanleeuw, André
Trouet, Peter Pokreisz, Daphne Hompes, Maria Debiec-Rychter, Raf Sciot,
Patrick Schöffski.
14.
5354 The guilty bystander model for electrochemotherapy of
cancer: Verification in vitro. W Clark Lambert, Gregory J. Tsongalis,
Claude E. Gagna, Muriel W. Lambert.
15.
5355 Oncolytic viral therapy with immune modulation is an
effective novel treatment strategy for non-small cell lung cancer.
Jianrui Liu, Jason Spurrel, Zhong Qiao Shi, WenQian Chen, Don G. Morris.
16.
5356 3D tissue-engineered bone marrow niche as novel method
to study pathophysiology and drug resistance in multiple myeloma.
Pilar de la Puente, Rebecca Gilson, Barbara Muz, Feda Azab, Justin King,
Samuel Achilefu, Ravi Vij, Abdel Kareem Azab.
Poster
Board
Abstract
Number
17.
5357 Inhibition of collagen receptor discoidin domain receptor-1
(DDR1) tyrosine kinase enhances cytotoxicity of anti-mesothelin
immunotoxin for cancer therapy. Fatima G. Ali-Rahmani, David
Fitzgerald, Scott Martin, Paresma Patel, Craig Thomas, Ira Pastan.
18.
5358 The hypoxia-activated EGFR-TKI TH-4000 overcomes
erlotinib-resistance in preclinical NSCLC models at plasma levels
achieved in a Phase 1 clinical trial. Adam V. Patterson, Shevan Silva,
Christopher Guise, Maria Abbattista, Matthew Bull, Huai-Ling Hsu, Charles Hart,
Jessica Sun, Angus Grey, Amir Ashoorzadeh, Robert Anderson, Jeff B. Smaill.
19.
5359 Antitumor efficacy of EC1456 in patient derived xenograft
models of ovarian, endometrial, NSCLC and TNBC. Joseph A. Reddy,
Alicia Bloomfield, Christina Taylor, Katherine Hargett, Melissa Nelson,
Christopher Leamon.
20.
5360 The preclinical profile of the duocarmycin-based HER2targeting ADC SYD985 predicts for clinical benefit in low HER2expressing breast cancers. Willem Dokter, Miranda van der Lee, Patrick
Groothuis, Ruud Ubink, Monique van der Vleuten, Tanja van Achterberg,
Eline Loosveld, Desirée Damming, Myrthe Rouwette, David Egging, Diels
van den Dobbelsteen, Patrick Beusker, peter goedings, Gijs Verheijden,
Jacques Lemmens, Marco Timmers.
21.
5361 In vitro results and electric fields simulations suggest Tumor
Treating Fields (TTFields) to be an effective treatment against
Mesothelioma. Moshe Giladi, Mijal Munster, Roni Blat, Rosa Schneiderman,
Yaara Porat, Zeev Bomzon, Noa Urman, Tali Voloshin, Eilon D. Kirson, Uri
Weinberg, Yoram Palti.
22.
5362 Andrographolide inhibits prostate cancer by modulating
chemokine and cytokines. Hina Mir, Neeraj Kapur, Rajesh Singh, Guru
Sonpavde, James W. Lillard, Shailesh Singh.
23.
5363 Navitoclax (Nav) and BMN 673 yield cytotoxicity with lower
doses than used for single agents in high-grade serous ovarian cancer
(HGSOC). Takuhei Yokoyama, Nicolas Gordon, Minshu Yu, Elise C. Kohn,
Jung-Min Lee.
24.
5364 Delayed progression of lung metastases in a triple-negative
breast cancer model following delivery of cytosine deaminase that
converts chemotherapeutic prodrug 5-fluorocytosine to 5-fluorouracil.
Louis Dore-Savard, Zhihang Chen, Paul T. Winnard, Balaji Krishnamachary,
Marie-France Penet, Venu Raman, Margaret E. Black, Zaver Bhujwalla.
25.
5365 Alternating electric fields (TTFields) in combination with
paclitaxel are therapeutically effective against ovarian cancer cells in
vitro and in vivo. Mijal Munster, Christopher P. Roberts, Eva M. Schmelz,
Moshe Giladi, Roni Blat, Rosa S. Schneiderman, Yaara Porat, Zeev Bomzon,
Noa Urman, Aviran Itzhaki, Tali Voloshin Sela, Shay Cahal, Eilon D. Kirson,
Uri Weinberg, Yoram Palti.
26.
5366 Propentofylline inhibits TROY/TNFRSF19 signaling to
enhance therapeutic efficacy in invasive glioblastoma cells. Harshil D.
Dhruv, Serdar Tuncali, Alison Roos, Patrick Tomboc, Nathan Jameson,
Ashley Chavez, Joseph Loftus, Michael E. Berens, Nhan L. Tran.
27.
5367 Discovery of dihydro-isoxazole derivatives as novel
inhibitors of NAMPT for the treatment of multiple myeloma. Dinesh
Chikkanna, Anirudha Lakshminarasimhan, Vinayak Khairnar, Sunil panigrahi,
Anuradha Ramanathan, Sumalatha Rani, Narasimha Rao, Karthikeyan S,
Kishore Narayanan, Sreevalsam Gopinath, Raghuveer Ramachandra,
Charamanna K. B., Shekar Chelur, Chetan Pandit, Murali Ramachandra.
28.
5368 Metarrestin effectively disassembles PNCs and inhibits
metastasis. Chen Wang, Kevin Frankowski, Teper Yaroslav, Samarjit
Patnaik, Frank Schoenen, Noel Southall, Wei Sun, Steve Titus, Lesley
Griner, Christopher Dextras, Jamey Sultan, Irawati Kandela, Marzena
Lewandowska, Yi-Ping Wen, John Norton, Jin Sol Kang, Andrew Mazar,
Wei Zhang, Jeffrey Aubé, Marc Ferrer, Udo Rudloff, Juan Jose Marugan,
Sui Huang.
29.
5369 Low asparagine synthetase expression and in vitro
sensitivity highlights L-asparaginase potential for the treatment of
aggressive lymphomas. Willy Berlier, Karine Aguera, Fanny Gallix, AnneMarie Chevrier, Alexandra Traverse-Glehen, Yann Godfrin.
30.
5370 The therapeutic strategy using Nek2 siRNA and 5FU for
cholangiocarcinoma cell. Toshio Kokuryo, Yukihiro Yokoyama, Junpei
Yamaguchi, Masato Nagino.
AACR ANNUAL MEETING 2015
POSTER SESSION
Poster Section 29 • Wednesday, 8:00 AM-12:00 PM
Experimental and Molecular Therapeutics
Histone Deacetylase Inhibitors, Methyltransferase Inhibitors, and Other Targets
(not eligible for CME credit)
Poster
Board
1.
Abstract
Number
5371 PRMT5 inhibitors as novel treatment for cancers.
Hendrik Falk, Richard C. Foitzik, Elizabeth Allan, Melanie
deSilva, Hong Yang, Ylva E. Bozikis, Marica Nikac, Scott R.
Walker, Michelle A. Camerino, Ben J. Morrow, Alexandra E.
Stupple, Rachel Lagiakos, Jo-Anne Pinson, Romina Lessene,
Wilhelmus J. Kersten, Danny G. Ganame, Ian P. Holmes, Gill E.
Lunniss, Matthew Chung, Stefan J. Hermans, Michael W.
Parker, Alison Thistlethwaite, Karen White, Susan A.
Charman, Brendon J. Monahan, Patricia Pilling, Julian
Grusovin, Thomas S. Peat, Stefan Sonderegger, Emma
Toulmin, Stephen M. Jane, David J. Curtis, Paul A. Stupple,
Ian P. Street.
2.
5372 Novel and selective inhibitors of histone
deacetylases (HDAC) 1 and 2 significantly enhance the
activity of the DNA methyltransferase inhibitor azacitidine
in acute myeloid leukemia (AML). Chengyin Min, Steven N.
Quayle, David Tamang, Simon S. Jones, Min Yang.
3.
5373 AK-1, a specific SIRT2 inhibitor, induces cell cycle
arrest by downregulating Snail in HCT116 human colon
carcinoma cells. MIN GYEONG CHEON, Ja-Eun Kim.
4.
5374 Development of a method to measure acetylated
histone H4 in the nuclei of circulating myeloid cells as a
surrogate tissue for the pharmacodynamics of HDAC
inhibitors in the treatment of solid tumors. Jamieson David,
Wai Wong, Gareth Veal.
5.
5375 Combined treatment of trichostatin A enhances
cytotoxic effects of sunitinib on renal cell carcinoma cells.
Hiromi Sato, Tatsuro Kashiba, Miaki Uzu, Takuya Fujiwara,
Yukihiro Shibata, Rina Suzuki, Katsunori Yamaura, Akihiro
Hisaka.
6.
5376 Identification of the first small molecule PRMT6
inhibitor tool compound. Allison Drew, Lorna Mitchell,
Nathalie Rioux, Kerren Swinger, Scott Ribich, Suzanne
Jacques-O’hagan, Trupti Lingaraj, Tim Wigle, Tom Riera,
Richard Chesworth, Jesse Smith.
7.
5377 The combination of HDAC inhibitors and
metformin as potential therapeutic agent for bladder
cancer. Peter J. Van Veldhuizen, Emma Borrego-Diaz Reyes,
Boumediene Bouzahzah, Benjamin Powers.
8.
5378 Epigenetic regugulation of osteosarcoma
metastatic phenotype via histone deacetylace inhibition.
Kurt R. Weiss, Xiaodong Mu, Daniel Brynien.
9.
5379 A potent EZH2 inhibitor exhibits long residence
time and anti-tumor activity. Heidi Ott, Glenn van Aller,
Jessica Ward, BaoChau Le, Cynthia Rominger, James Foley,
Susan Korenchuk, Charles McHugh, Michael Butticello,
Charles Blackledge, James Brackley, Joelle Burgess, Celine
Duquenne, Neil Johnson, Jiri Kasparec, Louis LaFrance, Mei Li,
Kenneth McNulty, Kenneth Newlander, Stuart Romeril,
Stanley Schmidt, Mark Schulz, Dai-Shi Su, Dominic Suarez,
Xinrong Tian, Christopher Carpenter, Juan Luengo, Ryan
Kruger, Steven Knight, Michael T. McCabe.
April 18-22, 2015 • Philadelphia, PA
Poster
Board
Abstract
Number
10.
5380 Selective HDAC inhibition by ricolinostat (ACY1215) or ACY-241 synergizes with IMiD®
immunomodulatory drugs in Multiple Myeloma (MM) and
Mantle Cell Lymphoma (MCL) cells. Steven N. Quayle, Ingrid
Almeciga-Pinto, David Tamang, Min Yang, Simon S. Jones.
11.
5381 Therapeutic potential of HDAC inhibitors in small
cell carcinoma of the ovary, hypercalcemic type (SCCOHT).
Yemin Wang, Pilar Ramos, Anthony N. Karnezis, Jeffrey M.
Trent, David G. Huntsman.
12.
5382 Epigenetic targeting of survivin enhances
paclitaxel-mediated antitumor activity against non-smallcell lung cancer. Shuiliang Wang, Ling Zhu, Zhiyong Zeng,
Lianghu Huang, Fengjin Lin, Rong Lin, Jin Wang, Jun Lu,
Qinghua Wang, Lingjing Lin, Huiyue Dong, Weizhen Wu, Kai
Zheng, Jinquan Cai, Shunliang Yang, Yujie Ma, Shixin Ye, Wei
Liu, Yinghao Yu, Bolin Liu, Jianming Tan.
13.
5383 DOT1L inhibitor EPZ-5676 synergizes with
cytarabine and azacitidine in preclinical models of MLLrearranged leukemia. Christine R. Klaus, Scott R. Daigle,
Vivek Chopra, Jeffrey A. Keats, Carly T. Campbell, Dorothy
Iwanowicz, Edward J. Olhava, Margaret P. Scott, Roy M.
Pollock, Robert A. Copeland, Jesse J. Smith, Jorge DiMartino,
Stephen J. Blakemore, Alejandra Raimondi.
14.
5384 Prolonged survival of the TH-MYCN murine model
of high-risk neuroblastoma, in response to the histone
deacetylase inhibitor panobinostat, is the result of both
apoptosis and differentiation. Kelly Waldeck, Carleen
Cullinane, Jake Shortt, Ben Martin, Kerry Ardley, Richard
Tothill, Grant McArthur, Paul J. Wood.
15.
5385 Anticancer effects of a novel histone deacetylase
inhibitor, SNUCH-1, in glioblastoma. Seung Ah Choi, Phi Ae
Kwak, Young Eun Lee, Ji Hoon Phi, Jung Won Choi, KyuChang Wang, Chul-Kee Park, Seung-Ki Kim.
16.
5386 Calothrixin A, a metabolite from Calothrix
cyanobacteria, inhibits class I histone deacetylases leading
to suppression of cell growth and induction of apoptosis in
human melanoma cells. Tripti Singh, Su Xu, Sadanandan
Velu, Santosh K. Katiyar.
17.
5387 ONC201/TIC10 is effective as a monoagent and
synergizes with chemotherapy to induce cell death in nonHodgkin’s lymphoma. Mala K. Talekar, David Dicker, Joshua
Allen, Wafik El-Deiry.
18.
5388 Methionine S-adenosyltransferase 2A (MAT2A)
inhibitors for cancer treatment. Wen Zhang, Vitaliy Sviripa,
David Watt, Chunming Liu.
Poster
:LJ[PVU
29
29
601
POSTER SESSION
Poster Section 30 • Wednesday, 8:00 AM-12:00 PM
Experimental and Molecular Therapeutics
Poster
:LJ[PVU
30
30
Kinase Inhibitors and Other Targets
(not eligible for CME credit)
Poster
Board
1.
2.
3.
4.
5.
6.
7.
8.
9.
10.
11.
12.
13.
14.
15.
602
Abstract
Number
5389 Novel kinase inhibitor for imatinib-resistant chronic myeloid
leukemia with T315I mutation. Soon-Sun Hong, Soo Jung Kim, Kyung
Hee Jung, Hong Hua Yan, Zhenghuan Fang, Joo Han Lim, Jeong Seon Ryu.
5390 The TRK inhibitor RXDX-101 enhances the efficacy of
temozolomide and irinotecan in a xenograft model of neuroblastoma.
Radhika Iyer, Rebecca L. Golden, Koumudi Naraparaju, Jamie L. Croucher,
Peng Guan, Gang Li, Zachary Hornby, Garrett M. Brodeur.
5391 Preclinical evaluation of AMG 337, a highly selective small
molecule MET inhibitor, in hepatocellular carcinoma. Zhiqiang Du, Sean
Caenepeel, Yuqing Shen, Karen Rex, Yanni Zhang, En-Tzu Tang, Ouhong
Wang, Wenge Zhong, Hui Zhou, Jacqueline Huang, Eric Huang, Liaoyuan
Hu, Angela Coxon, Mingqiang Zhang.
5392 Small molecule antagonists that mimic the dimerization
domains of the HGF/c-Met and MSP/RON growth factor systems inhibit
pancreatic cancer cell behavior and increase sensitivity to gemcitabine.
Kevin J. Church, Leen Kawas, Hank Harris, Brett R. Vanderwerff, Rachelle
R. Riggers, Joseph W. Harding.
5393 Evaluation of compounds developed against the TAM family
kinases. Hong Zhang, Zaihui Zhang, Xiaoqing Shi, Erica Lee, Rick Li,
Yuxiang Hu, Jun Yan, Jasbinder Sanghera.
5394 First-in-class dual PIM/FLT3 kinase inhibitor SEL24-B489 for
the treatment of hematological malignancies. Krzysztof Brzózka,
Wojciech Czardybon, Aniela Gołas, Renata Windak, Michał Gałe˛zowski,
Ewelina Gabor-Worwa, Bożena Winnik, Agnieszka Przybyłowicz, Maciej
Szydłowski, Emilia Białopiotrowicz, Tomasz Sewastianik, Elżbieta Ma˛dro,
Ewa Lech-Marańda, Krzysztof Warzocha, Przemysław Juszczyński.
5395 Anti-tumor activity of BMS-595, a novel CK2 kinase
inhibitor. Brent A. Rupnow, Chiang Yu, Jonathan G. Pabalan, Urvashi V.
Roongta, Jonathan S. Lippy, Ashok R. Dongre, Mary T. Obermeier, Aberra
Fura, Paul A. Elzinga, Benjamin J. Henley, Joseph Fargnoli, Francis Y. Lee,
William R. Foster, Christine M. Tarby, Brian E. Fink, John S. Tokarski,
Ashvinikumar V. Gavai, Tai W. Wong, John T. Hunt, Gregory D. Vite, Ashok
V. Purandare.
5396 Characterization of small molecule inhibitors of the PIM
kinases in in vitro models of hematological malignancies. Christine E.
Sastri, Nadia Guerrero, Dongyin Yu, Bethany Mattson, Ken Dellamaggiore,
Yajing Yang, Paul Hughes, Hui-Ling Wang, Victor Cee, Brian A. Lanman,
Liping Pettus, Anthony B. Reed, Bin Wu, Ryan Wurz, Andrew Tasker, Li-Ya
Huang, Daniel Branstetter, Karen Rex, Jeffrey Winston, Teresa L. Burgess,
Richard Kendall, J Russell Lipford.
5397 Characterization of INCB053914, a novel pan-PIM kinase
inhibitor. Niu Shin, Maryanne Covington, Richard Wynn, Yanlong Li,
Alexander Margulis, Qian Wang, Kathy Wang, Cindy Marando, Patricia
Feldman, Lynn Leffet, Karen Gallagher, Xin He, Hong Chang, He Zhang,
Hao Feng, Yun-Long Li, Chu-Biao Xue, Wenqing Yao, Timothy Burn, Kris
Vaddi, Sharon Diamond-Fosbenner, Swamy Yeleswaram, Gregory Hollis,
Robert Newton, Reid Huber, Peggy Scherle, Holly Koblish.
5398 In vivo development of pan-Pim kinase small molecule
inhibitors. Bethany Mattson, Christine. E. Sastri, Nadia Guerrero, Dean
Hickman, Jie Chen, Tian Wu, Hui-Ling Wang, Andrew Taskar, Brian
Lanman, Anthony B. Reed, Jude Canon, J. Russell Lipford, Karen Rex.
5399 Anti-cancer activity of a new LIM-Kinases inhibitor: ‘LIMPyr1’. Chloé Prunier, Julien Vollaire, Véronique Josserand, Anoek Zomer,
Amandine Hurbin, Renaud Prudent, Pascale Cohen, Jacco van Rheenen,
Jean-Luc Coll, Marc Billaud, Laurence Lafanechère.
5400 A novel combinatorial therapy for hepatocellular carcinoma
(HCC). Jyoti Srivastava, Devaraja Rajasekaran, Ayesha Siddiq, Rachel
Gredler, Chadia L. Robertson, Maaged A. Akiel, Xue-Ning Shen, Kareem A.
Ebeid, Aliasger K. Salem, Paul B. Fisher, Devanand Sarkar.
5401 TGF-␤ signaling inhibition as a potential approach to target
suboptimally debulked ovarian tumors. Wei Wei, Michael J. Birrer.
5402 A new anticancer strategy based on inhibiting mitochondrial
proline dehydrogenase (PRODH) and exploiting synthetic lethal
interactions with p53 restoration and/or glutaminase (GLS1) inhibition.
Gary K. Scott, Justine Rutter, Katya Frazier, Daniel Rothschild, Christina
Yau, Christopher Benz.
5403 Targeted therapy of non-small cell lung cancer (NSCLC) by
novel 6-pyrrolo[2,3-d]pyrimidine thienoyl antifolates with selective
transport by the proton-coupled folate transporter (PCFT). Mike R.
Wilson, Zhanjun Hou, Lei Wang, Si Wang, Manohar Ratnam, Aleem
Gangjee, Larry Matherly.
Poster
Board
16.
17.
18.
19.
20.
21.
22.
23.
24.
25.
26.
27.
28.
29.
30.
Abstract
Number
5404 PAK4 allosteric modulators (PAMs) repress the Wnt/␤catenin signaling pathway and tumor growth. William T. Senapedis,
Scott Donovan, Gali Golan, Dilara McCauley, Joel Ellis, Marsha Crochiere,
Trinayan Kashyap, Boris Klebanov, Sharon Shacham, Yosef Landesman,
Erkan Baloglu.
5405 Targeting STAT3 as a novel therapy for ovarian clear cell
carcinoma. Kristin L. Bixel, Uksha Saini, Jack Fowler, Sneja Rajendran,
Ross Wanner, Noriomi Matsumura, Kalman Hideg, Ikuo Konishi, David
Cohn, Selvendiran Karrupaiyah.
5406 Osteosarcoma cell lines response to approved and
investigational anticancer agents and statins along with gene and
microRNA expression. Gurmeet Kaur, Eric Polley, Joel Morris, Thomas
Silvers, Michael Selby, Rene Delosh, Julie Laudeman, Chad Ogle, Russell
Reinhart, Anne Monks, Annamaria Rapisarda, David Evans, Beverly A.
Teicher.
5407 T-type Ca2+ channel inhibitors sensitize ovarian cancer to
carboplatin through downregulation of survivin gene expression.
Barbara Dziegielewska, Eli V. Casarez, Wesley Z. Yang, Jaroslaw
Dziegielewski, Jill K. Slack-Davis.
5408 The novel retinamide VNLG-152, which targets translation
by promoting degradation of MAPK-interacting kinases, has
preferential activity in acute myeloid leukemia with FLT3-ITD. Sheetal
Karne, Karthika Natarajan, Senthilmurugan Ramalingam, Lalji K. Gediya,
Vincent C. Njar, Maria R. Baer.
5409 MEI-344, a novel isoflavone with activity as a mitochondrial
oxygenase inhibitor. Yefim Manevich, Miguel Quintela-Fandino, Paloma
Navarro, Carolyn Britten, Kenneth D. Tew, Danyelle M. Townsend.
5410 Aspirin attenuates tumor initiating cell growth and induces
reprogramming factors of mesenchymal to epithelial transition in
breast cancer cell. Gargi Maity, Archana De, Snigdha Banerjee, Amlan Das,
Sandipto Sarkar, Sushanta K. Banerjee.
5411 Repositioning HIV-based small molecule inhibitors of the
stress survival oncoprotein LEDGF/p75 to overcome taxane resistance
in prostate cancer. Leslimar Rios Colon, Catherine Elix, Ivana Alicea,
Anamika Basu, Christina Du Ross, Tino Sanchez, Nouri Neamati, Carlos
Casiano.
5412 Lysosome disruption rapidly and effectively induces necrosis
in aggressive thyroid carcinomas. Devora Champa, Antonio Di
Cristofano.
5413 Intracellular ATP reduction by an artificial protein as a novel
approach to cancer therapy. Dennis Datuin, Matt Hamada, Bernardo
Chavira, Andrew Fontes, Nagaraj Vinay Janthakahalli, Shaleen Korch.
5414 Activity of the pan-PIM kinase inhibitor INCB053914 in
models of multiple myeloma. Holly Koblish, Niu Shin, Leslie Hall,
Xiaoming Wen, Sybil O’Connor, Valerie Dostalik, Qian Wang, Kathy Wang,
Maryanne Covington, Cindy Marando, Kevin Bowman, Jason Boer, Krista
Burke, Ke Zhang, Hao Feng, Chu-Biao Xue, Yun-Long Li, Wenqing Yao,
Reid Huber, Kris Vaddi, Peggy Scherle.
5415 Therapeutic effects of TOPK inhibitor on triple-negative
breast cancer. Jae-Hyun Park, Takashi Miyamoto, Yo Matsuo, Yusuke
Nakamura.
5416 Activity of the pan-PIM kinase inhibitor INCB053914 in
models of acute myelogenous leukemia. Holly Koblish, Niu Shin, Leslie
Hall, Sybil O’Connor, Qian Wang, Kathy Wang, Lynn Leffet, Maryanne
Covington, Krista Burke, Jason Boer, Kevin Bowman, Ke Zhang, Hao Feng,
Chu-Biao Xue, Yun-Long Li, Wenqing Yao, Reid Huber, Kris Vaddi, Peggy
Scherle.
5417 The identification of BMS-595, an orally active imidazo[1,2b]pyridazine CK2 inhibitor with in vivo anti-tumor activity. Christine M.
Tarby, Liqi He, Brian E. Fink, Andrew Nation, Yufen Zhao, Soong-Hoon
Kim, Libing Chen, John S. Tokarski, Chiang Yu, Jonathan G. Pabalan,
Urvashi V. Roongta, Jonathan Lippy, Mary Obermeier, Paul A. Elzinga,
Aberra Fura, Benjamin Henley, Joseph J. Fargnoli, William R. Foster,
Ashvinikumar V. Gavai, Tai W. Wong, John T. Hunt, Gregory D. Vite, Ashok
V. Purandare, Brent A. Rupnow.
5418 Lipid modification of c-MYC promoter targeted
oligonucleotide stabilizes G-quadruplex formation and enhances its
growth inhibitory activity in leukemia cells. Francine Francine, Shelia D.
Thomas, Gilles Tapolsky, Donald M. Miller.
AACR ANNUAL MEETING 2015
POSTER SESSION
Poster Section 31 • Wednesday, 8:00 AM-12:00 PM
Experimental and Molecular Therapeutics
New Targets 2 / Novel Assay Technologies
Poster
:LJ[PVU
(not eligible for CME credit)
Poster
Board
1.
Abstract
Number
5419 Structure elucidation of G-quadruplex within the mid-region
of the kRAS promoter and identification of stabilizing small molecules
as promising transcriptional silencers. Rhianna K. Morgan, Tracy A.
Brooks, Khondaker M. Rahman.
2.
5420 Ribosomal protein-p53-MDM2 signaling by nucleolar stress
response and drug discovery. Kohichi Kawahara, Takuto Kawahata,
Fumito Horikuchi, Yohei Kamijo, Masatatsu Yamamoto, Yoshinari Shinsato,
Kentaro Minami, Kazunari Arima, Toshiyuki Hamada, Tatsuhiko Furukawa.
3.
5421
HER3 inhibition has little efficacy on hepatocellular
carcinoma cell lines. Yong-Shi Li, Yu-Yun Shao, Han-Yu Wang, Ann-Lii
Cheng, Chih-Hung Hsu.
4.
5422 Inhibition of oxidosqualene cyclase blocks proliferation and
survival of prostate cancer cells. Yayun Liang, Benford Mafuvadze,
Xiaoqin Zou, Cynthia Besch-Williford, Salman M. Hyder.
5.
5423 Identification of immunotargets in Hedgehog
medulloblastoma for immunotherapy. Grace S. Tan, Tom Curran.
6.
5424 Therapeutic targeting of KRAS mutation-driven tumor
progression in colorectal cancer. Christina Wu, Peng-Chan Lin, Po-Chen
Chu, Hsiao-Ching Chuang, Samuel Kulp, Tanios Bekaii-Saab, Ching-Shih
Chen.
7.
5425
8.
9.
An anti-Ephrin-A4 calicheamicin conjugate effectively
targets triple-negative breast and ovarian tumor-initiating cells to
result in sustained tumor regression. Marc Damelin, Alex Bankovich,
Albert Park, Jorge Aguilar, Wade Anderson, Marianne Santaguida, Sarah
Fong, Monette Aujay, Kiran Khandke, Virginia Pulito, Elana Ernstoff, Paul
Escarpe, Jeff Bernstein, Marybeth A. Pysz, Wenyan Zhong, Erik Upeslacis,
Judy Lucas, Justin Lucas, Timothy Nichols, Kathryn Loving, Orit Foord,
Johannes Hampl, Robert Stull, Frank Barletta, Hadi Falahatpisheh, Puja
Sapra, Hans Peter Gerber, Scott J. Dylla.
Poster
Board
17.
5435 A bioluminescent assay for measuring glucose uptake.
Michael P. Valley, Mary Sobol, Jolanta Vidugiriene, James J. Cali.
18.
5436 Targeting oncoproteins via disruption of proteostasis:
Identification of oncoprotein destabilizing agents using luciferase
tagged oncoproteins. Richard E. Middleton, Greg Olsen, Russell
McSweeney, Gang Lu, Wenhua Gao, Justin Roberts, Michael R. McKeown,
Mark A. Bittinger, Kwok-Kin Wong, James E. Bradner, William G. Kaelin.
19.
5437 A novel method to quantify gamma H2AX foci in circulating
tumor cells in patients receiving chemotherapy for colorectal cancer.
Matilde Saggese, Leah Ensell, Clare Vesely, Victoria Spanswick, Elena
Peruzzi, Diana Cunati, Giulio Signorini, John Hartley, Hendrik Tobias
Arkenau, Tim Meyer.
20.
5438 Multiplexed ICE COLD-PCR coupled to NGS and ddPCR
enables enhanced detection of low-level DNA mutations in tissues and
liquid biopsies. Katherine A. Richardson, Sarah Statt, Grant Wu, Karissa
Scott, Erin Montagne, Sheena Jensen, Courtney Cubrich, Phil Krzycki,
Jason Stoddard, Amy Kruempel, Emily McCutchen, Stephanie Veys, Kylee
Baughman, Sarah Cherubin, Vicki Rosendale, Jaclyn Pope, Paula Bartlett,
Phil Eastlake, Stephanie Peterson, Benjamin Legendre.
21.
5439 Development of a robust reporter-based T-cell activation
assay for bispecific therapeutic antibodies in immunotherapy. Pete
Stecha, Jamison Grailer, Zhi-jie Jey Cheng, Jim Hartnett, Frank Fan, Mei
Cong.
22.
5440 Novel PD-1 blockade bioassay to assess therapeutic
antibodies in PD-1 and PD-L1 immunotherapy programs. Zhi-Jie
J. Cheng, Natasha Karassina, Jamison Grailer, Jim Hartnett, Frank Fan, Mei
Cong.
23.
5441 Quantification of PIK3CA mutations in breast cancer patients
using peripheral blood. Atocha Romero, Fernando Moreno, Gloria
Serrano, Eduardo Diaz-Rubio, Trinidad Caldes, Jose Angel Garcia-Saenz.
24.
5442 Microscale methods for preparation and screening of
antibody-drug conjugates. Nicholas C. Yoder, Kalli C. Catcott, Molly A.
McShea, Carl Uli Bialucha, Parmita Saxena, Chen Bai, Kathy L. Miller,
Thomas G. Gesner, Mikias Woldegiorgis, Stuart W. Hicks, Megan E. Lewis,
Michael S. Fleming, Hans K. Erickson, Seth E. Ettenberg, Thomas A.
Keating.
25.
5443 Predictive simulation-driven personalization methodology
for refractory multiple myeloma. Nicole A. Doudican, Amitabha
Mazumder, Shireen Vali, Kabya Basu, Ansu Kumar, Neeraj Kumar Singh,
Zeba Sultana, Taher Abbasi.
26.
5444 Development of a noninvasive assay to determine drug
concentration in tumor during hsp90 inhibitor therapy. Tony Taldone,
Nagavarakishore Pillarsetty, Mark P. Dunphy, John F. Gerecitano, Eloisi
Caldas-Lopes, Brad Beattie, Radu I. Peter, Yanlong Kang, Anna Rodina,
Pengrong Yan, Erica M. DaGama Gomes, Alexander Bolaender, Christina
Pressl, Blesida Punzalan, Anson Ku, Thomas Ku, Smit Shah, Mohammad
Uddin, Mei H. Chen, Elmer Santos, Jacek Koziorowski, Adriana Corben,
Shanu Modi, Komal Jhaveri, Oscar Lin, Efsevia Vakiani, Yelena Janjigian,
Pat Zanzonico, Clifford Hudis, Steven M. Larson, Jason S. Lewis, Gabriela
Chiosis.
5426
Tumor cell surface-associated vacuolar-ATPase ‘a2’ isoform
promotes invasion by regulating matrix metalloproteinase activity in
ovarian cancer. Arpita Kulshrestha, Gajendra K. Katara, Sahithi Pamarthy,
Safaa A. Ibrahim, Alice G. Sachs, Kenneth D. Beaman.
5427 Small molecule inhibitors of Musashi family of RNA-binding
proteins. Lan Lan, Carl Appelman, Amber Smith, Jia Yu, Sarah Larsen,
Rebecca Marquez, Xiaoqing Wu, Hao Liu, Anuradha Roy, Asokan
Anbanandam, Ragul Gowthaman, John Karanicolas, Steven Rogers,
Jeffrey Aubé, Roberto De Guzman, Kristi Neufeld, Liang Xu.
Abstract
Number
10.
Sigma-2 receptor-induced cell death: a novel approach to
triple-negative breast cancer treatment. Zongyi Liu, Hilary E. Nicholson,
Wayne D. Bowen.
11.
5429 Inhibition of SMARCA2: a novel target for SMARCA4deficient lung adenocarcinoma. Phil Chapman, Nikki March, Graeme
Thomson, Emma Fairweather, Samantha Fritzl, James Hitchin, Nicola
Hamilton, Allan Jordan, Ian Waddell, Donald Ogilvie.
12.
5430 eEF1A2 is a new target for anticancer therapy. Alejandro
Losada, Maria José Muñoz, Carolina Garcia, Juan F. Martínez-Leal, Federico
Gago, Carmen Cuevas, Luis F. Garcia-Fernández, Juan M. Dominguez, Pilar
Lillo, Carlos M. Galmarini.
13.
5431 Polysialyltransferase ST8SiaII: A novel target for the
treatment of neuroblastoma. Sara M. Elkashef, Virginie Viprey, Rida F.
Saeed, Bradley R. Springett, Mark Sutherland, Paul M. Loadman, Laurence
H. Patterson, Steven D. Shnyder, Robert A. Falconer.
27.
5432 Discovery and characterization of USP22 inhibitors as novel
anti-cancer agents. Feng Wang, Timothy R. Stanek, Leelabati Biswas,
Matthew Kodrasov, James LaRocque, Jian Wu, David Sterner, Joseph
Weinstock, Michael Mattern, Steven B. McMahon, Suresh Kumar.
5445 Dual-color immunohistochemistry assays for measuring
Aiolos and Ikaros proteins in multiple myeloma patient samples. Yan
Ren, Maria Wang, Suzana Couto, Donna Hansel, Anita K. Gandhi, Patrick
Hagner, Anjan Thakurta, Rajesh Chopra, Mike Breider.
28.
5433 Discovery and development of novel USP2 inhibitors for
cancer therapy. Suresh Kumar, James P. LaRocque, Jeffrey G.
Marblestone, Jian Wu, Joseph Weinstock, David E. Sterner, Michael R.
Mattern.
5446 Continuous real-time measurement of live and dead cells in
culture over multiple days. Terry Riss, Jolanta Vidugiriene, Sarah
Duellman, Wenhui Zhou, Gediminas Vidugiris, Mike Valley, Jean Osterman,
Ruslan Arbit, Laurent Bernad, Poncho Meisenheimer, James J. Cali.
29.
5447 Association of the hedgehog signal pathway to Gefitinib
sensitivity in a 3D cancer cell lines screening. Gonzalo Castillo, Xiuyun
Jiang.
30.
5448 In vitro drug response (IVDR), biomarkers (BM) and clinical
outcome (CO) in malignant glioma (GM) patients. Ricardo J. Parker,
Michael Myers, Patric Schiltz.
14.
15.
16.
5428
5434 A high through-put bioluminescent assay to monitor the
deamidation of asparagine and isomerization of aspartate residues in
therapeutic proteins and antibodies. Said A. Goueli, Kevin Hsiao,
Rushikesh Patel, Vishal Nashine.
April 18-22, 2015 • Philadelphia, PA
31
31
603
POSTER SESSION
Poster Section 32 • Wednesday, 8:00 AM-12:00 PM
Experimental and Molecular Therapeutics
Poster
:LJ[PVU
32
32
Novel Mechanisms of Drug Response, Sensitivity, or Resistance 2
(not eligible for CME credit)
Poster
Board
Poster
Board
Abstract
Number
1.
5449 Transfection of connexin 43 enhances sunitinib-induced
apoptosis in malignant mesothelioma cells possibly via its interaction
with Bax. Miaki Uzu, Hiromi Sato, Tatsuro Kashiba, Takuya Fujiwara,
Yukihiro Shibata, Katsunori Yamaura, Akihiro Hisaka.
16.
5464 Host variation in OATP1B1 is associated with treatment
outcome in pediatric AML. Christina D. Drenberg, Stanley Pounds, Lei Shi,
Shelley Orwick, Lie Li, Shuiying Hu, Alice Gibson, Raul Ribeiro, Jeffrey
Rubnitz, Alex Sparreboom, Sharyn D. Baker.
2.
5450 Naturally occurring mutations in the MPS1 gene predispose
cells to kinase inhibitor drug-resistance. Mark D. Gurden, Isaac
Westwood, Amir Faisal, Sébastien Naud, Jack Cheung, Craig McAndrew,
Amy Wood, Jessica Schmitt, Kathy Boxall, Grace Mak, Paul Workman,
Rosemary Burke, Swen Hoelder, Julian Blagg, Rob Van Montfort, Spiros
Linardopoulos.
17.
5465 Systematic interrogation of druggable pathways in
pancreatic adenocarcinomas using pooled gene-knockdown lentiviral
libraries. Edgar Ferrer-Lorenzo, Daniel P. Nussbaum, Peter Winter, Kris
Wood.
18.
5466 Integrative TCGA analyses identify Basonuclin1 (BNC1) as a
key mediator for platinum resistance. Sherry Y. Wu, Justyna Filant,
Michael McGuire, Rajesha Rupaimoole, Sunila Pradeep, Anna Unruh,
Herbrich Shelley, Cristina Ivan, Ruder Dennis, Cristian Rodriguez-Aguayo,
Vasudha Sehgal, Takahito Miyake, Archana Nagaraja, Kshipra Gharpure,
Guillermo Armaiz, Rebecca Previs, Gabriel Lopez-Berestein, Prahlad Ram,
Keith Baggerly, Anil Sood.
19.
5467 BRCA1 N-terminal-deficient proteins provide PARP inhibitor
and platinum resistance. Yifan Wang, Andrea Bernhardy, Emmanuelle
Nicolas, Ryan Winters, Kathy Cai, Kelly Duncan, James Duncan, Maria
Harrell, Elizabeth Swisher, Neil Johnson.
3.
5451 Over-expression of NPM-ALK drives resistance to TKIs in
ALK+ ALCL but is toxic upon drug withdrawal, permitting prolonged
tumour control through discontinuous dosing. Soumya Sundara Rajan,
Amit Dipak Amin, Matthew Groysman, Praechompoo Pongtornpipat,
Jonathan Schatz.
4.
5452 Inhibition of sodium-independent and sodium-dependent
nucleobase transport activities by tyrosine kinase inhibitors. Vijaya L.
Damaraju, Michelle Kuzma, Carol E. Cass, Michael B. Sawyer.
5.
5453 Different mechanism of Oxaliplatin resistance in human
colorectal cancer cell lines. Tomoki Yamano, Shuji Kubo, Aya Yano,
Naohiro Tomita.
20.
5454 Wogonin overcomes cisplatin resistance of head and neck
cancer by targeting antioxidant defense mechanisms. Ji Won Kim, Eun
Hye Kim, Jin Young Park, Minsu Kwon, Jong-Lyel Roh.
5468 Tirapazamine as a strategy to prevent cell dissemination and
overcome drug resistance. Barbara Muz, Pilar de la Puente, Feda Azab,
Micah Luderer, Abdel Kareem Azab.
21.
5469 Dexamethasone interrupts paclitaxel-induced apoptosis in
solid tumor cells. Marianna Zavodovskaya, Carrie Brachmann, Jorge
DiMartino, Daniel Pierce.
22.
5470 Blocking wound-induced tumor repopulation between
chemotherapy cycles as a novel approach to abrogate
chemoresistance. Antonina V. Kurtova, Jing Xiao, Qianxing Mo, Senthil
Pazhanisamy, Ross Krasnow, Seth P. Lerner, Fengju Chen, Terrence Roh,
Erica Lay, Philip L. Ho, Keith S. Chan.
23.
5471 Identification of OAT1/OAT3 as contributors to cisplatin
nephrotoxicity. Shuiying Hu, Navjotsingh Pabla, Laura J. Janke, Lie Li,
Aksana Vasilyeva, Jason A. Sprowl, Alex Sparreboom.
5457 MAD2␥, a new MAD2 isoform, is ubiquitously expressed in
distinct cell lines, reduces mitotic arrest, and associates with resistance
to cisplatin-based chemotherapy in testicular germ cell tumors.
Alejandro Lopez-Saavedra, Rodrigo Caceres, Fernando Luna, Irwin
Hernandez, Luis A. Herrera.
24.
5472 Selinexor, a selective inhibitor of nuclear export (SINE), acts
through NF-␬B deactivation and combines with proteasome inhibitors
to synergistically induce tumor cell death. Yosef Landesman, Trinayan
Kashyap, Marsha Crochiere, Boris Klebanov, Sharon Friedlander, William
Senapedis, Robert Carlson, Michael Kauffman, Sharon Shacham.
10.
5458 Elevated level of Fibrillarin induces chemoresistance by
interfering p53 pathway in cancers. Teng Xu, Suthakar Ganapathy,
Meijun Long, Chul Ha, Zhi-Min Yuan, Hang Su.
25.
5473 Human cancer cells acquire chemoresistance to gemcitabine
mainly through loss-of-function mutations in the DCK gene. Akira Horii,
Yuriko Saiki, Tomohiro Nakano, Chiharu Kudo, Makoto Sunamura.
11.
5459 Overcoming resistance to HER2-targeting drugs using CDK8
inhibitors. Martina McDermott, Laura Ivers, Norma O’Donovan, John
Crown, Igor Roninson, Eugenia V. Broude.
26.
5474 PD-L1 regulates cisplatin chemoresistance in head and neck
squamous cell carcinoma. Randall S. Ruffner, Andrew Ramsey, Bert W.
O’Malley, Daqing Li.
12.
5460 Prevention of peritonitis carcinomatosa after adjuvant
chemotherapy by the inhibition of RNA polymerase in drug-tolerant
subpopulations. Satoshi S. Nishizuka, Kohei Kume, Kei Sato, Takeshi
Iwaya, Go Wakabayashi.
27.
5475 Cancer exosome promotes cisplatin resistance In bladder
cancer and inhibition of exosome sensitizes bladder cancer cells to
cisplatin chemotherapy. Chiahao Wu, Chris Silvers, Elizabeths Guancial,
Jong-Wei Hsu, Edward Messing, Yi-Fen Lee.
13.
5461 Triapine-mediated ABCB1 induction via PKC induces
widespread therapy unresponsiveness but is not underlying acquired
triapine resistance. Walter Miklos, Karla Pelivan, Christian Kowol, Rita
Dornetshuber-Fleiss, Melanie Spitzwieser, Margit Cichna-Markl, Gunda
Köllensperger, Bernhard Keppler, Walter Berger, Petra Heffeter.
28.
5476 A novel PARP inhibitor resistance mechanism mediated by
the RNA-binding protein HuR. Saswati N. Chand, Akshay R. Kamath,
Nicole Meisner-Kober, Charles J. Yeo, Jordan M. Winter, Jonathan R.
Brody.
29.
14.
5462
Extracellular ATP promotes cancer cell drug resistance to
tyrosine kinase inhibitors by competing for the ATP-binding site of
tyrosine kinase. Xuan Wang, Yanrong Qian, Yunsheng Li, Xiaozhuo Chen.
5477 MERIT40 is an Akt substrate that promotes resolution of DNA
damage induced by chemotherapy. Kristin K. Brown, Laleh MontaserKouhsari, Andrew H. Beck, Alex Toker.
30.
15.
5463
5478 Curcumin mediates reversion to oxaliplatin-acquired
resistance in colorectal cancer cell lines through modulation of nuclear
factor ␬B (NF␬B) and cyclin-dependent kinase 5 (CDK5). Vicenç Ruiz
de Porras, Sara Bystrup, Anna Martinez-Cardus, Alba Ginés, Laura Layos,
José Luis Manzano, Cristina Bugés, Albert Abad, Eva Martinez-Balibrea.
6.
7.
8.
9.
604
Abstract
Number
5455 Surface accumulation of receptor tyrosine kinases upon
treatment with tyrosine kinase inhibitors and resulting enhancement of
activity upon treatment cessation. Anne-Mette Bjerregaard, Michael V.
Grandal, Camilla Frohlich, Trine Lindsted, Christina Egebjerg, Ivan D.
Horac, Michael Kragh, Mikkel W. Pedersen.
5456 FGF9 gene amplification can induce resistance to anti-EGFR
therapy in colorectal cancer. Takuro Mizukami, Yosuke Togashi, Eri
Banno, Masato Terashima, Marco A de velasco, Kazuko Sakai, Yoshihiko
Fujita, Shuta Tomida, Takako Eguchi Nakajima, Narikazu Boku, Kazuto
Nishio.
Role of the endothelin axis in astrocyte and endothelial cell
mediated chemoprotection of cancer cells. Mark S. Kim, Hyun Jin Choi,
Ho-Jeong Lee, Junqin He, Qiuyu We, Robert R. Langley, Sin-Jin Kim, Isaiah
J. Fidler.
AACR ANNUAL MEETING 2015
POSTER SESSION
Poster Section 33 • Wednesday, 8:00 AM-12:00 PM
Experimental and Molecular Therapeutics
Pharmacogenomics
Poster
:LJ[PVU
(not eligible for CME credit)
Poster
Board
Abstract
Number
1.
5479 PGx of gemcitabine in pancreatic ADK: Where did
we go wrong. Cindy SERDJEBI, Florence GATTACCECA,
Martina SCHNEIDER, Carole MONTERYMARD, Jaic CARIO,
Karine LE MALICOT, Madani RACHID, Bruno LACARELLE,
Jean-François SEITZ, Joseph CICCOLINI, Laetitia DAHAN.
2.
5480 Effects of UGT1A1 genotype on pharmacokinetics
and toxicities of belinostat administered by continuous
infusion in two clinical trials. Andrew K. Goey, Tristan M.
Sissung, Cody J. Peer, Sheryl Ehrlich, Christina Bryla, Arlene
W. Berman, Sanjeeve Balasubramaniam, Arun Rajan,
Giuseppe Giaccone, Susan E. Bates, William D. Figg.
3.
4.
5.
6.
5481 Effect of genetic polymorphisms on erlotinib
pharmacokinetics and toxicity in Japanese patients with
non-small-cell lung cancer. Chihiro Endo-Tsukude, Ji-ichiro
Sasaki, Sho Saeki, Norihiro Iwamoto, Megumi Inaba, Sunao
Ushijima, Hiroto Kishi, Shinji Fujii, Hiroshi Semba, Kosuke
Kashiwabara, Yukari Tsubata, Yuki Kai, Hideyuki Saito,
Takeshi Isobe, Hirotsugu Kohrogi, Akinobu Hamada.
5482 CYP2D6 genotype and response to neoadjuvant
tamoxifen therapy: a prospective study in Japan. Hitoshi
Zembutsu, Seigo Nakamura, Sadako Akashi, Takashi
Kuwayama, Chie Watanabe, Hiroyuki Takei, Takashi Ishikawa,
Yoshie Hasegawa, Soo Chin Lee, Tan Ern Yu, Ayami
Matsukata, Hiroshi Matsumoto, Goro Kutomi, Yusuke
Nakamura.
5483 CYP19A1 genetic variation is a potential predictor
of outcome in ER-positive postmenopausal early breast
cancer patients treated with tamoxifen. Wing-Yee Lo,
Werner Schroth, Reiner Hoppe, Marjanka Schmidt,
Montserrat Garcia-Closas, Paul Pharaoh, Per Hall, Douglas
Easton, Peter Fasching, Hiltrud Brauch, in collaboration with
the Breast Cancer Association Consortium.
5484 FGFR2 amplification is predictive of sensitivity to
regorafenib in gastric and colorectal cancers. Yongjun Cha,
Hwang-Phill Kim, Sae-won Han, Jiyeon Yun, Sang-Hyun
Song, Tae-You Kim.
7.
5485 Coactivator PPARGC1B Ala203Pro polymorphism
is linked with estrogen-related receptor function and
breast cancer outcome. Pilar H. Saladores, Reiner Hoppe,
Wing-Yee Lo, Sibylle Cocciardi, Ute Hofmann, Ute Hamann,
Peter Fasching, Marcus Schmidt, Hiltrud Brauch, Werner
Schroth.
8.
5486 Identification of novel candidate genes
associated with sorafenib cytotoxicity. Daniel J. Crona,
Oscar Suzuki, O. Joseph Trask, Bethany Parks, Amber Frick,
Timothy Wiltshire, Federico Innocenti.
9.
5487 Functional analysis of rare dihydropyrimidine
dehydrogenase variants relevant to 5-fluorouracil toxicity.
Shikshya Shrestha, Steve Offer, Robert B. Diasio.
April 18-22, 2015 • Philadelphia, PA
Poster
Board
Abstract
Number
10.
5488 Utilizing a pathway based analysis of genome
wide association data to identify biomarkers of toxicity in
breast cancer patients. Behzad Bidadi, Krishna R. Kalari,
Matthias Rubner, Alexander Hein, Matthias W. Beckmann,
Peter A. Fasching, Brigitte Rack, Wolfgang Janni, Richard
Weinshilboum, Liewei Wang.
11.
5489 A genome-wide association study identifies novel
loci associated with taxane-related sensory neuropathy in
breast cancer patients enrolled in a cooperative group
clinical trial (SWOG S0221). Lara Sucheston-Campbell,
Alyssa Clay, William E. Barlow, G. T. Budd, Dan Stram, Chris
Haiman, Li Yan, Gary Zirpoli, Song Yao, Dawn Hershman,
Kathy S. Albain, Daniel F. Hayes, Halle Moore, Timothy J.
Hobday, James A. Stewart, Claudine Isaacs, Muhammad
Salim, Julie R. Gralow, Gabriel N. Hortobagyi, Robert B.
Livingston, Xin Sheng, Deanna L. Kroetz, Christine B.
Ambrosone.
12.
5490 Implementation of genetic sequencing in breast
and ovarian cancer patients: a cost analysis. Marissa A.
Olson, Seth Tutera, Casey Williams.
13.
5491 Sequential use of first and second generation TKIs
are effective on prolonged overall survival in elderly
population affected by Ph+ acute lymphoblastic leukemia:
the GIMEMA experience. Chiara Sartor, Cristina
Papayannidis, Alfonso Piciocchi, Antonella Vitale, Ilaria
Iacobucci, Simona Soverini, Pier Luigi Lollini, Francesco Di
Raimondo, Stefania Paolini, Massimiliano Bonifacio, Angelo
Michele Carella, Mario Cazzola, Antonio Cuneo, Pietro Leoni,
Mario Luppi, Enrica Morra, Giorgina Specchia, Loredana Elia,
Robin Foà, Michele Baccarani, Giovanni Martinelli.
14.
5492 Functional characterization of human toll-like
receptor 5 (TLR5) genetic variants. Andrzej J. Wierzbicki,
Araba A. Adjei, Nuttapong Ngamphaiboon, Thanyanan
Reungwetwattana, Andrei V. Gudkov, Alex A. Adjei.
15.
5493 Genome-wide study of carboplatin and paclitaxel
disposition in ovarian cancer patients. Bo Gao, Yi Lu,
Annemieke J. Nieuweboer, Hongmei Xu, Jonathan Beesley,
Ingrid Boere, Anne-Joy M. de Graan, Peter de Bruijn, Howard
Gurney, Catherine Kennedy, Yoke-Eng Chiew, Sharon E.
Johnatty, Philip Beale, Michelle Harrison, Craig Luccarini,
Alison M. Dunning, Ron H. Mathijssen, Paul Harnett,
Rosemary L. Balleine, Georgia Chenevix-Trench, Stuart
MacGregor, Anna deFazio.
16.
5494 Cost analysis of genomic-directed therapy in
patients with metastatic lung and colorectal cancers. Seth
Tutera, Marissa Olson, Casey Williams, Brian Leyland-Jones,
Mark Huber, Heidi McKean, Addison Tolentino.
17.
5495 Identification of markers predictive of
phosphoramide mustard (PM) cellular sensitivity in
lymphoblast cell lines. Lata Chauhan, Brooke L. Fridley, Alice
Wang, Jatinder K. Lamba.
33
33
605
POSTER SESSION
Poster Section 34 • Wednesday, 8:00 AM-12:00 PM
Experimental and Molecular Therapeutics
Poster
:LJ[PVU
34
34
Role of the Microenvironment and Tumor Metabolism in Therapeutic Response
(not eligible for CME credit)
Poster
Board
Poster
Board
Abstract
Number
9.
5504 Penfluridol suppresses triple negative breast
cancer metastasis to brain by inhibiting ␣6␤4 integrins.
Alok Ranjan, Parul Gupta, Sanjay Srivastava.
5497 Cabozantinib eradicates de novo castrateresistant PTEN/p53 deficient murine prostate cancer via
activation of neutrophil-mediated anti-tumor innate
immunity. Akash Patnaik, Kenneth Swanson, Katja Helenius,
Thornley Thomas, Athalia Pyzer, Vilmosne Csizmadia, Sabina
Signoretti, Todd Morgan, Yugang Wang, Olivier Elemento,
Lily Wang, Elena Levantini, John Clohessy, John Asara, David
Smith, Jacalyn Rosenblatt, David Avigan, Steven Balk, Lewis
Cantley.
10.
5505 MyD88-dependent signaling decreases the antitumor efficacy of epidermal growth factor receptor
inhibition in head and neck cancer cells. Andrean L.
Simons-Burnett, Adam T. Koch, Laurie Love-Homan, Aditya
Stanam.
11.
5506 Anti-angiogenic effects of zoledronic acid on
osteotropic breast cancer cells. Cynthia Jackson, William
Whalen, Shana Morshedian, Jason A. Bush.
3.
5498 Multiple mechanisms of action may contribute to
the lymphoma cell-killing activity of SH7139. Monique C.
Balhorn, Saphon Hok, Rod Balhorn.
12.
5507 Characterization of ADC bystander killing in
admixed tumor model. Fu Li, Kim K. Emmerton, Mechthild
Jonas, Xinqun Zhang, Che-Leung Law.
4.
5499 Necuparanib affects tumor progression and
invasion in a 3D co-culture system of pancreatic cancer
cells and stellate cells. Silva Krause, Amanda Weyers, Katie
Loveluck, Birgit Schultes.
13.
5.
5500 A 3D tumor tissue microphysiological system for
realistic tumor microenvironment mimicry and therapeutic
modeling. Agua Sobrino, Dúc Phan, Steven C. George,
Christopher C.W. Hughes.
5508 Fucoidan from Turbinaria conoides attenuates
pancreatic cancer progession by regulating p53 - NF␬B
crosstalk. Caroline R. Delma, Guru Prasad Srinivasan, Nune
Raviprakash, Sunil K. Manna, Somasundaram T.
Somasundaram, Natarajan Aravindan.
14.
6.
5501 Antagonism of sorafenib and regorafenib actions
by epidermal growth factor in hepatoma cells. Brian I. Carr,
Rosalba D’Alessandro, Maria Grazia Refolo, Catia Lippolis,
Caterina Messa, Aldo Cavallini.
5509 A drug-screening model to identify compounds
active in cells under metabolic stress. Paola Pellegrini,
Martin Haraldsson, Annika Jenmalm Jensen, Thomas
Lundbäck, Angelo De Milito.
15.
5510 Tamoxifen induces estrogen receptorindependent bioenergetic stress: A synthetic lethality
approach to target tumor metabolism. Natalie A. Daurio,
Stephen Tuttle, Constantinos Koumenis.
16.
5511 Endoxifen inhibits polyamine biosynthetic
enzyme activity and up-regulates metabolizing enzymes,
spermine oxidase (SMO) and acetyl spermine oxidase
(APAO)in breast cancer. T. J. Thomas, Hui-Chen Hsu, Mervi
Hyvonen, Tuomo Keinanen.
17.
5512 Preclinical evaluation of the recombinant human
arginase PEG-BCT-100 leading to arginine deprivation in
sarcomas. Chi Tung Choy, Hio Teng Cheong, Kin Pong U, Chi
Hang Wong, Herbert Ho Fung Loong.
1.
5496 Effect of BTK inhibitors on differentiation of
human monocyte-derived dendritic cells. Zhijian Sun,
Dongping Zhou, Lusong Luo.
2.
7.
8.
606
Abstract
Number
5502 IAP inhibitor CUDC-427 induces tumor regression
or stasis in preclinical models of B cell lymphoma. Ze Tian,
Kaiming Sun, Troy Patterson, Ruzanna Atoyan, Mylissa Borek,
Maria Samson, Brianne Hantzis, Anna W. Ma, Steven
Dellarocca, Brian Zifcak, Guangxin Xu, Jing Wang.
5503 Panaxynol, a potential treatment for colitis,
selectively targets pro-inflammatory macrophages for
DNA damage and apoptosis. Anusha Chaparala, Deepak
Poudyal, Xiangli Cui, Bin Li, Erin E. Witalison, Taixing Cui,
Lorne J. Hofseth.
AACR ANNUAL MEETING 2015
POSTER SESSION
Poster Section 36 • Wednesday, 8:00 AM-12:00 PM
Chemistry
Drug Delivery
Poster
:LJ[PVU
(not eligible for CME credit)
Poster
Board
Abstract
Number
Poster
Board
Abstract
Number
1.
5513 Employing a unique panel of breast cancer
cellular lipids extracts in the development of a novel
nanoliposome drug platform. Hanan M. Alharbi, Robert B.
Campbell.
15.
5527 Oral administration of a nano-enabled form of
Met-Enkephalin peptide controls pancreatic cancer
growth. Preethi Marimuthu, Ijeoma F. Uchegbu, Andreas G.
Schätzlein.
2.
5514 Pharmacokinetics of BIND-014 (docetaxel
nanoparticles for injectable suspension) in preclinical
species and patients with advanced solid tumors. Jason
Summa, Daniel Von Hoff, Jasgit Sachdev, Monica Mita,
Patricia LoRusso, Peter Eisenberg, Howard Burris, Lowell
Hart, Hagop Youssoufian, Donald Parsons, Susan Low.
16.
5528 Development and evaluation of cell membrane
lipid-extracted nanoliposomes (CLENs) for the treatment
of cancer using cellular models of human pancreatic
cancer. Taha Y. Alqahtani, Robert Campbell.
17.
5529 The advanced strategy for novel EGCG derivative
modified liposome with high targeting ability to tumor.
Ikumi Sugiyama, Kunihiro Kaihatsu, Nobuo Kato, Yasuyuki
Sadzuka.
18.
5530 Chitosan amphiphile nanoparticles reduced the
myelosuppressive effects of lomustine. Funmilola A. Fisusi,
Omotunde Okubanjo, Kar Wai Chooi, Andreas G. Schatzlein,
Ijeoma F. Uchegbu.
19.
5531 Combination drug delivery using PBM
nanoparticle to improve prostate cancer therapy. Rajesh
Singh, Shailesh Singh, Guru P. Sonpavde, James W. Lillard.
20.
5532 Polymeric albumin-free paclitaxel intraperitoneal
therapy demonstrates superior efficacy over nabpaclitaxel intravenous therapy in a mouse model of
metastatic ovarian cancer. Kouros Motamed, Neveen Said.
21.
5533 A local chemotherapy with hyaluronan-cisplatin
conjugate significantly attenuates growth of lung
adenocarcinoma xenografts in mouse model. Susumu
Ishiguro, Deepthi Uppalapati, Shuang Cai, Katie Turner, Jacob
Hodge, Laird Forest, Masaaki Tamura.
22.
5534 Novel pluronic F127-coated paclitaxel
nanoparticles formulation for pancreatic cancer. Murali M.
Yallapu, Neeraj Chauhan, Sheema Khan, Meena Jaggi, Aditya
Ganju, Diane M. Maher, Mara C. Ebeling, Subhash C. Chauhan.
23.
5535 Non-invasive cellular nano-permeabilization to
enhance drug delivery and improve therapeutic outcome
in solid tumors: Mitigating the path to destruction. Meena
Augustus, Rajah V. Kumar.
24.
5536 KB-164, a novel and highly potent Src family
kinase inhibitor, reduces cancer cell invasion and
abrogates downstream oncogenic pathways in triple
negative breast cancer. Rabia A. Gilani, Kristoffer R.
Brandvold, Li Wei Bao, Sameer Phadke, Michael E. Steffey,
Matthew B. Soellner, Sofia D. Merajver.
25.
5537 Nanoparticle delivery of an SN38 conjugate is
more effective than Irinotecan in a mouse model of
Neuroblastoma. Radhika Iyer, Jamie L. Croucher, Michael
Chorny, Jennifer L. Mangino, Ivan S. Alferiev, Robert J. Levy,
Venkatadri Kolla, Garrett M. Brodeur.
26.
5538 A pH-responsive doxorubicin-lipid conjugate
loaded nanomedicine for breast cancer treatment. Feng Li,
Marilyn Saulsbury, Simone Heyliger, Mikhail Bondarev,
Chengan Du, Corinne C. Ramaley, KiTani P. Lemieux.
27.
5538A Cell size-specific intracellular delivery. May Tun
Saung, Armon Sharei, Viktor Adalsteinsson, Andrew Liss,
Nahyun Cho, Tushar Kamath, Camilo Ruiz, Jesse Kirkpatrick,
Robert Langer, Christopher Love, Klavs Jensen.
3.
5515 Neoadjuvant chemoradiotherapy for rectal cancer
with CRLX101, an investigational nanoparticle-drug
conjugate with a camptothecin payload. XI TIAN, Minh
Nguyen, Henry Foote, Kyle T. Wagner, Hanna K. Sanoff,
Autumn J. McRee, Bert H. O’Neil, Benjamin F. Calvo, William
A. Blackstock, Joel E. Tepper, Edward Garmey, Scott Eliasof,
Andrew Z. Wang.
4.
5516 Biodistribution of liposomal docetaxel prodrug
MNK-010 in mice bearing A549 human NSCLC xenografts.
Richard M. Fitch, James H. Wible, James A. Blackledge,
William D. McGhee.
5.
5517 Polymeric nanogel-based treatment regimen for
enhanced efficacy and sequential administration of
synergistic drug combination in pancreatic cancer. Kruti S.
Soni, Michael A. Hollingsworth, Prakash Radhakrishnan,
Tatiana K. Bronich.
6.
5518 Development of bio-affinity nanoparticles:
Applications for cancer imaging and therapeutics. Idit
Dotan, Philip J. Roche, Elliot Mitmaker, Mark A. Trifiro,
Miltiadis Paliouras.
7.
5519 Engineered protein nanocage for targeted
delivery of siRNA to cancer cells. Eun Jung Lee, Yoosoo
Yang, In-san Kim, Kwangmeyung Kim, Jeewon Lee.
8.
5520 HER2-targeted gold nanoparticles produce
potent antitumor effects on human gastric cancer cells.
Tetsushi Kubota, Shinji Kuroda, Katsuyuki Aoyama, Hiroshi
Tazawa, Shunsuke Kagawa, Toshiyoshi Fujiwara.
9.
10.
5521 Interleukin-4 receptor-targeted liposomal
doxorubicin for enhanced targeted drug delivery and
antitumor effect in colorectal cancer. Chih-Yung Yang, ChiHong Lin, Jeng-Kai Jiang.
5522 Combination of a supramolecular
nanotherapeutic targeting MEK and immune checkpoint
inhibitor exerts a synergistic antitumor outcome. Ashish A.
Kulkarni, Venkata Sabbisetti, Prithvi R. Pandey, Shiladitya
Sengupta.
11.
5523 A novel aptamer targeting agent for prostate
cancer. Bethany Powell Gray, Linsley Kelly, Matthew Levy,
Bruce A. Sullenger.
12.
5524 Comparison of c-Myc inhibitor effectiveness in
various cancer cell lines. Marija Kuna, Drazen Raucher.
13.
5525 Antibody/drug-conjugated micelle as a versatile
platform technology for targeted tumor delivery. Mitsunori
Harada.
14.
5526 Deciphering the basis of CendR-mediated
penetration into tumors. Hongbo Pang, Gary B. Braun,
Tomas Friman, Erkki Ruoslahti.
April 18-22, 2015 • Philadelphia, PA
36
36
607
POSTER SESSION
Poster Section 37 • Wednesday, 8:00 AM-12:00 PM
Chemistry
Poster
:LJ[PVU
37
37
Natural Products
(not eligible for CME credit)
Poster
Board
1.
2.
3.
4.
5.
6.
7.
8.
9.
10.
11.
12.
14.
15.
16.
17.
608
Abstract
Number
5539 Antiproliferative and apoptotic effects of some
African natural products in solid and hematopoietic
malignant cell lines. Olufemi E. Akanni, Martin R. Berger.
5540 Antitumor efficacy of synthetic formulations of
active components in Arum palaestinum extracts in head
and neck squamous cell carcinoma. Vikalp Vishwakarma,
Kyle Crooker, Vusala Snyder, Jeffrey Straub, Caitlin Cole,
Annie Lee, Lisa S. Bittel, Sufi Thomas.
5541 Natural products as possible anti-cancer agents
for digestive malignancies. Koh Miura, Masayuki Satoh,
Makoto Kinouchi, Kuniharu Yamamoto, Yasuhiro Hasegawa,
Yoichiro Kakugawa, Masaaki Kawai, Kiyoshi Uchimi, Hiroki
Aizawa, Hiroto Sakurai, Tsuneaki Fujiya.
5542 Flaxseed and its lignan component protect from
asbestos-induced inflammation in mice. Steven M. Albelda,
Ralph A. Pietrofesa, Craig W. Menges, Joseph R. Testa, Melpo
Christofidou-Solomidou.
5543 Elucidating the cytotoxic effects of
taxol,camptothecin and Lobostemon fruticosus extracts
on non-small cell lung cancer. Lesetja R. Motadi, Lungile
Ndlovu.
5544 Attempts to synthesize 5,7-dihydroxy-3H-1,2dithiolo[4,3-d]- pyrimidine, M-47, a potential new
treatment for drug- resistant breast cancer. Canio J.
Marasco, Joseph A. Dunn, Paula J. Pera, Alexander E.
Macubbin.
5545 Deguelin selectively inhibits proliferation of
luminal androgen receptor (LAR) triple-negative breast
cancer cells. Andrew J. Robles, Shengxin Cai, Robert H.
Cichewicz, Susan L. Mooberry.
5546 A natural alkaloid, berberine, as a novel
transcriptional repressor of RET proto-oncogene in
medullary thyroid carcinoma. Daekyu Sun, Vishnu
Kumarasamy.
5547 Anti-proliferative activity of hydnocarpin, a
natural lignan, is associated with the inhibition of Wnt/␤catenin signaling pathway via axin turnover in colon
cancer cells. Won Kyung KIM, Min Ai LEE, Hyen Joo PARK,
Ji-Young HONG, Sam Sik KANG, Sang Kook LEE.
5548 Reishi reduces the phosphorylation of STAT-3 in
inflammatory breast cancer in vitro and in vivo models.
Michelle M. Martínez-Montemayor, Luis A. Cubano, Yaliz
Loperena.
5549 Anti-proliferative effect of Oman’s medicinal
plants derived active principles on breast cancer cells
(MDA MB 231). Lukmanul Hakkim.
5550 Corilagin, an anti-tumor herb medicine, sensitizes
paclitaxel and carboplatin by primarily inhibiting
glycolysis pathways in epithelial ovarian cancer. Luoqi Jia,
Hongyan Jin, Minzhi Lv, Naiqing Zhao, Shaosong Liu,
Zhizhong Zheng, Yiling Lu, Yanling Ming, Yinhua Yu.
5552 Medicinal plants show anticancer splicing activity
of apoptotic genes. Zodwa Dlamini, David Bates.
5553 In vivo and in vitro effect of Withania somnifera
extract on the proliferation of side population (CD44HIGH
/CD24LOW ) cells sorted from MDA-MB-231 breast cancer
cells. Kamel F. Khazal.
5554 Cisplatin in combination with a potential
antiestrogen wedelolactone applied to different
gynaecological tumor models. Sadia Sarwar, Jun Q. Yu,
Fazlul Huq.
5555 Combined effect of modified citrus pectin and
ionizing radiation on survival and metastatic activity of
prostate cancer cells. Isaac G. Eliaz, Sefora Conti, Akiva
Vexler, Ben Koren, Nir Honig, Natan Shtraus, Yaron Meir,
Shahar Lev-Ari, Ilan Ron.
Poster
Board
18.
19.
20.
21.
22.
23.
24.
25.
26.
27.
28.
29.
30.
Abstract
Number
5556 Enhancing response of Ganoderma lucidum
(Reishi) and lapatinib in HER2+ inflammatory breast
cancer cells. Yismeilin Feliz-Mosquea, Ivette Suarez-Arroyo,
Yaliz Loperena, Luis A. Cubano, Michelle M. MartinezMontemayor.
5557 Chemotherapeutic and chemomodulatory effects
of naturally occurring O-naphthoquinone and related
coumarins against solid tumor cells in-vitro. Mohammed A.
Baghdadi, Fahad A. Al-Abbasi, Ali M. El-Halawany, Ahmed M.
Al-Abd.
5558 Growth inhibitory effect of perganum, sage, and
olive leaves plant extracts on breast and lung cancer cell
lines. Carla Gibbs, Ola Almusallam, Trent E. Malone, Elbert L.
Myles.
5559 Novel synthetic pyridyl analogues of CDDO-Im
with improved stability and their potential use in cancer
prevention. Martine Cao, Evans Onyango, Charlotte Williams,
Darlene Royce, Gordon Gribble, Michael Sporn, Karen Liby.
5560 Quercetin overcomes chemotherapy resistance in
triple negative breast cancer. Asha Srinivasan,
Chellappagounder Thangavel, Yi Liu, Sunday Shoyele, Robert
B. Den, Ponniah Selvakumar, Ashakumary
Lakshmikuttyamma.
5561 Violacein inhibits matrix metalloproteinase
mediated CXCR4 expression: Potential anti-tumor effect in
cancer invasion and metastasis. Venkataswarup Tiriveedhi.
5562 BreastDefend enhances the effects of tamoxifen
in estrogen receptor-positive human breast cancer in vitro
and animal models in vivo. Shujie Cheng, Mark Alvarado,
Jagadish Loganathan, Victor Castillo, Georg Sandusky, Isaac
Eliaz, Daniel Sliva.
5563 Tripterygium induces apoptosis in NSCLC via
mitochondria dysfunction. Xing-Xing Fan, Na Li, Jin-Lin Wu,
Yan-Ling Zhou, Liang Liu, Jian-Xing He, Elaine L. Leung.
5564 Total synthesis of 6-deoxypladienolide D and
assessment of splicing inhibitory activity in a mutant
SF3B1 cancer cell line. Kenzo Arai, Silvia Buonamici, Betty
Chan, Laura Corson, Atsushi Endo, Baudouin Gerard, MingHong Hao, Craig Karr, Kazunobu Kira, Linda Lee, Xiang Liu,
Jason T. Lowe, Tuoping Luo, Lisa A. Marcaurelle, Yoshiharu
Mizui, Marta Nevalainen, Morgan Welzel O’Shea, Eun Sun
Park, Samantha A. Perino, Sudeep Prajapati, Mingde Shan,
Peter G. Smith, Parcharee Tivitmahaisoon, John Yuan Wang,
Markus Warmuth, Kuo-Ming Wu, Lihua Yu, Huiming Zhang,
Guo Zhu Zheng, Gregg F. Keaney.
5565 Antitumor activities of psammaplin A analogues
in human lung cancer cells. Yoonho Shin, Suckchang Hong,
Jongheon Shin, Hyeung-geun Park, Sang Kook Lee.
5566 Carnosic acid induces apoptosis through
inhibition of STAT3 signaling and production of ROS in
human colon cancer HCT116 cells. In Gyeong Chae, Mi-Hee
Yu, Ki-Woong Park, Kyung-Soo Chun.
5567 Anti-angiogenic activity of Thio-Cl-IB-MECA, a
novel A3 adenosine receptor agonist, by regulating of
PI3K/AKT/mTOR and ERK signaling pathways in
endothelial cells. Jedo Oh, Gi Dae Kim, Lak Shin Jeong,
Sang Kook Lee.
5568 Inhibitory Effect of Partial Electron Decoupling
Agents as an Alternate Therapy for Cancer. Omar Bagasra,
Kareem Heslop, Krystal Livingston, Keneisha Corbett,
Amarachi O. Ejiawoko, Leanna Sealey.
AACR ANNUAL MEETING 2015
POSTER SESSION
Poster Section 38 • Wednesday, 8:00 AM-12:00 PM
Epidemiology
Cancer Risk/Mortality: Exposures, Biomarkers, and Genetics 2
(not eligible for CME credit)
Poster
Board
Abstract
Number
Poster
Board
Abstract
Number
1.
5569 p73 dinucleotide polymorphism genotyping of
human cancer cell lines. L. Michael Carastro, Kaia K.
Hampton, Ricardo A. Cordova Estupinan, Hyun Y. Park,
Dongwha Kim, Jong Y. Park.
13.
5581 A model incorporating spirometry to predict
absolute risk of lung cancer: The UK Biobank prospective
cohort study. David C. Muller, Mattias Johansson, Paul
Brennan.
2.
5570 Heterogeneity of luminal breast cancer
characterized by immunohistochemical expression of
basal markers. Hyuna Sung, Jenny Chang-Claude, Jonine
Figueroa, Heli Nevanlinna, Graham G. Giles, Angelia Cox,
Simon S. Cross, Melissa C. Southey, Catriona McLean, Manjeet
K. Bolla, Mitul Shah, Alison M. Dunning, Joe Dennis, Qin
Wang, Kyriaki Michailidou, Douglas F. Easton, Paul D.
Pharoah, Mark E. Sherman, Montserrat Garcia-Closas,
Xiaohong R. Yang.
14.
5582 Survey of oral cancer screening participants
reveals widespread misconceptions about oral cancer risk
factors, independent of educational background. Cariad
Chester, Jean Sabile, Grace Cho, Annie Hu, Ryoko Hamaguchi,
Lauren Ellis, Jonathan S. Erdman, David Praharaj, Abhinav
Golla, John Sunwoo.
16.
5584 Exhaled breath as diagnostic tool for malignant
pleural mesothelioma. Kevin Lamote, Filip Lardon, Joris Van
Cleemput, Kristiaan Nackaerts, Olivier Thas, Jan P. van
Meerbeeck.
17.
5585 Analysis of saliva samples from healthy adults in
north central Florida for human papillomavirus infection.
Michelle M. Hwang, Hyun-Ji Choi, Taimour Y. Langaee,
Henrietta L. Logan, Kevin P. Raisch.
18.
5586 Breast cancer risk prediction: An update to the
Rosner-Colditz breast cancer incidence model. Megan Rice,
Shelley Tworoger, Susan Hankinson, Rulla Tamimi, A Heather
Eliassen, Graham Colditz, Bernard Rosner.
19.
5587 Personalized risk prediction tool for esophageal
adenocarcinoma in Caucasian population. Xia Pu, Jaffer A.
Ajani, Jian Gu, Xiangjun Gu, Yuanqing Ye, Xifeng Wu.
20.
5588 Nevus count and dermoscopic pattern associated
with MC1R RHC-variant alleles in a case-control study of
melanoma. Phil McClenahan, Kasturee Jagirdar, Katie Lee,
Elizabeth McEniery, Sam Beh, Brian Burke, David L. Duffy, H.
Peter Soyer, Richard A. Sturm.
21.
5589 Age-stratified risk of unexpected uterine sarcoma
following surgery for presumed benign leiomyoma.
Andrew S. Brohl, Li Li, Vaagn Andikyan, Angela Cioffi, Joel T.
Dudley, Andrew Kasarskis, Robert G. Maki.
22.
5590 Reliability of medical records in diagnosing
inflammatory breast cancer in Egypt. Lynne Le, Catherine
Schairer, Ahmed Hablas, Mohamed Ramadan, Sofia Merajver,
Ibrahim Seifeldein, Amr Soliman.
23.
5591 Factors associated with HPV vaccine initiation
among males aged 11-26 years attending outpatient
clinics in the Baltimore Metro Area during 2012 - 2013.
Megan Clarke, Darcy F. Phelan-Emrick, Francesca Coutinho,
Betty Chou, Corinne E. Joshu.
25.
5593 Cigarette smoke and therapeutic response to
chemotherapy and radiotherapy in cancer cells. Graham W.
Warren, Michelle Romano, Samantha Sobus, Sundaravadivel
Balasubramanian.
26.
5594 Progression of paraproteinemia in HIV-positive
versus HIV-negative patients. Erin Jou, Oleg Gligich, Alvita
C. Chan, Diwakar Mohan, Uriel R. Felsen, Sabarish Ayyappan,
Henny H. Billett, Edwin P. Hui, Anthony T. Chan, Radha
Raghupathy.
3.
5571 Technologies for molecular epidemiology in
cancer. Rao L. Divi, Mukesh Verma, Anthony Dickherber.
4.
5572 Tracking the functional analysis of cancer risk
variants. Sharna Tingle, Danielle Carrick, Sheri Schully, Mindy
Clyne, Stefanie A. Nelson.
5.
5573 Effects of endocrine disruptors on rat mammary
transcriptome at critical developmental windows. Kalpana
Gopalakrishnan, Qian Li, Yula Ma, Luca Lambertini, Jia Chen,
Susan Teitelbaum, Fabiana Manservisi, Laura Falcioni,
Luciano Bua, Fiorella Belpoggi.
6.
5574 High prevalence of germline TP53 mutations in
young osteosarcoma cases. Lisa J. Mirabello, Meredith
Yeager, Phuong L. Mai, Julie Gastier-Foster, Richard Gorlick,
Chand Khanna, Ana Patiño-Garcia, Luis Sierrasesúmaga,
Fernando Lecanda, Irene L. Andrulis, Jay S. Wunder, Nalan
Gokgoz, Donald A. Barkauskas, Xijun Zhang, Aurelie Vogt,
Kristine Jones, Joseph F. Boland, Stephen J. Chanock, Sharon
A. Savage.
7.
8.
9.
11.
12.
5575 Obesity and genomic changes in patients with
myelodysplastic syndromes. Aziz Nazha, David Seastone,
Hideki Makishima, Matt Kalaycio, Hetty E. Carraway, Anjali S.
Advani, Ahamd Zarzour, Jennifer Carew, Aaron T. Gerds, Sudipto
Mukherjee, Jaroslaw P. Maciejewski, Mikkael A. Sekeres.
5576 MnSOD polymorphism is associated with
ototoxicity in pediatric medulloblastoma patients. Austin
L. Brown, Philip J. Lupo, Mehmet F. Okcu, Ching C. Lau, Surya
P. Rednam, Michael E. Scheurer.
5577 Text-mining methods applied to clinical records
support an association between androgen deprivation
therapy and subsequent cardiometabolic disease. Kevin T.
Nead, Gregory L. Gaskin, Cariad Chester, Nigam H. Shah,
Nicholas J. Leeper.
5579 Medication exposures and subsequent
development of Ewing sarcoma: a review of FDA adverse
event reports. Judith U. Cope, Gregory H. Reaman, Joseph
M. Tonning.
5580 Characterization of HPV integration sites in the
human genome. Clara Bodelon, Micahel Untereiner, Svetlana
Vinokurova, Mitchell J. Machiela, Nicolas Wentzensen.
April 18-22, 2015 • Philadelphia, PA
Poster
:LJ[PVU
38
38
609
14_15AM_Wed_Layout 1 3/27/15 12:25 PM Page 610
LATE-BREAKING POSTER SESSIONS
Wednesday, 8:00 a.m.-12:00 p.m.
Halls B-E, Pennsylvania Convention Center
Abstracts will be available online and in the Proceedings Part 2.
Section 40
Section 41
610
Late-Breaking Research: Prevention Research
Late-Breaking Research: Molecular and Cellular Biology 4
AACR ANNUAL MEETING 2015
14_15AM_Wed_Layout 1 3/27/15 12:25 PM Page 611
NCI/NIH-SPONSORED SESSION (not eligible for CME credit)
Wednesday, 10:00 a.m.-11:30 a.m.
Room 105, Pennsylvania Convention Center
Resources for Achieving Truly Transdisciplinary Science:
Current Models from NCI-Funded Initiatives
Moderator: Krista A. Zanetti, National Cancer Institute, Rockville, MD
Transdisciplinary research is defined as research efforts conducted by investigators from different
disciplines working jointly to create new conceptual, theoretical, methodological, and translational
innovations that integrate and move beyond discipline-specific approaches to address a common
problem. When compared with traditional unidisciplinary research, transdisciplinary research has
considerable potential to accelerate scientific discovery and its translation to practice. Current NIH
transdisciplinary research initiatives include the National Institutes of Health Centers for Population
Health and Health Disparities (CPHHD) and National Cancer Institute Transdisciplinary Research on
Energetics and Cancer Initiative (TREC).
The CPHHD program responds to a strategic priority at the NIH to address disparities and inequities in
the prevalence and outcomes of several diseases, particularly cancer and heart disease. This program
requires transdisciplinary research involving social, behavioral, biological, and genetic research to
improve knowledge of the causes of health disparities and devise effective methods of preventing,
diagnosing, and treating disease and promoting health. The program began in 2003 and has funded
19 Centers since its inception, with 10 of the Centers being supported by the NCI.
The TREC initiative is a scientific research effort aimed at reducing cancer linked with obesity, poor
diet, and low levels of physical activity. The NCI established the TREC initiative in 2005 in response to
growing public health concern with overweight and obesity in the United States and mounting
evidence that obesity plays a role in the development of many types of cancer. The Centers included
scientists from multiple disciplines and encompassed projects spanning the basic biology and genetics
of behavioral, socio-cultural, and environmental influences on nutrition, physical activity, weight,
energy balance, energetics, and cancer risk. The current TREC initiative expands into other research
areas including cancer survivorship, childhood obesity, genomics, and environmental aspects of
obesity that include use of tools such as geospatial analysis.
This session will include a brief introduction and presentations by researchers who have been funded
and/or are currently funded through the CPHHD program and TREC initiative. The session will highlight
and discuss the necessary resources and strategies to address the scientific and logistic complexity of
large transdisciplinary initiatives, including a discussion of leadership and management challenges and
communications and decision-making procedures. Specifically, the presentations in this session will
highlight best practices for performing transdisciplinary research as modeled though the CPHHD and
TREC initiatives and will include perspectives from basic, social, clinical, and behavioral sciences
researchers. This session will provide a venue to explore the opportunities and challenges to achieve
truly transdisciplinary research from these varying scientific perspectives. The goal of this session will
be to provide a forum at which investigators with extensive experience in performing transdisciplinary
research within large initiatives can stimulate discussion and ideas for improving collaborations to
prevent, diagnose, and treat cancer and promote health. Moreover, attendees will benefit from a deeper
understanding of how large transdisciplinary collaborations are developed and managed effectively to
address critical research questions.
Speakers:
Sarah Gehlert, Washington University, St. Louis, MO
Marian L. Neuhouser, Fred Hutchinson Cancer Research Center, Seattle, WA
Nathan A. Berger, Case Western Reserve University, Cleveland, OH
Kathryn H. Schmitz, University of Pennsylvania, Philadelphia, PA
April 18-22, 2015 • Philadelphia, PA
611
14_15AM_Wed_Layout 1 3/27/15 12:25 PM Page 612
MAJOR SYMPOSIA
Wednesday, 10:00 a.m.-12:00 p.m.
Room 204, Pennsylvania Convention Center
The Bayard D. Clarkson Symposium:
Room 113, Pennsylvania Convention Center
Stem Cells and Cancer Cell of Origin
Enhancing Efficacy of Cancer
Immunotherapy by Use of Ablative Therapy
Chairperson: Connie J. Eaves, BC Cancer Agency,
Vancouver, BC, Canada
Chairperson: Bo Lu, Thomas Jefferson University Hospital,
Philadelphia, PA
Tumors arise as rare events from cells present in established
tissues, typically through a multistep process that may span
many years and likely multiple cell generations. Most tumors
with the attributes of invasive malignant cells are also
capable of continuous growth in vivo through the
generation of a self-sustaining progeny line; hence the
concept of tumor stem cells. As in normal tissues,
heterogeneity of biological as well as phenotypic features is
also a cardinal feature of the individual cells produced by
malignant populations. However, tumors are not only
genetically perturbed populations, they are also constantly
evolving genetically – characteristics that add further
causes of diversification in their make-up. These issues
underscore the importance of clonal tracking methods to
analyze the process of tumor initiation, establishment and
maintenance. This Symposium will highlight new and
unexpected insights obtained using clonal approaches to
delineating the process of tumor propagation and evolution
in various different tissues in vivo.
Combining immune checkpoint inhibitors such as PD1 or
PDL1 inhibitors and ablative radiotherapy has the
theoretical advantage of inducing synergistic immune
response against cancer cells that have developed
metastases. Potential therapeutic gain from such
combination in stage IV cancer patients will be
unprecedented and of high clinical impact. The speakers in
this session will provide preclinical results and clinical data
to demonstrate viability of such strategy as well as the
need for optimization. These investigations will provide
valuable guidance for designing relevant clinical trials of
combing immunotherapy with ablative radiotherapy.
10:00 a.m.
Introduction
10:10 a.m.
Defining the origin of tumor heterogeneity
in epithelial cancers [SY45-01]*
Cedric Blanpain, Université Libre de
Bruxelles, Bruxelles, Belgium
10:30 a.m.
10:35 a.m.
10:00 a.m.
Introduction
10:10 a.m.
Targeting immune checkpoints in cancer
therapy: New insights and opportunities
James P. Allison, The University of Texas MD
Anderson Cancer Center, Houston, TX
10:30 a.m.
Discussion
10:35 a.m.
Tapping the potential of immunogenic
modulation to attack malignant cells
that survive therapy
James W. Hodge, National Cancer Institute,
Bethesda, MD
Discussion
10:55 a.m.
Discussion
Tumor-propagating cells in non-small
cell lung cancer
Carla F. Kim, Children’s Hospital Boston,
Boston, MA
11:00 a.m.
Radiation-mediated DNA sensing pathway for
immunity and tumor regression [SY39-03]*
Yang-xin Fu, University of Chicago, Chicago, IL
11:20 a.m.
Discussion
10:55 a.m.
Discussion
11:25 a.m.
11:00 a.m.
Clonal dynamics in gastrointestinal cancers
Hanno Glimm, National Center for Tumor
Diseases, Heidelberg, Germany
Immune responses to DNA damage and
DNA modulation in cancer cells
Drew M. Pardoll, Johns Hopkins Kimmel
Comprehensive Cancer Center, Baltimore, MD
11:20 a.m.
Discussion
11:45 a.m.
Discussion
11:25 a.m.
Barcoding reveals new outputs of normal
and malignant mammary cells
Connie J. Eaves, BC Cancer Agency,
Vancouver, BC, Canada
11:50 a.m.
General Discussion
11:45 a.m.
Discussion
11:50 a.m.
General Discussion
*An extended abstract for this presentation is available in the Invited Abstracts section of the Proceedings (the abstract number is listed in brackets above).
612
AACR ANNUAL MEETING 2015
14_15AM_Wed_Layout 1 3/27/15 12:25 PM Page 613
Room 120, Pennsylvania Convention Center
10:50 a.m.
Epigenetic dysregulation as the
intermediary from cancer risk-associated
genetic variant to cancer development
Megan P. Hitchins, Stanford University Cancer
Center, Palo Alto, CA
11:05 a.m.
Discussion
11:10 a.m.
Immunomodulatory and tumor cell killing
effects of the demethylating agent 5azacytidine in ovarian cancer
**Katherine B. Chiappinelli, Johns Hopkins
School of Medicine, Baltimore, MD
11:25 a.m.
Discussion
11:30 a.m.
Reprogramming of the epigenome by MLL
links early life environmental exposures to
adult cancer risk
Cheryl Lyn Walker, Texas A&M University
Health Science Center, Houston, TX
11:45 a.m.
Discussion
11:50 a.m.
General Discussion
Epigenetic Mechanisms in Cancer Risk
Chairperson: Cheryl Lyn Walker, Texas A&M University
Health Science Center, Houston, TX
Methylation of cytosine (5-mC) bases in DNA, one of the
first epigenetic mechanisms known to participate in cancer
development, has now come of age, and moved into the
realm of personalized medicine with the emergence DNA
methylation biomarkers with predictive potential for cancer
risk and response to therapy. However, the field continues
to discover new epigenetic mechanisms that contribute to
cancer etiology. These include the recently discovered
oxidized 5-mC bases, such as 5-hydroxymethylcytosine.
This discovery has brought with it a new appreciation that
the dynamics of DNA methylation/demethylation play an
important role in the etiology of many cancers. It is now
also becoming clear that epigenetic alterations contribute
to the development hereditary cancers. The epigenetic
landscape greatly influences the penetrance of inherited
mutations in genes that predispose to cancer, and in some
settings, constitutional “epimutations” disrupt expression
of these genes via epigenetic rather than mutational
mechanisms to increase cancer risk. Unlike mutations,
“epimutations” exhibit non-Mendelian inheritance and can
be reversible between generations. Finally, epigenetic
programmers are emerging as a unique target for
environmental exposures early in life, which disrupt the
activity of epigenetic “readers, writers, and erasers” to
reprogram the epigenome and increase individual risk of
developing cancer in adulthood.
10:00 a.m.
Introduction
10:10 a.m.
Title and speaker to be announced
10:25 a.m.
Discussion
10:30 a.m.
Deciphering the sixth base
(5-hydroxymethylcytosine) in the
cancer genome
Yun (Nancy) Huang, Texas A&M University
Health Science Center, Houston, TX
10:45 a.m.
Discussion
*An extended abstract for this presentation is available in the Invited Abstracts section of the Proceedings (the abstract number is listed in brackets above).
**NextGen Star, selected to give a talk by the AACR President and Annual Meeting Program Chairperson through a competitive application process designed
to bring more visibility to early-career scientists. Abstract can be found in the Invited Abstracts: NextGen Stars section of the Proceedings.
April 18-22, 2015 • Philadelphia, PA
613
14_15AM_Wed_Layout 1 3/27/15 12:25 PM Page 614
MAJOR SYMPOSIA
Wednesday, 10:00 a.m.-12:00 p.m.
Grand Ballroom (300 Level), Pennsylvania
Convention Center
Innate and Adaptive Immunity In Cancer
Chairperson: Douglas T. Fearon, Cold Spring Harbor
Laboratory, Cold Spring Harbor, NY, and Weill Cornell
Medical College, New York, NY
A characteristic of cancers is their association with a
stromal microenvironment that is replete with cells of the
innate immune system, which has been likened to a
“chronic healing wound” and a tissue-protective process.
Conversely, cancers also frequently induce adaptive
immune responses that lead to the accumulation of
cancer-specific CD4+ and CD8+ T cells, which could cause
tissue injury that, in this instance, would be beneficial for
the host. The speakers in this session will discuss our
understanding of the interplay of innate and adaptive
immunity that leads to the promotion or suppression of
tumor growth.
10:00 a.m.
Introduction
10:10 a.m.
Regulatory T cells in cancer
Alexander Rudensky, Memorial Sloan
Kettering Cancer Center, New York, NY
Room 103, Pennsylvania Convention Center
Nucleotide Metabolism in Cancer Cell
Growth and Survival
Chairperson: Brendan D. Manning, Harvard School of
Public Health, Boston, MA
In recent years, studies on cancer cell metabolism have led
to the reemergence of interest in the role of nucleotide
metabolism in cancer progression and treatment. It is now
evident that cancer cells exhibit metabolic strategies to
increase their nucleotide pools to meet the demands for
RNA and DNA synthesis to fuel cell growth and
proliferation. Unlike the normal cells from which they arise,
cancer cells are believed to acquire their nucleotides
primarily through de novo synthesis. Importantly, as
exhibited with classic cancer drugs, such as 5-fluorouracil
and methotrexate, targeting this nucleotide pool offers a
promising therapeutic approach. This session will discuss
recent advances in delineating the diverse mechanisms
used by cancer cells to synthesize or obtain nucleotides
and potential areas of vulnerability related to nucleotide
synthesis and use.
10:00 a.m.
Introduction
10:30 a.m.
Discussion
10:10 a.m.
10:35 a.m.
Discovery of intratumoral, antitumoral
pathways through dynamic imaging
Matthew Krummel, University of California,
San Francisco, CA
Induction of de novo nucleotide synthesis
by oncogenic signaling pathways
Brendan D. Manning, Harvard School of
Public Health, Boston, MA
10:30 a.m.
Discussion
10:55 a.m.
Discussion
10:35 a.m.
11:00 a.m.
Tumor-associated macrophages: From
mechanism to therapy
Jeffrey W. Pollard, The Queens Medical
Research Institute, Edinburgh, United Kingdom
One-carbon flux in cancer cells
Joshua D. Rabinowitz, Princeton University,
Princeton, NJ
10:55 a.m.
Discussion
11:00 a.m.
One carbon metabolism and cancer
[SY42-03]*
Karen H. Vousden, Beatson Institute for
Cancer Research, Glasgow, United Kingdom
11:20 a.m.
Discussion
11:25 a.m.
MTH1 inhibition for depersonalized
anticancer treatment
Thomas Helleday, Karolinska Institute,
Stockholm, Sweden
11:45 a.m.
Discussion
11:50 a.m.
General Discussion
11:20 a.m.
Discussion
11:25 a.m.
Immune suppression by T cell exclusion in
pancreatic cancer [SY41-04]*
Douglas T. Fearon, Cold Spring Harbor
Laboratory, Cold Spring Harbor, NY, and Weill
Cornell Medical College, New York, NY
11:45 a.m.
Discussion
11:50 a.m.
General Discussion
*An extended abstract for this presentation is available in the Invited Abstracts section of the Proceedings (the abstract number is listed in brackets above).
614
AACR ANNUAL MEETING 2015
14_15AM_Wed_Layout 1 3/27/15 12:25 PM Page 615
10:00 a.m.
Introduction
10:10 a.m.
Stereochemistry matters: L-2HG as a tumor
response to hypoxia [SY43-01]*
Craig B. Thompson, Memorial Sloan Kettering
Cancer Center, New York, NY
foundation for understanding the scope and relationships
of genomic alterations in human cancers. The National
Cancer Institute recognized that global proteomic
characterization of genomically annotated TCGA samples,
leveraging recent dramatic improvements in the depth and
quantitative capability of mass spectrometry-based
proteomics, could provide complementary as well as
unique information about cancer biology and signaling that
cannot be inferred from genomic analyses alone. This
session will present results of the proteomic and
phosphoproteomic analyses of breast, colon, and ovarian
tumor TCGA samples conducted by the Clinical Proteomic
Tumor Analysis Consortium. The unique information that
global MS-based proteomics provides will be emphasized,
together with integrated analysis of the relationships
between genomic and proteomic characteristics. The
increasing importance of targeted mass spectrometry to
develop and apply highly multiplexed thematic panels of
quantitative assays to study cancer pathways of interest
will also be highlighted.
10:30 a.m.
Discussion
10:00 a.m.
Introduction
10:35 a.m.
Mismatch repair, gut microbiota, and the
etiology of colon cancer [SY43-02]*
Alberto Martin, University of Toronto,
Toronto, ON, Canada
10:10 a.m.
Proteogenomic analysis of human colon and
rectal cancer [SY44-01]*
Daniel C. Liebler, Vanderbilt University,
Nashville, TN
10:55 a.m.
Discussion
10:30 a.m.
Discussion
11:00 a.m.
Modulating the oncometabolite 2hydroxyglutarate in cancer
Marion Dorsch, Agios Pharmaceuticals,
Cambridge, MA
10:35 a.m.
Proteogenomic and phosphoproteomic
analysis of breast cancer [SY44-02]*
Philipp Mertins, Broad Institute of MIT and
Harvard, Cambridge, MA
11:20 a.m.
Discussion
10:55 a.m.
Discussion
11:25 a.m.
Epigenetics and TCA cycle metabolites
Navdeep S. Chandel, Northwestern
University, Chicago, IL
11:00 a.m.
Proteogenomic and phosphoproteomic
analysis of ovarian cancer [SY44-03]*
Karin D. Rodland, Pacific Northwest National
Laboratory, Richland, WA
11:45 a.m.
Discussion
11:20 a.m.
Discussion
11:50 a.m.
General Discussion
11:25 a.m.
Targeted MRM mass spectrometry enables
highly multiplexed quantification of cell
signaling in response to DNA
damage [SY44-04]*
Amanda G. Paulovich, Fred Hutchinson
Cancer Research Center, Seattle, WA
11:45 a.m.
Discussion
Room 201, Pennsylvania Convention Center
Oncometabolites
Chairperson: Craig B. Thompson, Memorial Sloan Kettering
Cancer Center, New York, NY
Cancer-inducing mutations have long been shown to alter
proteins that participate in signal transduction and/or
transcription. Recently, it has become apparent that cancerassociated mutations in metabolic enzymes can also play a
pathogenic role. These mutations result in accumulations of
metabolites which contribute to cellular transformation.
Additional evidence suggests that oncometabolites can also
be produced in trans during wound repair and inflammation,
and contribute to early steps in transformation. Examples of
these concepts will be presented.
Room 121, Pennsylvania Convention Center
Proteogenomics and Phosphoproteomics in
Cancer: Analysis of the TCGA Tumor Samples
Co-Chairpersons: Steven A. Carr, Broad Institute of MIT
and Harvard, Cambridge, MA; Douglas R. Lowy, National
Cancer Institute, Bethesda, MD
The Cancer Genome Atlas has provided an important
*An extended abstract for this presentation is available in the Invited Abstracts section of the Proceedings (the abstract number is listed in brackets above).
April 18-22, 2015 • Philadelphia, PA
615
14_15AM_Wed_Layout 1 3/27/15 12:25 PM Page 616
RECENT ADVANCES IN EPIDEMIOLOGY AND PREVENTION RESEARCH
Wednesday, 10:00 a.m.-12:00 p.m.
Room 119, Pennsylvania Convention Center
Early Detection and Overdiagnosis in Cancer
Chairperson: Denise R. Aberle, UCLA David Geffen School of Medicine, Los Angeles, CA
The session will discuss the broader notion of early detection and overdiagnosis of cancer. The session
will include a general overview of the goals of screening and overdiagnosis as a harm of screening.
The evidence for overdiagnosis across several tumor types and potential approaches to better
characterize and communicate the notion of overdiagnosis are discussed. Specific considerations of
early detection and overdiagnosis are reviewed in the context of breast and lung cancer screening.
10:00 a.m.
An overview of overdiagnosis
Edward F. Patz, Jr., Duke University Medical Center, Durham, NC
10:25 a.m.
Discussion
10:30 a.m.
Lung cancer screening: Early detection and overdiagnosis
Denise R. Aberle, UCLA David Geffen School of Medicine, Los Angeles, CA
10:55 a.m.
Discussion
11:00 a.m.
Breast cancer screening: Early detection and overdiagnosis
Otis W. Brawley, American Cancer Society, Atlanta, GA
11:25 a.m.
Discussion
11:30 a.m.
Panel Discussion
616
AACR ANNUAL MEETING 2015
14_15AM_Wed_Layout 1 3/27/15 12:25 PM Page 617
RECENT ADVANCES IN ORGAN SITE RESEARCH
Wednesday, 10:00 a.m.-12:00 p.m.
Room 108, Pennsylvania Convention Center
Room 114, Pennsylvania Convention Center
Barrett’s Esophagus: Models, Genomics,
and Genetics
Colorectal Cancer Subtypes: How Many,
How Meaningful?
Chairperson: Anil K. Rustgi, University of Pennsylvania
School of Medicine, Philadelphia, PA
Chairperson: Alberto Bardelli, IRCC, University of Turin
Medical School, Candiolo, Italy
Barrett’s esophagus (BE) is the leading recognizable risk
factor for esophageal adenocarcinoma (EAC). Dietary and
lifestyle variables, such as cigarette smoking, obesity, and
eradication of H. pylori infection, play contributing roles in
these conditions. This session will emphasize using mouse
models to understand the cellular origin of BE through
lineage labeling, modeling BE through other platforms
(namely 3-D organoid cultures) and presenting current
knowledge on the genomics and genetics of BE and EAC.
Colorectal cancers (CRC) are presently classified based on
clinical and histopathological features. Recently, several
groups used unsupervised clustering of large gene
expression datasets to delineate previously uncharted CRC
subtypes. Depending on the classification, CRC
transcriptional subtypes variably overlap with other
molecular traits including microsatellite instability,
methylation, and the mutational status of the RAS
signaling pathway. This session will provide the most
recent updates on this subject, as well as major advances
on the biological and clinical significance of molecular
classification of colorectal tumors.
10:00 a.m.
Introduction
Anil K. Rustgi, University of Pennsylvania
School of Medicine, Philadelphia, PA
10:05 a.m.
Mouse models and cell of origin for Barrett’s
esophagus
Timothy C. Wang, Columbia University
Medical Center, New York, NY
10:00 a.m.
Colorectal cancer subtypes with different
characteristics and cellular phenotypes
Anguraj Sadanandam, The Institute of Cancer
Research, Sutton, United Kingdom
10:25 a.m.
Discussion
10:20 a.m.
Discussion
10:30 a.m.
Using 3-D organoid culture systems to
model inflammatory microenvironments in
Barrett’s esophagus
John P. Lynch, University of Pennsylvania,
Philadelphia, PA
10:25 a.m.
Consensus on CRC subclassification,
biological interpretation, and clinical
applications
Sabine Tejpar, Catholic University of Leuven,
Leuven, Belgium
10:50 a.m.
Discussion
10:45 a.m.
Discussion
10:55 a.m.
Functional genomics of Barrett’s esophagus
and esophageal adenocarcinoma
Adam J. Bass, Dana-Farber Cancer Institute,
Boston, MA
10:50 a.m.
Colorectal cancer subtyping: From human
tumors to preclinical models and back
Enzo Medico, IRCC, University of Torino,
Candiolo, Italy
11:15 a.m.
Discussion
11:10 a.m.
Discussion
11:20 a.m.
Insights from the genetics of familial
Barrett’s esophagus
Amitabh Chak, Case Western Reserve
University, Cleveland, OH
11:15 a.m.
Molecular subtypes of colon cancer and
immune reaction
Pierre Laurent-Puig, University of Paris V
René Descartes, Paris, France
11:40 a.m.
Discussion
11:35 a.m.
Discussion
11:45 a.m.
Panel Discussion
11:40 a.m.
Panel Discussion
April 18-22, 2015 • Philadelphia, PA
617
14_15AM_Wed_Layout 1 3/27/15 12:25 PM Page 618
RECENT ADVANCES IN ORGAN SITE RESEARCH
Wednesday, 10:00 a.m.-12:00 p.m.
Room 115, Pennsylvania Convention Center
Room 118, Pennsylvania Convention Center
Heterogeneity and Microenvironment:
Drivers of Breast Cancer Evolution
Pancreatic Cancer in 2015: An Integrated
View of a Complex Disease
Chairperson: Jeffrey M. Rosen, Baylor College of Medicine,
Houston, TX
Chairperson: Christine A. Iacobuzio-Donahue, Memorial
Sloan Kettering Cancer Center, New York, NY
This session will focus on our current understanding of the
role of intratumoral heterogeneity and the
microenvironment on breast tumor evolution. Questions to
be addressed will be: 1) How does our understanding of
paracrine signaling pathways in normal development
provide new insights into functional pathways involved in
intratumoral heterogeneity? 2) What is the impact of
genetic heterogeneity on the progression from in situ to
invasive breast cancer and from primary breast cancer to
metastatic disease in treatment naive patients? 3) How can
intratumoral heterogeneity in clinical breast cancer be
measured and what type of heterogeneity is important? 4)
How can we identify the “real” drivers of breast
tumorigenesis? 5) What type of stromal heterogeneity
exists in triple-negative breast cancer and how is this
associated with patient outcome?
Accumulating evidence indicates the multifactorial nature
of PDA neogenesis, behavior, and progression. These
include both cell-autonomous and non-cell autonomous
factors such as somatic genetic alterations, epigenetic
modifications, immunologic suppression, metabolic
dysregulation and stromal remodeling, among others.
Indeed, this multitude of factors likely influence one
another over the natural history of the neoplasm
culminating in the lethal phenotype encountered at
diagnosis. The extent to which these factors play a role
throughout carcinogenesis and progression, at distinct
time points or within specific contexts remains to be
clarified. The goal of this session is to therefore provide
participants an integrated overview of the most current
understanding of pancreatic cancer through distinct
examples of cutting edge research in the field related to
pancreatic cancer risk, early genetic events, whole genome
sequencing, and metastasis.
10:00 a.m.
Developmental insights into tumor
heterogeneity
Jeffrey M. Rosen, Baylor College of Medicine,
Houston, TX
10:20 a.m.
Discussion
10:25 a.m.
Making sense of intratumor genetic
heterogeneity and breast cancer
Jorge S. Reis-Filho, Memorial Sloan Kettering
Cancer Center, New York, NY
10:00 a.m.
Branched chain amino acid metabolism in
pancreatic cancer risk
Brian M. Wolpin, Dana-Farber Cancer
Institute, Boston, MA
10:15 a.m.
Discussion
10:20 a.m.
Transcriptional mechanisms for autophagy
regulation and metabolic reprogramming in
pancreatic cancer
**Rushika M. Perera, Massachusetts General
Hospital Cancer Center, Harvard Medical
School, Boston, MA
10:45 a.m.
Discussion
10:50 a.m.
Clinical and functional relevance of
intratumor heterogeneity in breast cancer
Kornelia Polyak, Dana-Farber Cancer
Institute, Boston, MA
10:35 a.m.
Discussion
11:10 a.m.
Discussion
10:40 a.m.
11:15 a.m.
Stromal heterogeneity in triple-negative
breast cancer
Morag Park, Canadian Institutes of Health
Research, Montréal, QC, Canada
KRAS and immunity
Dafna Bar-Sagi, New York University
Langone Medical Center, New York, NY
10:55 a.m.
Discussion
11:00 a.m.
Genetic subtypes of pancreatic cancer
Andrew V. Biankin, University of Glasgow,
Glasgow, United Kingdom
11:15 a.m.
Discussion
11:20 a.m.
Genetic and phenotypic heterogeneity in
pancreatic cancer progression
Christine A. Iacobuzio-Donahue, Memorial
Sloan Kettering Cancer Center, New York, NY
11:35 a.m.
Discussion
11:40 a.m.
Panel Discussion
11:35 a.m.
Discussion
11:40 a.m.
Panel Discussion
*An extended abstract for this presentation is available in the Invited Abstracts section of the Proceedings (the abstract number is listed in brackets above).
**NextGen Star, selected to give a talk by the AACR President and Annual Meeting Program Chairperson through a competitive application process designed
to bring more visibility to early-career scientists. Abstract can be found in the Invited Abstracts: NextGen Stars section of the Proceedings.
618
AACR ANNUAL MEETING 2015
14_15AM_Wed_Layout 1 3/27/15 12:25 PM Page 619
PLENARY SESSION
Wednesday, 12:00 p.m.-1:30 p.m.
Terrace Ballroom I-IV (400 Level), Pennsylvania Convention Center
AACR Annual Meeting 2015 Highlights: Vision for the Future
Chairperson: Nancy E. Davidson, University of Pittsburgh Cancer Institute, Pittsburgh, PA
12:00 p.m. Introductory remarks
Nancy E. Davidson, University of Pittsburgh Cancer Institute, Pittsburgh, PA
12:05 p.m. Basic research
Lewis C. Cantley, Sandra and Edward Meyer Cancer Center at Weill Cornell Medical College,
New York, NY
12:25 p.m. Clinical and translational research
Carlos L. Arteaga, Vanderbilt-Ingram Cancer Center, Nashville, TN
12:45 p.m. Early detection and prevention research
William G. Nelson, Johns Hopkins Kimmel Comprehensive Cancer Center, Baltimore, MD
1:05 p.m. Wrap up and vision for the future
José Baselga, Memorial Sloan Kettering Cancer Center, New York, NY
April 18-22, 2015 • Philadelphia, PA
619